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Abstract 
There is increasing interest in the use of small field of view (SFOV) portable gamma 
cameras in medical imaging. A novel hybrid optical-gamma camera (HGC) has been 
developed through a collaboration between the Universities of Leicester and 
Nottingham. This system offers high resolution gamma and optical imaging and shows 
potential for use at the patient bedside, or in the operating theatre. The aim of this thesis 
was to translate the HGC technology from in vitro laboratory studies to clinical use in 
human subjects.  
 
Pilot studies were undertaken with the HGC as part of this thesis. Furthermore, efforts 
have been made to transform the HGC technologies into a new medical device, known 
as Nebuleye. Initial physical evaluation of the pre-production prototype camera was 
carried out as part of the device developmental process, highlighting some aspects of 
the design that require further modification. A complete and rigorous testing scheme to 
assess the pre-production prototype camera has been developed and successfully 
implemented. The newly introduced tests enabled the system uniformity, system 
sensitivity, detector head shielding leakage, optical-gamma image alignment and 
optical image quality of the hybrid camera to be assessed objectively. This harmonised 
testing scheme allows characterisation and direct comparison of SFOV gamma 
cameras.  
 
In vitro and in vivo preclinical imaging was undertaken to examine the performance of 
the SFOV gamma cameras for experimental animal studies. The results of animal study 
have shown for the first time the feasibility and performance of these SFOV gamma 
cameras for imaging mice injected with a newly developed 111In labelled hybrid tracer. 
Further investigations are needed to improve the system resolution and prepare the 
camera system for combined gamma-near infrared fluorescence imaging in future.   
 
A systematic in vitro laboratory assessment method has been established to examine 
the imaging performance of the SFOV gamma camera in radioguided sentinel lymph 
node biopsy (SLNB) and radioactive seed localisation procedures for breast cancer 
surgery. Further preparatory work was undertaken to carry out a pilot clinical trial of 
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the use of the pre-production prototype camera in sentinel node localisation procedures 
during breast cancer surgery. The clinical study protocol and routine quality control 
procedures have been established and are suitable for future use. Baseline data on the 
camera performance assessed using the routine quality control scheme have been 
obtained.  
 
Finally, the capabilities of the SFOV gamma camera were assessed. This has provided 
baseline data on user feedback and the imaging consequences on operator motion 
effects, as well as examining the detectability of a range of radionuclides, including 
99mTc, 111In, 123I, 125I and 75Se. The first clinical results of the use of the HGC in clinical 
hybrid optical-gamma imaging in patients administered with 99mTc and 123I labelled 
radiopharmaceuticals have been reported. This clinical study has demonstrated the 
feasibility and capability of HGC in various clinical applications performed at the 
patient bedside, which included patients undergoing bone, thyroid, lacrimal drainage 
and lymphatic imaging as well as DaTscan studies.    
 
In conclusion, the work in this thesis has demonstrated the successful translation of an 
SFOV hybrid gamma camera for clinical use.  This system would be ideally suited for 
use in the operating theatre for radioguided procedures such as sentinel node detection 
and tumour localisation. This system also offers potential for use with the new 
generation of hybrid fluorescent-radionuclide tracers currently under development. 
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Introduction  
 
 
 Diagnostic Nuclear Medicine 
The discovery of natural radioactivity in uranium ore in 1896 by Henri Becquerel led 
to the further discovery of other new radioactive elements by Marie Curie, who first 
used the terms ‘radioactive’ and ‘radioactivity’. During the mid-1920s, George de 
Hevesy carried out studies of metabolic pathways by administering radionuclides to 
rats, thus establishing the principle of the radiotracer. Frédéric Joliot Curie and Irène 
Joliot Curie reported the first production of artificial radioactive material in 1934 [1] 
and it is believed that John H. Lawrence has successfully made his first attempt to treat 
leukaemia by using an artificial radionuclide, named phosphorus-32 [2]. These studies 
established the fundamental principles for the application of radionuclides in medicine.                   
 
There are three main types of nuclear medicine procedure practiced worldwide, namely 
imaging procedures, non-imaging procedures and therapeutic procedures. Diagnostic 
nuclear medicine is the medical speciality that utilises radioactive tracers in the 
diagnosis of disease. It is based on the understanding of the physiological uptake and 
clearance of an administered radiolabelled tracer known as a radiopharmaceutical. Once 
administered to the patient the radiopharmaceutical will concentrate in the organ or 
system of interest while emitting radiation, principally gamma rays due to the physical 
process of radioactive decay. The energy of these gamma photons allows a significant 
number to penetrate through body tissues and be detected using dedicated gamma 
cameras and scanners that can image the spatial distribution of the radioactivity in the 
body. Figure 1.1 gives a summary illustration of the processes of a nuclear medicine 
imaging.  
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Figure 1.1: The typical processes of a nuclear medicine imaging procedure. (a) SPECT-CT imaging with 
patient lying on couch; (b) SPECT-CT image of lumbar spine with fracture; (c) myocardial perfusion 
image (Images taken from [3]); and (d) whole body bone scintigraphy (Image taken from [4])   
 
Imaging studies require imaging systems such as gamma cameras, Single Photon 
Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) 
camera systems to acquire the gamma images of radioactivity distribution within the 
patient’s body. This technology plays an important role in the identification of a range 
of medical conditions including malignant diseases, heart disease, brain disorders and 
organ function. These gamma images compliment other diagnostic information 
provided by imaging techniques such as computed tomography (CT), magnetic 
resonance imaging (MRI) and ultrasonography to improve the accuracy in disease 
diagnosis, cancer treatments planning and evaluating treatment response. With the 
widespread development of nuclear imaging and computer emission tomography 
technology, there are about 33 million diagnostic nuclear medicine examinations 
carried out globally in a year [5].  
 
 Physics in Nuclear Medicine 
Radiation is a form of energy. There are two types of radiation used in nuclear medicine, 
particulate radiation and electromagnetic radiation, which are emitted from 
radionuclides through the radioactive decay processes. Particulate radiation is energy 
in the form of kinetic energy of mass in motion, originating from the process of 
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radioactive decay, nuclear reactions and from cosmic rays. Examples of these radiations 
are energetic electrons (e), protons (p), neutrons (n) and alpha particles (α).   
 
Electromagnetic radiation is a form of energy in motion with no mass and charge. It 
propagates through space as either waves or discrete packets of energy, called photons 
or quanta, at the speed of light by oscillating electrical and magnetic fields. The 
relationship of wavelength, λ and frequency,  of the electromagnetic radiation is given 
by Equation 1.1. 
 λ ×  = c 1.1 
 
where c is the velocity of light in vacuum, which is approximately 3 × 108 m.s-1. The 
basic unit of energy is the electron volt (eV). One eV is defined as the energy acquired 
by an electron when accelerated through an electric potential difference of one volt. 
The energy E (in kilo eV) and the wavelength of its associated electromagnetic field λ 
(in nanometers) are related by Equation 1.2. Figure 1.2 illustrates the examples of 
different form and applications over the range of the electromagnetic spectrum. 
 
 
E=
1.24
λ
 1.2 
     
  
Figure 1.2: Electromagnetic spectrum taken from [6]. 
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 Radioactive decay 
An atomic nucleus is characterised by the number of protons and neutrons within the 
positively charged core. The combinations of protons and neutrons produce either 
stable or unstable nuclei. The ratio of the number of neutrons to the number of protons 
(N/Z) determines the stability degree of a nucleus. A radionuclide, which has an 
unstable nucleus, emits radiation in the process of achieving a more stable configuration 
of protons and neutrons in the nucleus. The process is called radioactive decay or 
radioactive disintegration. It is spontaneous and involves the conversion of mass into 
energy. It is described in terms of probabilities and average disintegration rates during 
a period of time. If a number of radioactive atoms N present in a radionuclide, the 
disintegration rate at that time (t) is given by Equation 1.3. 
 
 dN
dt
=-N 1.3 
 
where  is the decay constant of the radionuclide. The disintegration rate A is referred 
to as the radioactivity or the activity of the radionuclide and has dimensions of 
disintegration per second (dps). The Systeme International (SI) unit of activity is the 
becquerel (Bq). From a knowledge of the decay constant and the initial amount of 
radioactivity, the total number of radioactive atoms can be determined by Equation 1.4.  
 
 Nt=N0e
-t 1.4 
 
where N0 and Nt are the number of radioactive atoms at t = 0 and time t respectively. 
Since activity A is proportional to the number of atoms N, therefore it can be calculated 
by Equation 1.5. 
 
 At=A0e
-t 1.5 
 
The decay factor e-t is an exponential function of time t. Each radionuclide has its 
characteristic properties include the decay mode and type of emissions, the transition 
energy and the average lifetime of a nucleus of the radionuclide prior decay process.   
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 Physical half-life 
The physical half-life (t½) of a radionuclide is defined as the time required reducing its 
initial activity level to half. It is related to the decay constant  by Equation 1.6.  
 
 
=
0.693
t
½
 1.6 
The mean life  of a radionuclide is the average lifetime of the atoms in a sample. It is 
related to the decay constant and half-life as follows: 
 
 
τ=
1

= 
t
½
0.693
=1.44 t
½
 1.7 
 
For medical applications, the elimination of a radiopharmaceutical from any organ or 
tissue depends on both the physical half-life (Tp or t½) and biological half-life (Tb) of 
the radiopharmaceutical. The half-life associated with radioactive decay is categorised 
as the physical half-life while biological half-life is defined as the time required to 
excrete half of the administered radiopharmaceutical from biologic system. The 
effective decay constant (e) is related to p and b by Equation 1.8.  
 
 λe= λp+λb 1.8 
 
Therefore, the effective half-life, Te can be derived as Equation 1.9.  
 
  
Te=
Tp × Tb
Tp + Tb
 1.9 
   
 Radionuclides  
The radiation emitted following radioactive decay of a radionuclide during its natural 
tendency to achieve stability allows for many healthcare applications. Nuclear medicine 
procedures involve the mapping of radioactivity distributions in organs and tissues 
offers information on the physiology and metabolism of organs and biologic systems 
using sophisticated radiation detector. These radionuclides are all man-made and can 
be classified as reactor-produced radionuclides (e.g. Molydenum-99 and Iodine-131) 
or accelerator-produced radionuclides (e.g. Fluorine-18). Table 1.1 shows the physical 
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characteristic of radionuclides commonly used in nuclear medicine. The selection of 
the medicinal radionuclides for specific procedure needs to take into considerations of 
the following factors: 
a) type and energy of emissions: gamma photons for imaging, alpha or beta 
particles with high energy (~1 MeV) for therapy; 
b) physical half-life: relative short half-lives (measured in minutes, hours or days); 
c) chemical properties: simple chemical technique for attaching the radionuclide 
to the ligand; 
d) cost and/or complexity of preparation: ease and relative low cost of production 
and ready availability.  
 
Table 1.1: Commonly used radionuclide in nuclear medicine adapted from [7]. 
Nuclide Physical half-
life 
Mode of 
decay (%) 
-ray energy* 
(MeV) 
-ray abundance 
(%) 
Positron Emission Tomography (PET) imaging 
C6
11  20.4 min 𝛽+ (100) 0.511 
(annihilation) 
200 
N7
13  10 min 𝛽+ (100) 0.511 
(annihilation) 
200 
O8
15  2 min 𝛽+ (100) 0.511 
(annihilation) 
200 
F9
18  110 min 𝛽+ (97) 
EC (3) 
0.511 
(annihilation) 
194 
Ga31
68  68 min 𝛽+ (89) 
EC (11) 
0.511 
(annihilation) 
178 
Single Photon Emission Computed Tomography (SPECT) imaging 
Ga31
67  78 hr EC (100) 0.093 
0.184 
0.300 
0.393 
40 
20 
17 
5 
𝑆𝑒34
75  119.78 days EC 0.136 
0.265 
59.2 
59.8 
Mo42
99  66 hr 𝛽− (100) 0.181 6 
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Nuclide Physical half-
life 
Mode of 
decay (%) 
-ray energy* 
(MeV) 
-ray abundance 
(%) 
0.740 
0.780 
12 
4 
Tc43
99𝑚  6.0 hr IT (100) 0.140 90 
In49
111  2.8 days EC (100) 0.171 
0.245 
90 
94 
I53
123  13.2 hr EC (100) 0.159 83 
Tl81
201  73 hr EC (100) 0.167 
X-ray  
(0.069-0.083) 
9.4 
93 
Therapeutic 
P15
32  14.3 day 𝛽− (100) - - 
𝑌39
90  64.1 hr 𝛽−  - - 
I53
131  8.0 days 𝛽− (100) 0.284 
0.364 
0.637 
6 
81 
7 
𝐿𝑢71
177  6.73 days 𝛽−  0.208 11 
𝑅𝑎88
223  11.44 days α 0.154 5.6 
Note: 
*-rays with abundance less than 4% have not been cited.  
d, deuteron; EC, electron capture; f, fission; IT, isomeric  transition; n, neutron; p, proton; min, minutes; hr, hours.  
Data from Browne E, Finestone RB. Table of Radioactive Isotopes. New York: Wiley; 1986 and [8]. 
 
 Radiopharmaceuticals 
A radiopharmaceutical is a specific radiotracer in which the radionuclide is labelled to 
a molecule that has useful biomedical properties for diagnostic or therapeutic purposes. 
The biochemical and physiological behaviour can be traced, either in vitro or in vivo, 
following the administration of the radiopharmaceutical, subsequently resulting in 
diagnostic information or a therapeutic effect. The administration technique is usually 
either orally or intravenously in a single dose. These radiolabelled molecules are unique 
and easily detected, there are no differences in physical and chemical properties to the 
unlabelled molecules however the label between radionuclide and molecule must be 
firmly bounded [9]. In addition, the following factors should be considered when 
selecting a biochemical compound as a radiopharmaceutical: 
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a) non-toxic nature 
b) the mechanism of localisation in the desired organ or compartment 
c) the specific activity of chemical compound 
d) the radiochemical purity 
e) the biological half-life 
   
The synthesis of radiopharmaceuticals involves the handling of radioactive substances 
and chemical processing in designated radiopharmaceutical production facilities. It 
ranges from simple preparation using radiopharmaceutical kits to complex synthesis 
process carried out in a purpose-built hot cell. Dispensing and supply of radionuclide 
at a hospital facility is usually carried out using a radionuclide generator, for example 
99Mo/99mTc generator. The elution process of this generator is based on the separation 
of a short lived daughter radionuclide (99mTc) from a long parent lived radionuclide 
(99Mo). The production methods of these radiopharmaceuticals are required to adhere 
to regulatory compliance as required by national authorities such as US Food and Drug 
Administration (FDA) and UK Medicines and Healthcare products Regulatory Agency 
(MHRA) and are subject to strict quality control tests. Table 1.2 summarises commonly 
used radiopharmaceuticals in nuclear medicine procedures, in particular SPECT 
imaging.  
 
Table 1.2: Commonly used radiopharmaceuticals in SPECT imaging.  
Chemical form Clinical Use 
99mTc-nanocolloid human serum albumin Lymphatic imaging 
99mTc-Mercaptoacetyltriglycine Renography 
99mTc-Macroaggregated Albumin 
(MAA) 
Pulmonary blood flow (lung scan) 
99mTc-Diethylene Triamino Penta Acetic 
Acid (DTPA) 
Renal blood flow, function and 
excretion (Renogram) 
99mTc-Methylene DiPhosphonate (MDP) Skeletal studies (bone scan) 
99mTc-Sodium Pertechnetate Thyroid, salivary gland, brain and 
nasolacrimal drainage imaging 
99mTc-Red Blood Cells Cardiac function and blood pool scans 
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Chemical form Clinical Use 
99mTc-Sestamibi 
99mTc-Tetrofosmin 
Myocardial perfusion   
Myocardial perfusion 
99mTc-Hexa Methylene Propylene Amine 
Oxime (HMPAO) 
Cerebral blood flow and scans for 
infection 
123I-Ioflupane  Parkinson’s disease/Dopamine 
transporter imaging  
123I-Sodium Iodide Thyroid scan 
111In-pentetreotide Somatostatin receptor scintigraphy 
 
 Gamma Camera 
The initial focus of nuclear medicine studies was related to the measurement of thyroid 
function. A Geiger counter was placed over the patient’s neck to detect the gamma rays 
emitted from the thyroid after the administration of 131I [10]. The ratio between the 
detected count rates measured at neck and a known standard determined the percentage 
of thyroid uptake, and provided an indication of whether thyroid uptake was normal or 
abnormal. The disadvantages of this technology were that it did not outline which parts 
of thyroid were abnormal and it deposited a high radiation dose to the patient.  
 
In 1951, Cassen et al. [11] from the University of California, Los Angeles developed a 
moving collimated scintillation detector, called a rectilinear scanner as shown in Figure 
1.3(a). The automated detector was moved backwards and forwards in a series of 
parallel lines across patient’s neck while another part of the system held a pen which 
moved synchronously over a sheet of paper producing black marks and later used a 
colour display to plot the distribution in proportion to the intensity of gamma rays 
detected.  
 
The concept of the gamma camera was invented by Hal Anger in 1952 whilst working 
at the Donner Laboratory, the University of California in Berkeley, USA.  The early 
prototype consisted of a pinhole collimator and a sodium iodide flat intensifying screen 
placed in front of a photographic plate which was able to produce a clinical relevant 
image showing gamma-ray distributions emitted from the patient (Figure 1.3 (b)). The 
sensitivity of the camera was low resulting in long imaging times and requiring 
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relatively high amounts of radioactivity to be administered to the study subject to 
produce images.  
 
Anger enhanced the prototype design by replacing the gamma ray detector with a 4-
inch diameter scintillator coupled to an array of seven photomultiplier tubes (PMTs) 
and applied ‘Anger arithmetic’ to determine the position of the scintillation event that 
occurred in the crystal by comparing the voltages collected in individual PMTs. 
Typically, a gamma camera consists of a collimator, scintillation detector, PMTs, pulse 
height analyser, X-Y positioning circuits and an image display with an image recording 
or storage device.  
 
 
Figure 1.3: The evolution of gamma camera technologies from early (a) rectilinear scanner "Picker 
Magna Scanner" [12], (b) Anger camera [12], single-head LFOV gamma camera [13] to state-of-art 
SPECT-CT imaging system [3].  
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When a radiation source is placed nearby the camera system, the incoming gamma rays 
will pass through the collimator and interact with the detector. The detector, usually 
made of a scintillation crystal (such as NaI(Tl)), converts the energy from the gamma 
ray to a flash of light. The light photons are detected by an array of PMTs adjacent to 
the detector and the events are computed and mapped out as the gamma image display. 
In modern gamma camera systems, advanced digital electronics and software are used 
to process the image data obtained from the PMT units.  
 
 Detector head 
The functions of the detector head are to detect gamma rays and produce analysable 
electrical signals that represent the incident radiation events. The head is covered by 
lead shielding around the back and sides to prevent gamma rays from entering from 
these directions. A collimator is fitted at the front of the detector to allow incoming 
gamma photons travelling in the desired directions to pass through and reach the 
detector.  Figure 1.4 shows the schematic diagram of a detector head of gamma camera.  
 
 
Figure 1.4: Components in the detector head of a gamma camera taken from [12]. 
 
 Collimator  
Collimators are made of lead or other materials with high atomic number that can 
absorb gamma radiation. They have holes to allow gamma rays travelling along the 
direction of holes to reach the detector crystal. Photons emitted in any other direction 
are absorbed by the septa between the holes. Figure 1.5 shows different types of 
collimator that may be used to project incident gamma rays onto the detector of a 
gamma camera.  
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Figure 1.5: Four types of collimator used in gamma camera system. O, radioactive object; I, projected 
image. Image taken from [14]. 
 
1.2.1.1.1 Parallel hole collimators 
Parallel-hole collimators are the most commonly used collimator on modern gamma 
cameras. They are constructed with holes that are parallel to each other and 
perpendicular to the detector face. The lead walls between the holes are called 
collimator septa, with thicker walls for higher energy radionuclides. Parallel-hole 
collimators are categorised based on the energy of radionuclide used and the resolution 
and sensitivity they provide in imaging as following: 
a) Low energy general purpose collimator (LEGP) 
b) Low energy high resolution collimator (LEHR) 
c) Low energy high sensitivity collimator (LEHS) 
d) Medium energy collimator 
e) Ultra-high energy collimator 
 
1.2.1.1.2 Pinhole collimator 
A pinhole collimator has a single and small pinhole aperture, usually 2-4 mm in 
diameter. It is constructed using lead, tungsten or platinum. The size of aperture 
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determines both the spatial resolution and the sensitivity; a smaller aperture giving 
increased spatial resolution and decreased sensitivity and vice versa for a larger 
aperture. During image acquisition, gamma rays passing through the pinhole aperture, 
project an inverted image of the original sources onto the crystal. The image is 
magnified when the distance b from the source to the pinhole is smaller than the 
collimator cone length f; while it is minified if the sources are further away (refer Figure 
1.5(a). The relationship between image size I and object size O is given by Equation 
1.10. 
 
 I
O
=
f
b
 1.10 
 
The size of the imaged area may vary with distance from the pinhole collimator. The 
diameter of the image area projected onto the detector, D’ can be determined by 
 
 
D'=
D
I
O⁄
 
1.11 
 
where D is detector diameter and I/O is the magnification factor.  
  
1.2.1.1.3 Converging and diverging collimators 
Converging collimators are designed with tapered holes converging towards object 
direction. It is used to magnify the image where the organ of interest is smaller than the 
size of detector. Diverging collimators are made with tapered holes that are divergent 
from the crystal site. It demagnifies images of objects which are larger than the size of 
the detector.   
 
 Scintillation crystal detector 
Scintillation detector technologies have been widely used as gamma-ray converters in 
medical imaging. Most gamma cameras have traditionally utilised inorganic 
scintillation crystals such as thallium doped sodium iodide (NaI(Tl)) or thallium doped 
cesium iodide CsI(Tl) with typical thickness of 6.4 - 18.4 mm as the gamma detector. 
Table 1.3 summarises various inorganic scintillation crystal used in gamma camera and 
PET camera systems. This material emits scintillation photons following the absorption 
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of the energy deposited by the incident gamma photons that are detected by an 
electronic light sensor such as photomultiplier tube. Impurities (known as activators) 
are added to the pure crystal to modify the energy structure so that multiple energy 
states are created between the conduction and valence bands. These energy states have 
narrower energy gaps resulting in a lower energy of the emitted photons, usually in the 
visible range and prevents self-absorption.  
 
Table 1.3: Properties of various inorganic scintillation crystal used in gamma camera [15-17]. 
Scintillator NaI(Tl) CsI(Tl) LaCl3(Ce) LaBr3(Ce) YAlO3(Ce) 
Density (g cm-3) 3.67 4.51 3.86 5.30 5.50 
Effective atomic 
number (Z) 
50 54 - - 39 
Linear attenuation 
coefficient at 140 
keV (cm-1) 
3.12 4.53 2.82 3.42 1.81 
Peak emission 
wavelength (nm) 
415 550 330 358 350 
Decay time (ns) 230 1000 20 (70%), 
231 (30%) 
35 (90%) 30 
Light yield 
(photons/keV) 
38 54 49 61 21 
 
Figure 1.6 illustrates the energy band structure of an inorganic scintillator. During the 
interaction of the incident gamma photons with the scintillator, many electron-hole 
pairs are created. The positive holes move to a location with lower ionisation energy, 
usually the activator, and subsequently ionise it. The excited electrons elevate to the 
conduction band and move freely through the crystal until they encounter an ionised 
site. The recombination of the excited electron and the ionised site makes the 
configuration unstable (activator excited states), then the de-excitation process occurs 
with the emission of scintillation photons [18].   
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Figure 1.6: Energy band structure of an inorganic scintillation crystal. 
 
The main characteristics of a scintillator are the intrinsic detection efficiency, the light 
conversion efficiency and the phosphorescent decay time. The intrinsic detection 
efficiency depends on the linear attenuation coefficient of the scintillator which could 
determine the optimum thickness of the crystal in stopping incoming gamma photon. 
Light conversion efficiency is the amount of light produced per keV of absorbed 
photon. Phosphorescent decay time is the time required for the light to be emitted. Each 
parameter partly determines the energy resolution and the maximum counting rate of 
the detector respectively. 
 
 Photomultiplier tube 
The scintillation photons emitted are sparse and weak for image formation, so they must 
be amplified. Amplification is achieved using the photomultiplier tubes (PMT) attached 
to the back of the crystal. A PMT consists of a vacuum glass tube with a photocathode 
at the front which converts light photons into electrons and a series of electrodes known 
as dynodes that amplify the number of electrons produced for each incident event. A 
gamma camera can have a number of tubes in its array, typically 30 – 100 in most 
modern cameras. These are closely packed for example in a hexagonal pattern to ensure 
minimum gaps are left between the tubes. The base of each PMT is connected to a pre-
amplifier circuit. The amplified output from the PMT is passed to the position logistic 
circuits, where signals detected are recorded and processed. This information is then 
output to a computer system where the data is analysed. 
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 Solid State Detector 
In recent years, there has been an increased use of semiconductor detectors in gamma 
cameras. The most commonly used semiconductor detector materials for this 
application are cadmium telluride (CdTe) or cadmium zinc telluride (CdZnTe or CZT). 
Table 1.4 summarises various semiconductor detector used in gamma camera systems. 
When a gamma ray interacts with a semiconductor detector, it is converted to an 
electronic signal within a single process. Semiconductor detectors are normally poor 
electrical conductors. However, an incident photon will produce ionisation in the 
depletion region, where it enables excited electrons flow freely. The electrical charge 
produced can be collected by an external applied voltage. The size of the electrical 
signal is proportional to the amount of radiation energy absorbed.  
  
Table 1.4: Properties of semiconductor detectors used in gamma camera [15, 16]. 
Detector Si CdTe CZT HgI2 
Density (g cm-3) 2.33 5.85 5.82 6.40 
Effective atomic number (Z) 14 48-52 30-52 53-80 
Linear attenuation coefficient at 140 keV (cm-1) 0.02 3.22 3.07 8.03 
Average energy per electron-hole pair (eV) 3.61 4.43 ~5 4.20 
Electron mobility (cm2/V.s) 1500 1000 1350  100 
Hole mobility (cm2/V.s) 600 80 120 4 
Note: Si-Silicon; HgI2-mercuric iodide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Schematic diagram of a CZT semiconductor detector (Vb: bias voltage, T: material thickness, A: anode, 
P: pixel size).  
    
 Pulse height analyser 
The pulse height analyser (PHA) analyses the amplitude of the output pulse from the 
amplifier and determines the energies of detector photon events. The feature selects 
Cathode Anode 
Vb 
A 
P 
Electrons 
Holes 
Incident 
photons 
T 
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only those photons of desired energy range to be counted by the use of appropriate peak 
and window settings.  
 
 Positioning Circuit 
The X-Y positioning circuit uses a ‘voltage divider’ to weight the output of each tube 
corresponding to the X, Y location of the point of interaction of the gamma rays on the 
crystal [19]. All PMTs are connected through capacitors to four directional terminals: 
X+, X-, Y+ and Y-. A resistive or capacitive network assigns relative values 
proportionally to the four signals obtained from the PMTs registering the event. 
 
 Gantry 
The purpose of the gantry is to hold the detector head firmly and allow it to be 
positioned near to patient during image acquisition. The gantry is designed to support 
the heavily mounted detector head whilst providing motorised features for gantry 
movement and positioning. For modern gamma cameras, ring-style gantries are more 
common. All the motions of gantry are motorised and controlled by the operator or set 
for scanning procedures by computer.        
 
 SPECT and other hybrid modalities   
The introduction of scanning gamma camera technology has formed the basis of Single 
Photon Emission Computed Tomography (SPECT), an emission tomographic imaging 
technique which utilises a single or multiple-headed gamma camera mounted on a 
mechanical rotating gantry as shown in Figure 1.3 (c). These camera detectors can 
rotate around the patient detecting gamma events and producing a cross sectional 
tomographic image using reconstruction software (in the same way as X-ray computed 
tomography (CT) image formation) or a whole body image as shown in Figure 1.8 (a). 
In 1963, Kuhl and Edwards [20] has demonstrated the early concept of SPECT. Early 
attempts in producing 3-D images on a conventional gamma camera was achieved by 
rotating the patient in front of a stationary camera. Over the decades, SPECT 
technologies have expanded to become reliable, robust and widely accepted nuclear 
imaging procedures. The same cameras can scan over the patient to produce a whole 
body image or can be controlled as organ-specific SPECT systems for abdominal, brain, 
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cardiac or breast imaging. These techniques allow the three-dimensional (3-D) 
visualisation of radiotracer distributions in the body.  
 
 
 
 
 
Figure 1.8: Example of (a) whole body bone scintigraphy (anterior and posterior views; images taken from [4]) and 
3-D SPECT images.  ((b) Myocardial perfusion study (short axis, horizontal and vertical long axis views) showing 
the radiotracer distribution in the different regions of the myocardium ( images taken from [3]); (c) Transverse slices 
of the reconstructed brain SPECT image of 123I-Ioflupane (DaTscanTM)).  
 
More recently, the fusion of dual modalities into a single multimodality imaging device 
has resulted in the creation of Single Photon Emission Computed Tomography-
Computed Tomography (SPECT-CT) camera systems. In 1990 Hasegawa et al. [21] 
reported the simultaneous transmission-emission imaging which formed the basis of 
SPECT-CT development. The first commercial SPECT-CT was introduced in 1999, a 
year earlier than the official launch of Positron Emission Tomography-Computed 
Tomography (PET-CT).  
 
These hybrid imaging modalities offer the fusion of gamma and CT images to enable 
the overlay of physiological tracer uptake with the cross sectional anatomical detail. 
The CT information also aids in attenuation correction and organ localisation, as well 
as providing diagnostic quality CT images. Figure 1.9 shows an example of fused 
SPECT-CT images in a patient with an ectopic parathyroid adenoma. The tremendous 
success of these hybrid cameras, led to the integration of the magnetic resonance (MR) 
scanner with either the PET or SPECT camera, allowing the fusion of nuclear images 
with MR images having superior soft tissue contrast when compared with CT [22].  
a b 
c 
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Figure 1.9: Example SPECT-CT images in a patient with an ectopic parathyroid adenoma in the upper 
mediastinum, right paratracheal region (as indicated by the centre of the red-cross). The fused anatomical 
and physiological details provides valuable information to aid surgical procedures [23].  
    
 Bedside imaging 
Most nuclear medicine procedures are carried out in the nuclear medicine department 
since gamma cameras are large bulky devices, installed in purpose built rooms. This 
requires the patient to attend the department in order to undergo the imaging 
investigation. As a consequence, this restricts the type of patient who can access the 
services and patients from the operating theatre, intensive care unit and accident and 
emergency department cannot always attend. The use of mobile or portable gamma 
cameras enables bedside investigations which may be of value in those hospital 
departments.  
 
The application of nuclear medicine techniques outside of the department has a long 
history. The concept of radioguided surgery using a gamma probe, which was reported 
approximately 60 years ago [24], enabled the intraoperative detection of radionuclide 
in the operating theatre. Selverstone et al. [24] at Harvard Medical School reported on 
the use of a Geiger Müller tube device to detect the beta radiation emitter, phosphorus-
32 in patients with brain tumours. The counts in the area of suspected tumour and 
normal brain tissue were detected by the device at various time intervals and various 
depths beneath the cerebral cortex to demarcate the boundary of tumour margins.  
 
Perkins et al. [25, 26] described a range of bedside nuclear medicine investigations 
employing gamma probes in the intensive care unit and operating theatre. These 
developments originated from the use of gamma probes for the detection of the uptake 
of 99mTc bone scanning agents, in particular osteoid osteoma, a benign condition that 
predominantly occurs in young children and adolescents. In addition, the increasing use 
of gamma probes in sentinel lymph node biopsy procedures in the staging and 
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management of breast cancer drove the evolution of gamma probe technology and the 
widespread acceptance of nuclear medicine procedures during surgery. Since then, the 
evolution of gamma detection probe technology in intraoperative procedures has 
immensely developed and has become an established discipline within the practice of 
surgery.  
   
The development of small field of view (SFOV) gamma cameras offers the capability 
of intraoperative imaging during surgical procedures. For use in the operating theatre, 
gamma cameras must be compact enough to be handheld by the surgeon or other theatre 
staff. As indicated by the name, SFOV gamma cameras are considerably smaller in 
comparison with conventional large field of view (LFOV) gamma cameras. Advances 
in low profile detector technologies have enabled the introduction of smaller imaging 
systems with the cameras held on an articulated arm mounted on a small trolley or 
handheld by the operator during use. 
 
 Mobile Gamma Cameras 
Small single-headed cameras mounted on a mechanical trolley have been available over 
the past 20 years. These cameras enabled a range of clinically important imaging 
investigations to be undertaken whilst the patient is lying on a standard bed outside of 
nuclear medicine department. In 1973, Hurwitz et al. [27] reported preliminary 
experience with a “portable” scintillation camera in the operating room or other 
locations previously believed to be inaccessible for diagnostic nuclear medicine.  The 
camera was a modified standard Anger scintillation camera with a 0.5-inch NaI(Tl) 
crystal of 12 inches in diameter, mounted on a movable stand.  
 
Figure 1.10 shows a mobile digital gamma camera from Digirad Corporation (San 
Diego, CA, USA) which is currently available. This system has a field of view 
measuring 311 mm × 396 mm produced by a solid-state segmented CsI(Tl) crystal 
detector with a silicon photodiode and is suitable for detecting gamma energies between 
50 keV and 350 keV with the aid of the interchangeable collimators. The camera can 
be manoeuvred manually despite having a weight of 305 kg.  
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Figure 1.10: A solid-state mobile gamma camera-Digirad ergo™ Imaging System by Digirad (Taken 
from [28]). 
 
Figure 1.11 shows another example of commercially available mobile gamma camera 
produced by Mediso Medical Imaging (Budapest, Hungary), namely NuclineTM TH. 
The camera detector comprises an NaI(Tl) scintillation crystal with a thickness of 
6.5 mm backed by PMTs. The detector head is available in sizes of 230 mm × 210 mm, 
260 mm × 246 mm and 300 mm × 300 mm. The system weighs 180 kg and the gantry 
is equipped with motorised height adjustment and interchangeable collimators. A 
separate computer console is used for image acquisition.   
 
 
Figure 1.11: A mobile gamma camera-Mediso ‘NuclineTM TH’ (Taken from [13]). 
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Another example of an organ-specific gamma camera is called the CardiotomTM system 
[29]. This gamma camera system combines a commercially available detector system 
attached with a rotatable parallel and slanted-hole collimator (ectomography) to 
produce tomographic images. The camera weighs 320 kg and is primarily designed for 
cardiac studies at the patient bedside. Table 1.5 provides summary of mobile gamma 
cameras available at the time of writing.  
 
Table 1.5: Examples of clinical mobile gamma camera systems. 
Camera Detector Nominal 
FOV 
(mm) 
Weight 
(kg) 
Applications 
NuclineTM TH 
(Mediso)  
NaI(Tl), 
PMT 
260 × 246 180 Cardiac, thyroid imaging 
[13] 
ergo™ Imaging 
System 
(Digirad)  
CsI(Tl), 
silicon 
photodiode 
311 ×  396 305 Cardiac, breast, and other 
bedside imaging [28] 
2020tc imager 
(Digirad)   
CsI(Tl), 
silicon 
photodiode 
212 ×  212 386 Lung, thyroid, cardiac, 
mammoscintigraphy, 
bedside imaging [30] 
CardiotomTM 
(Adolesco)  
NaI(Tl), 
PMT (Sopha 
DS7) 
Ø 400  320 Cardiac imaging [29] 
Picola − 
Scintron®  
NaI(Tl), 
PMT 
Ø 254 NA Thyroid imaging [31] 
Solo Mobile™ 
(DDD-
Diagnostic A/S) 
NaI, PMT Ø 210 < 270 Thyroid, parathyroid, 
cardiac, sentinel node 
imaging [32] 
Ø denotes diameter of circular FOV.   
 
 Handheld Gamma Cameras 
More recent technological advancement in gamma camera detector design has led to 
the innovation of portable compact SFOV gamma cameras. Possibly the earliest 
concept of the handheld gamma imaging system was introduced by Barber et al. [33], 
in which prototype devices were small enough to be inserted into the upper or lower 
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gastrointestinal tract to image the distribution of tumour-seeking radiotracers. The 
design provided flexibility for handheld use in additional areas of clinical investigation 
when compared to a mobile gamma camera. These cameras were not intended to 
replace the standard LFOV gamma cameras, but have been used for additional clinical 
applications, in particular for intraoperative imaging. This has resulted in a number of 
vibrant research initiatives worldwide for exploring the development of robust, user-
friendly and ergonomical SFOV gamma camera systems [34-37]. 
 
Similar to standard gamma cameras, the main features of compact imaging devices are 
the imaging detector, collimator, shielding, electronic readout circuitry and image 
acquisition and image processing software. The size and weight of the camera head 
represents the most important characteristic of an SFOV camera in terms of ease of use 
and manoeuvrability near the patient. From the literature it can be seen that the weight 
of SFOV gamma camera heads used for clinical application has been between 320 g 
[38] and 2490 g [39] while the detector size varied from 8.192 mm × 8.192 mm [40] up 
to 127 mm × 127 mm [41]. Based on the literature review, there are five commercially 
available SFOV gamma cameras whilst at least 10 prototype cameras are still at an 
experimental stage. Table 1.6 summarises the characteristics of SFOV gamma cameras 
that are currently in development, or in clinical use. 
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Table 1.6: Characteristics of SFOV imaging systems. 
Note: NA-information not available; L-length; PA-parallel hole; *-without collimator; Ø-diameter of circular FOV; †-commercially available; IPSD- intensified position-sensitive diode; 
MAPMT-multi-anode photomultiplier tube; PSPMT-position-sensitive photomultiplier tube. 
 
 
 
Camera Detector Detector head Collimator Energy range (keV) 
/radionuclide 
detected 
Clinical application & reference 
Type/material Size 
(FOV) 
(xyz) 
(mm) 
Matrix 
size 
Size 
(mm) 
Weight 
(g) 
Type Material 
IOGC  Hg12, electrodes 23.75 × 
23.75 × 1 
16 × 16 43 × 45  NA PA Tungsten  99mTc, 57Co, 241Am NA  [42] 
HGC  CsI(Tl), 
EMCCD 
8.192 × 
8.192 × 
1.5 
128 × 
128 
Ø 115 × 
171 (L) 
1500 Pinhole Tungsten 30 – 245 Bone imaging, lacrimal drainage scan, 
thyroid imaging, lymphatic scan [43-45] 
POCI 2  CsI(Na), IPSD Ø 40 × 3 50 × 50 Ø 95 × 
90 
1200 PA lead 99mTc, 57Co SLN detection with breast cancer [46, 47]  
TreCam  LaBr3:Ce, 
MAPMT 
49 × 49 × 5 16 × 16 NA 2200 PA lead 99mTc, 57Co SNOLL [48-50] 
Mediprobe  CdTe:Cl 14.08 × 
14. 08 × 1 
256 × 
256 
200 × 
70 × 30 
1500* Pinhole Tungsten 99mTc, 57Co SLN detection with melanoma cancer [51]  
eZ Scope †  CZT 32 × 32 × 5 16 × 16 74 × 72 
× 210 
820 PA NA 71 - 364 Intraoperative imaging for primary 
hyperparathyroidism [52, 53]  
MGC500  CdTe 44.8 × 
44.8 
32 × 32 82 × 86 
× 205 
1400* PA Tungsten 550 keV  Lymphoscintigraphy with oral cancer [54-
56]  
IHGC  NaI(Tl), 
PSPMT 
50 × 50 × 6  
 
29 × 29 64 × 64 
× 76 
1100 PA lead 30-300 SLN detection with breast or melanoma 
cancer [57, 58]  
IP †  CsI(Tl), PSPMT 44.1 × 
44.1 × 5  
18 × 18 NA 1200 PA tungsten 50-250 SLN detection with breast cancer [59-61]  
GE  CZT 40 × 40 16 × 16 150 (L) 1200 PA NA 40 - 200 NA [62] 
Sentinella 
102 †   
CsI(Na), 
PSPMT 
40 × 40 300 × 
300 
80 × 90 
× 1500 
1000* Pinhole lead 50 - 200 SLN detection with breast, penile, prostate 
cancer,  intraoperative imaging for primary 
hyperparathyroidism [63-68]  
GCOI  CsI(Tl), PSPMT 38.4 × 
38.4 × 4 
24 × 24 NA NA PA NA 60 - 300 NA [69] 
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Table 1.6: Characteristics of SFOV imaging systems (cont’d). 
Note: NA-information not available; L-length; PA-parallel hole; *-without collimator; Ø-diameter of circular FOV; †-commercially available; IPSD- intensified position-sensitive diode; 
MAPMT-multi-anode photomultiplier tube; PSPMT-position-sensitive photomultiplier tube; SiPM-silicon photomultiplier. 
 
Camera 
Detector Detector head Collimator Energy range 
(keV) 
/radionuclide 
detected 
Clinical application & reference 
Type/ 
material 
Size (FOV) 
(xyz) (mm) 
Matrix 
size 
Size 
(mm) 
Weight 
(g) 
Type Material 
CrystalCam 
†  
CZT 40 × 40 16 × 16 65 × 65 × 
180 
800 PA Tungsten 30-250 SLN detection with breast and melanoma 
cancer [34, 70-72]  
Minicam 2 †   CdTe 40 × 40 16 × 16 250 × 70 
× 170 
700 PA Tantalum 30-200 SLN localisation [73]  
MRG15  CsI(Tl), SiPM 13.2 × 13.2 × 
5 
4 × 4 114 × 32 
× 26 
320 PA  NA 99mTc, 57Co NA [38]  
CarollRes  GSO:Ce, 
MAPMT 
50 × 50 8 × 8 78 × 78 × 
275 
2490 PA  Lead 99mTc, 57Co SLN detection with breast cancer [39, 74]  
Medica 
GammaCA
M/OR  
NaI(Tl), 
PSPMT   
127 × 127 × 
6 
56 × 56 NA NA PA NA 99mTc SLN detection with breast cancer [41, 75]  
DEPICT CZT 44 × 44 × 5 22 × 22 216 × 
200 × 93 
NA PA  Lead/ 
Tungsten 
30 – 3000 dosimetry of molecular radiotherapy [76, 77] 
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 Camera Detectors 
One of the main factors that made the innovation of a miniature-size SFOV gamma 
camera possible was the availability of suitable compact detectors. Based on the reports 
published since 1997, most SFOV gamma cameras have used either scintillation 
crystals [43, 50, 64, 78-81] or semiconductor [51, 52, 56, 62, 71, 73, 77, 82] detectors. 
The most commonly used scintillation crystals are thallium or sodium-doped cesium 
iodide (CsI(Tl) and CsI(Na)), NaI(Tl) and cerium-doped lutetium oxyorthosilicate 
(LSO). The semiconductor detector materials used in SFOV gamma cameras are either 
cadmium telluride (CdTe) or cadmium zinc telluride (CdZnTe or CZT).  
 
During earlier development, Patt et al. [42] developed a 256-element mercuric iodide 
(HgI2) detector array which was intended to be used as an intraoperative gamma 
camera. A novel SFOV gamma camera based on yttrium aluminium perovskite 
activated by cerium (YAP:Ce) coupled with intensified position-sensitive diode (IPSD) 
[83] has also been developed. A few years later, the compact position-sensitive 
photomultiplier tube (PSPMT) was recognised as a key development in small camera 
design and these have been used in cameras with CsI(Tl) [78, 79], NaI(Tl) [75, 80], 
cerium doped orthosilicate of gadolinium (Gd2SiO5:Ce or GSO) [81] and cerium-doped 
halide (LaBr3:Ce) scintillators [50]. Lees, et al. have developed a high resolution SFOV 
gamma camera using a columnar CsI(Tl) coupled to electron multiplying charge 
coupled device (EMCCD) [84, 85] which is described in more detail in Chapter 2. 
Figure 1.12 shows an example of the SFOV gamma camera, IP Guardian 2 with 
detector consisting of CsI(Tl) scintillator coupled to PSPMT.  
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Figure 1.12: Example of SFOV gamma camera with CsI(Tl) scintillation detector coupled to PSPMT (IP 
Guardian2, Li-Tech, Roma, Italy). Photograph courtesy of Domenico Rubello, MD, Rovigo, Italy.   
 
As for semiconductor-based gamma cameras, several camera systems have been 
produced using CdTe [51, 56, 73, 79] or CZT [52, 62, 71]. Figure 1.13 shows an 
example of compact gamma camera equipped with CZT semiconductor detector, the 
CrystalCam (Crystal Photonics GmbH, Berlin, Germany). This system is designed to 
be an “imaging gamma probe” and has a range of tungsten collimators for use with 
different energy radionuclides.  
 
Figure 1.13: CrystalCam imaging probe with a semiconductor detector. Image courtesy of Thomas 
Barthel, Crystal Photonics GmbH, Berlin, Germany.  
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 Camera Collimators 
The most common types of collimator used in SFOV gamma camera are either pinhole 
[36, 43, 51, 86, 87] or parallel-hole [46, 50, 52, 56, 62, 71, 73, 77-79, 81, 88, 89]. These 
have been constructed from dense metal radiation absorbers, namely lead or tungsten. 
A range of pinhole collimators with different aperture sizes have been used. These 
range between 0.5 mm and 4 mm, which providing different choices for various clinical 
applications. On the other hand, parallel-hole collimators have been fabricated with 
parallel holes, either in square or hexagonal shape. These include low energy high 
sensitivity (LEHS), low energy high resolution (LEHR) and low energy general 
purpose (LEGP) collimators.   
 
Figure 1.14 (left) shows an example of an SFOV gamma camera with a pinhole 
collimator, Sentinella 102 (Oncovision, Valencia, Spain). The camera consists of an 
interchangeable pinhole collimator and a single CsI(Na) crystal backed by a position 
sensitive photomultiplier tube. Figure 1.14 (right) gives another example of an SFOV 
gamma camera with parallel-hole collimator, namely Mini Gamma Camera 500 
(MGC500) (Acrorad Co. Ltd, Okinawa, Japan). The parallel-hole collimator is a 
combination of 100 pieces of tungsten mesh sheets with the thickness of 0.1 mm 
respectively. Each sheet having square openings measuring 1.2 mm × 1.2 mm with 
0.2 mm pitch. 
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Figure 1.14: SFOV gamma camera mounted on an articulated arm and cart based system (left) with 
pinhole collimator, Sentinella 102 (image courtesy of Victoria García, OncoVision, Spain) and (right) 
MGC 500 with parallel-hole collimator (Taken from [54]).  
 
 Aims of the thesis 
The previous sections have provided an introduction to the gamma camera and nuclear 
medicine techniques. The work of this thesis was carried out between 2014 and 2017 
to investigate the clinical use of a newly developed prototype SFOV Hybrid Gamma 
Camera (HGC) and its pre-production prototype device (Nebuleye). 
 
This thesis aims to translate the HGC technology from in vitro laboratory studies to 
clinical use in human subjects. In order to achieve the aims, the following objectives 
needed to be addressed: 
a) to characterise the pre-production SFOV hybrid optical-gamma camera; 
b) to assess the performance of the SFOV hybrid optical-gamma cameras in 
clinical settings; 
c) to assess the application of the SFOV hybrid optical-gamma cameras in 
preclinical imaging; 
d) to characterise and gain knowledge of the pre-production camera prior to use in 
the clinic;   
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e) to explore the clinical applications of the HGC. 
 
 Thesis organisation 
  Chapter 2 provides an overview of the design of SFOV gamma cameras, in 
particular the prototype Hybrid Gamma Camera (HGC) and the pre-production 
prototype Nebuleye mini gamma camera. 
  Chapter 3 investigates the characteristics of the pre-production prototype 
Nebuleye mini gamma camera and compares these with HGC. 
  Chapter 4 explores the potential use of the cameras in preclinical imaging. 
  Chapter 5 examines the performance capabilities of the camera for future use 
in breast cancer surgery. 
  Chapter 6 presents the preparatory studies of the pre-production prototype 
Nebuleye mini gamma camera prior to surgical use. 
  Chapter 7 assesses the capabilities of the pre-production prototype Nebuleye 
mini gamma camera. 
  Chapter 8 describes the first use of the HGC in a clinical setting. 
  Chapter 9 provides the conclusions of the current work and suggests future 
research studies. 
 
Throughout this thesis, the term of the SFOV gamma camera was used to indicate either 
HGC, Nebuleye or other portable gamma cameras. The HGC indicates the laboratory 
prototype hybrid optical-gamma camera developed by the Universities of Nottingham 
and Leicester. The Nebuleye indicates the pre-production prototype hybrid optical-
gamma camera fabricated by the industrial partner for commercialisation purposes.  
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The SFOV Hybrid Optical Gamma 
Cameras 
 
 
2.1 Introduction 
Advances in radiation detector technologies have led to a reduction in the size of 
gamma cameras, leading to the production of compact devices. The Space Research 
Centre at the University of Leicester in collaboration with Radiological Sciences at the 
University of Nottingham and Medical Physics at the Nottingham University Hospitals 
NHS Trust have successfully transferred the use of a charge-coupled device (CCD) 
from space research to an imaging system suitable for biomedical applications [84]. 
Further equipment development has resulted in the production of the first laboratory 
prototype of the handheld SFOV Hybrid Gamma Camera (HGC).  
 
The first prototype camera head consisted of a pinhole collimator, photon detector and 
cooling unit contained in a plastic enclosure which was connected to an electronics 
control unit and controlled by a personal computer (PC). The detector was a CsI(Tl) 
columnar scintillation crystal (Hamamatsu Photonics UK Ltd., Welwyn Garden City, 
UK) coupled to a CCD (CCD97 BI, e2v Technologies Ltd., Chelmsford, UK) 
surrounded by 3-mm thick tungsten shielding. A Peltier cooling element and a 
thermoelectric cooler was used to regulate the operating temperature of the CCD.  
 
With the aid of Biomedical Catalyst Funding awarded by Innovate UK, the camera 
design was further developed in partnership with industrial partners, Gamma 
Technologies Limited (Leicester, UK) and Xstrahl Limited (Surrey, UK). This mini 
gamma camera system was known as Nebuleye and was designed as a medical device 
intended for commercialisation. The camera system comprised of a cart with the camera 
head mounted on a positioning arm, two touch screen monitor displays with integrated 
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PC and an electronic control unit. This chapter summarises the evolution of the 
prototype HGC and introduces the newly manufactured Nebuleye as show in Figure 
2.1. The following sections provide detailed descriptions of the HGC used in the 
experimental work.  
 
   
   
Figure 2.1: Evolution of HGC from early laboratory prototype towards medical device standard. 
 
2.2 Early development 
The initial design concept of the handheld gamma camera was pioneered in the Space 
Research Centre, University of Leicester. Lees et al. [84] reported a low cost, 
scintillator-coated, collimated imager, known as High Resolution Gamma Imager 
(HRGI). The device utilised a charge-coupled device CCD38-20 manufactured by e2v 
Technologies (formerly EEV Ltd.) as the photon detector which was originally used for 
dental x-ray imaging. A layer of scintillation crystal gadolinium oxysulfide (Gd2O2S), 
which is also known as Gadox, with various thicknesses ranging from 100 to 500 µm 
was coupled to the CCD and encapsulated within a plastic casing. The CCD detection 
technology had originally been developed for use in X-ray astronomy [90, 91]. It was 
used on XMM-Newton EPIC for high performance x-ray imaging while the scintillator 
materials was utilised on Chandra HRI for improving x-ray detector efficiency. With 
an increase in the scintillator thickness, the detection efficiency of the imager increased 
with a consequent degradation of spatial resolution from 0.44 to 0.60 mm. The first 
image of a 99mTc line source (Figure 2.2) were obtained demonstrating potential use in 
nuclear medicine [84].  
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Figure 2.2: (Left) Image of a 1 mm diameter 99mTc line source with acquisition time of 300 s using HRGI. 
(Right) 241Am slit image with acquisition time of 100 s using modified HRGI. Images taken from [84, 
92]. 
 
Improvements in the performance of the imager were subsequently reported [92] to 
address several shortfalls which were identified in the previous work. The upgraded 
HRGI consisted of CCD55-30 (e2v Technologies, UK) coated with 500 µm-thick 
terbium-doped gadolinium oxysulfide (Gd2O2S(Tb)) scintillator layer [93], parallel 
hole lead collimator and a Peltier cooler (Melcor thermoelectric device) [94] with a 
finned forced-air heat-sink. The detector was packed in a protective plastic box which 
made it easier to use and compact enough to be handheld (Figure 2.3). This version of 
the camera was operated in photon counting mode in order to reduce the multiplicative 
noise associated with the amplification process. The Peltier cooler aided in reducing the 
operating temperature to approximately -5 ºC subsequently enabling a drop of dark 
current to 10 electrons/pixel/second. A dry nitrogen atmosphere was maintained in the 
detector housing to prevent condensation on the CCD.  
 
  
Figure 2.3: (Left) High Resolution Gamma Imager showing water cooling tubing and electronics cables 
(right) high resolution parallel holes collimator (Taken from [92]). 
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2.3 Mini Gamma Ray Camera 
Further development of the camera resulted in the fabrication of a new prototype, called 
the Mini Gamma Ray Camera (MGRC) (Figure 2.4). The design of the gamma camera 
was enhanced to offer high spatial resolution imaging with potential for medical and 
veterinary applications [43]. The gamma ray detector was changed from the Gadox 
scintillator to thallium-doped cesium iodide (CsI(Tl)) (Hamamatsu Photonics UK Ltd., 
Welwyn Garden City, UK). The CCD was an inverted mode, back illuminated electron 
multiplying CCD (EMCCD) (CCD97 BI, e2v Technologies Ltd., Chelmsford, UK) 
[95]. It was coupled to the scintillation crystal with Dow Corning optical grease. The 
same thermoelectric technology used in HRGI was utilised in this camera. The sides 
and back of the detector were surrounded by 4 mm thick lead shielding to minimise 
detection of scattered photons and background radiation. The outer cover of the camera 
was a 10 mm-thick aluminium casing.  
 
This version of the camera design allowed interchangeable collimators, either parallel 
hole as mentioned in Section 2.2 or pinhole.  Two pinhole collimators of 0.5 mm and 
1.0 mm in pinhole diameter with an angular aperture of 60 degrees were fabricated from 
tungsten discs, with dimensions of 6 mm in thickness and 45 mm in diameter. Image 
acquisition was carried out using a bespoke programme (IDL software, Exelis Visual 
Information Solutions, Inc., Boulder, CO, USA).  The design of the MGRC offered 
detection of photons with an energy range between 20 and 140 keV, spatial resolution 
of approximately 1 mm (full width at half maximum (FWHM)) and better detection 
efficiency. Pilot clinical gamma imaging was carried out in Medical Physics at Queen’s 
Medical Centre to study the feasibility of using the MGRC in clinical environment. A 
gamma image of the thumb of a volunteer who was administered with 99mTc-
hydroxymethylene diphosphate (HDP) for a bone scan was reported [43]. 
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Figure 2.4: (Left) MGRC prototype in a box shaped and (right) schematic of the main camera head 
components.  
 
2.4 Compact Gamma Camera 
The box shaped camera head of the MGRC was relatively bulky and difficult to hold 
by the operator during use. In addition, based on the initial assessment of the gamma 
images, it was found that there was high level of noise present in the images which 
degraded the image quality [43]. This may have been due to insufficient shielding 
around the camera head. As a result, further improvements particularly on the cooling 
system and shielding were made in the new version of the camera, which was named 
Compact Gamma Camera (CGC). The heat exchanger was changed to a paraffin based 
phase-change material (PCM) which reduced the CCD temperature to -13°C in a 
cooling process without the need for electrically powered fans. This minimised the risk 
of contamination as the PCM was encapsulated in the camera head allowing heat 
exchanges to take place without the involvement of air flow. Further development of 
the camera was in collaboration with De Montfort University’s Regional Design Unit 
to consider the camera ergonomics and manufacturing design. The camera head was 
designed with a ridged surface to provide good grip for holding during imaging. Figure 
2.5 shows a photograph and schematic of the CGC. A non-toxic plastic enclosure 
provided both thermal and electrical isolation, as well as being easy to clean in case of 
contamination with dirt or biological fluids. The shielding material around the back and 
side of the detector was changed to 3 mm-thick tungsten material having a gamma-ray 
transmission of 1.74 ×10-5 at 140 keV. 
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collimator 
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Figure 2.5: (Left) Photograph and (right) schematic diagram of the CGC with ergonomic casing design.  
 
2.5 Hybrid Gamma Camera  
The combination of dual imaging modalities in medical applications such as Positron 
Emission Tomography (PET) and Single Photon Emission Computed Tomography 
(SPECT) combined with Computed Tomography (CT) has provided considerable 
added value in patient diagnosis and management. These technologies provide both 
functional and anatomical information to clinicians to assist with disease management. 
Inter-modality image fusion has provided registration of functional and anatomical 
details corresponding to the tissue metabolism along with its associated spatial location 
within the anatomical structures. Building on the success of the development work 
between Leicester and Nottingham resulted in the innovation of the Hybrid Gamma 
Camera (HGC) (Figure 2.6) [40, 44]. This was a new concept in portable imaging 
systems, which was not only applicable for medical diagnosis purposes, but also for 
environmental surveying and monitoring and the localisation of radioactive sources 
[96].  
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Figure 2.6 (Left) Photograph of the detector head of the HGC prototype (protective casing removed) with 
the optical camera and mirror fixed on the optical mount. (Right) Diagram of the HGC illustrating the 
transmission of gamma and optical photons from the source to reach the detectors.  
 
A simple modification was made to the CGC (as described in Section 2.4) where a 
mount was designed to hold a small optical camera and mirror. This allowed the gamma 
photons from the source to pass through the mirror and collimator to reach the 
scintillator detector and subsequently to form a gamma image; while the reflection of 
optical photons by the mirror to the optical camera generated an optical image. Both 
gamma and optical cameras were co-aligned in a position that provided fused gamma 
and optical images with corresponding spatial alignment. Figure 2.7 shows a 
photograph and schematic diagram of a HGC.  
 
Both optical and gamma cameras were connected to the readout and control electronic 
systems by a USB cable and D-type cable respectively and were controlled by a 
standard desktop computer or laptop. Further improvement to the HGC involved an 
increase of the thickness of the crystal scintillator, fabrication of an additional 1 mm 
diameter pinhole collimator and incorporation of uEye XS Industrial Camera (IDS 
Imaging Development Systems GmbH, Obersulm, Germany) [97]. The camera head 
weighed approximately 1.2 kg.  
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Figure 2.7: (Left) Photograph of the HGC held on an articulated arm. (Right) Cross-sectional schematic 
diagram of the HGC.  
 
2.5.1 Gamma camera components 
2.5.1.1 Scintillator 
The HGC utilised either a 600 µm or 1500 µm thick columnar scintillator (Hamamatsu 
Photonics UK Ltd., Welwyn Garden City, UK) (Figure 2.8). This detector enabled the 
design of the camera to detect over an energy range between 30 and 140 keV with an 
expected photon absorption ranging from ~38% to 100% [37]. The advantages of the 
CsI(Tl) scintillation detector are high atomic number (54), high density (~4.5 g cm-3) 
and good light yield (54 photons/keV). The maximum wavelength of the photon 
emission is 565 nm which has a good match to the spectral sensitivity of the CCD and 
quantum efficiency of over 90 % at the peak wavelength. The columnar-shaped CsI(Tl) 
(Figure 2.9) enabled the reduction of spread of the light in the scintillator along the 
transmission path to the CCD. The crystal was held in place on the CCD using a flexible 
Kapton window. 
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Figure 2.8: Photograph of the scintillator (red circle) coupled to the CCD. Image courtesy of Space 
Research Centre, University of Leicester.  
 
 
 
 
Figure 2.9: The image of the crystal sample acquired by a scanning electron microscope (SEM) illustrates 
the columnar shape of the material which acts as a light tunnel to guide the scintillation photons to CCD. 
Image courtesy of Space Research Centre, University of Leicester.  
 
2.5.1.2 CCD 
A CCD is an electronic device that converts light into an electric charge and processes 
it into electronic signals. The EMCCD is a frame transfer device which includes an 
imaging and storage section on the CCD chip. Light photons exposed to the image 
section are converted to charge within the integration time to form an image. This image 
is then shifted to the storage section prior to read out register. Next, the individual pixel 
charge is passed to the multiplication register where electron multiplication (avalanche 
multiplication) occurs, then it is presented to the output amplifier for readout.  
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The HGC utilised an EMCCD (CCD97 BI, e2v Technologies Ltd., Chelmsford, UK), 
which was first used by the Space Research Centre in astronomical research (Figure 
2.10). The CCD was a back illuminated sensor in which the light receiving surface 
(silicon) at the front was back-thinned to enhance the amount of light captured, thus 
improving quantum efficiency. The CCD read out was using Correlated Double 
Sampling and had an extra gain register controlled by the application of a high voltage 
clock pulse (40-50 V). It had a noise of 8 electron/pixel/frame (at 293 K and 30 Hz). 
Table 2.1 shows the technical details of the CCD.   
  
 
Figure 2.10: Example of the EMCCD chip utilised in the HGC [95]. 
 
Table 2.1: Characteristic of the CCD97 BI. 
Active image area 8.192 × 8.192 mm 
Image section active pixels 512(horizontal) × 512(vertical) * 
Image pixel size 16 × 16 µm 
Operating temperature (°C) -55 to +60 
*pixels binned to 128 × 128 resulting pixel size of 64 × 64 µm 
 
2.5.1.3 Collimator 
Gamma camera collimators are usually made of dense metal and are attached in front 
of the scintillator detector, allowing the incoming gamma photons to be channelled 
through the collimator hole(s) to reach the crystal detector. The HGC used a pinhole 
collimator (having a hole diameter of either 0.5 mm or 1.0 mm) fabricated by Ultimate 
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Metals Limited (Leighton Buzzard, UK) from tungsten 6 mm in thickness and 45 mm 
in diameter (Figure 2.11). A pinhole collimator was chosen to:  
i. increase the FOV (as the CCD had a small area); 
ii. ease of construction; 
iii. maintain the compactness of the camera. 
 
 
Figure 2.11: Bespoke pinhole collimator for HGC with pinhole diameters of 1 mm (left) or 0.5 mm 
(right). 
 
A 60 degrees acceptance angle was used for each pinhole. This gave a nominal FOV of 
approximately 40 mm × 40 mm at a distance of 25 mm from the camera surface. Figure 
2.12 illustrates the relationship between the source-to-collimator distance (SCD) and 
the field of view (FOV). Based on the detector size and location within the camera head, 
the FOV at certain distances was estimated [14]. The images generated were in a 
square-shape due to the shape of the detector used in this camera.  
 
 
x (mm) 50 100 150 200 250 300 350 
y (mm) 40 80 120 160 200 240 280 
Figure 2.12: Relationship between the SCD (x) and vertical or horizontal size (y) of the FOV. 
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2.5.1.4 Shielding and casing 
Shielding of the gamma camera blocks all unwanted, background or scattered radiation 
that would result in image degradation. The sides and back of the detector in the HGC 
was surrounded by tungsten shielding 3 mm in thickness. The tungsten collimator 
formed the front surface of the camera. In addition, the detector was surrounded by 
4 mm thick aluminium camera housing (except the window which is 1 mm thick) which 
attenuated most of the lower energy photons. Figure 2.13 illustrates the shielding 
components of the HGC.     
 
 
Figure 2.13: Shielding materials surrounded the detector at the tip of the camera head. (Brown: 6 mm 
tungsten; green: 3 mm tungsten; purple: 1 mm tungsten; yellow: 4 mm aluminium except the window to 
the pinhole which was 1 mm thick)  
 
The shielding and the detector head were enclosed in 3-D printed plastic enclosure to 
facilitate both electrical and thermal isolation. The outer surface of the plastic enclosure 
was produced in a fine textured finish to allow sufficient grip for holding, and also easy 
to maintain cleanliness and minimise contamination should the camera come into 
unintentional contact with patients or biological fluids. Customised 3-D printing 
technology was also applied to the fabrication of the protective nose casing (Figure 
2.14) which covered the tip of the camera head. The casing was designed with a 
transparent window principally to allow optical light to pass through while preventing 
contamination to the camera detector.  
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Figure 2.14: Custom made protective casing with the transparent window for HGC. 
 
2.5.1.5 Cooling system 
The number of electrons known as dark noise to be generated was proportional to the 
operating temperature of the CCD, which was regulated by a Peltier cooler. The CCD 
used in this camera was backed with a Peltier cooling package. Thermoelectric coolers 
operate based on the Peltier effect where heat is extracted or absorbed when an electric 
current flows through the junctions of two different materials. The Peltier cooler of the 
CCD was coupled to an organic PCM (PlusICE A-32, PCM Products Limited, Yaxley, 
Cambridgeshire, UK) with paraffin compounds and it was able to reduce the CCD 
operating temperature to -10 °C (measured by Fenwal thermistor part number 196-
302LAD-002 (Honeywell, Mansfield, TX, USA)) [95]. 
 
2.5.2 Optical camera components 
2.5.2.1 Optical camera  
To design the HGC small enough to be handheld, the size and weight of the optical 
camera are major considerations together with the optical camera performance. In the 
HGC, a lightweight, compact, high quality camera, named uEye XS Industrial Camera 
(IDS Imaging Development Systems GmbH, Obersulm, Germany) was used to capture 
the photographic image and video. This camera containing a 5.04 Megapixel 
complementary metal–oxide–semiconductor (CMOS) sensor to deliver a high quality 
images with accurate colour reproduction. The camera was integrated with the HGC 
controlling computer using a USB 2.0 interface and Mini B USB 2.0 connector. Table 
2.2 shows the technical details and performance of the camera.   
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Table 2.2: Technical specifications of uEye XS Industrial Camera used in HGC [97]. 
Optical size 3.620 × 2.720 mm 
Pixel size 1.4 µm 
Resolution 2592 (Horizontal) × 1944 (Vertical) pixel 
Frame rate free-run mode 15 frame per second 
Operating temperature 0 to +55 °C 
Dimensions (Height/Width/Length) 26.5 mm × 23.0 mm × 21.5 mm 
Weight  12 g 
 
2.5.2.2 Mirror 
A flat mirror was mounted in front of the collimator at an angle of 45o to reflect light 
photons to the optical camera assembly. The mirror was 1 mm in thickness and made 
from soda lime glass. It allowed the incident gamma photons to pass through with 
minimal absorption (<3%) [40] and scatter while the optical photons are reflected.      
 
2.5.2.3 Optical rig 
The optical mount as shown in Figure 2.15 was important in the HGC design in order 
to provide accurate and fixed positioning of the optical camera and mirror, so that the 
FOV of each detector was identical and independent of the source-to-detector distance.  
 
 
Figure 2.15: Photographs of the optical rig mounted with the mirror and optical camera. 
 
2.5.3 Software and electronics 
A bespoke software programme named “University of Leicester Space Research Centre 
CCD Control and Acquisition (version SVN75-HW2)” (Figure 2.16) was written using 
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IDL (Exelis Visual Information Solutions, Inc., Boulder, CO, USA) to control the 
hardware of HGC for image frame acquisition, formation and post-processing. The 
programme ran on an HP laptop computer in which connected to an electronic control 
box as shown in Figure 2.17 using a standard USB2 cable. The camera head was 
connected to the electronics control box via a 25-way insulated cable.   
 
 
Figure 2.16: CCD Control and Acquisition user interface in the IDL environment. 
 
 
Figure 2.17: Photograph of the electronic control box and cable connections (front view). 
 
2.5.4 Image acquisition, processing and storage 
2.5.4.1 Gamma image 
The HGC acquired the gamma images over a period of time and the raw images were 
stored in .rec file extension. Subsequently, the images were analysed on a frame by 
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frame basis using a “blob-detection” algorithm with automatic scale selection, i.e. to 
find the best fit of a Gaussian distribution to each individual light splash. The scale-
space theory [43] allowed the analysis of the two-dimensional (2-D) image. It created 
a scale-space representation from each frame of the image through the convolution of 
the image with Gaussian kernels of increasing scale. A scale normalised Hessian matrix 
(Laplace operator) was applied to each layer of scale-space representation. Local 
maxima in this 3-D scale space stack corresponded to a “bright blob” (point of interest) 
with the location of the blob given by the position of the maxima in the original image 
dimensions, and the scale of the blob given by the position of the maxima in the scale 
dimension [98].  
  
As the scale produced was limited by the discrete values chosen for creating the scale-
space representation, an additional peak fitting algorithm was applied to the scale 
dimension to interpolate, and therefore improved the accuracy of the result. Stepping 
through the frames that make up the image, every gamma interaction could be 
characterised by a representative Gaussian with a peak intensity, A, and a standard 
deviation, σ. An energy spectrum histogram was created by taking the product of σ and 
A for all scintillator events [98]. The blobbed image data were then stored in .btx file 
extension.  
 
The blobbed image can be displayed in either centre point or cumulative modes. Centre 
point mode image displayed the peak of the Gaussian fit of individual light splash as a 
single event; while cumulative mode image displayed the whole Gaussian fit of light 
splashes with a peak amplitude A and a standard deviation σ. These images were 
displayed in the IDL software and stored either in Digital Imaging and Communications 
in Medicine (DICOM), Tagged Image File Format (TIFF) or Joint Photographic 
Experts Group (JPEG) image format. Gamma image data analysed in this way (in 
DICOM or TIFF extension), could also be quantified. Customised metadata were also 
stored however these were incompatible with the standard nuclear medicine 
workstation.     
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2.5.4.2 Optical image 
The current version of the optical camera was embedded with a compact chipset for 
space-saving and economic reasons. The generated optical images were auto-corrected 
with parameter of auto gain, exposure, contrast correction, and white balance. Image 
data was stored in JPEG image format with the colour precision of 32 bits per pixel 
(RGB). Simple metadata were also stored with the information limited to image size, 
data precision and file size.    
 
2.5.4.3 DICOM image compatibility 
Digital Imaging and Communications in Medicine (DICOM) is a harmonised standard 
in digital medical imaging developed by the American College of Radiology (ACR) 
and the National Electrical Manufacturers Association (NEMA). It provides necessary 
tools for diagnostically accurate representation and processing of medical imaging data 
[99]. These include protocols of data format, storage, transfer and display to encompass 
all functional aspects of digital imaging. DICOM enables the integration of a group of 
medical devices, such as workstations, printers and picture archiving and 
communication systems (PACS) from different manufacturers. Each device is required 
to state the DICOM classes in which it supported in the DICOM Conformance 
Statements.      
 
A consistent set of data formats enables interchange of various type of medical imaging 
information on different media. Any digital image file that compliant with part 10 of 
DICOM Standard are considered as “DICOM files”. The file consists of image data sets 
and header. Each header generally contains important information related to the image 
data sets, such as patient demographics, image acquisition parameter and so on. These 
DICOM attributes are organised in a standardised series of tag, for example acquisition 
date in the tag of “0008,0022”.  
 
The “DICOM gamma images” produced by the current version of HGC were not 
compatible with the DICOM 3.0 Standard, therefore they were not interchangeable or 
readable by any clinical workstation within the hospital environment. One requirement 
of the study was to reproduce these gamma images to a DICOM 3.0 standard. 
MATLAB® R2015b (The MathWorks, Inc., Natick, Massachusetts, USA) provides the 
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function of writing a DICOM image. Firstly the attributes of the image header were 
identified and compared with the header of the image generated by a clinical LFOV 
gamma camera (Nucline™ X-Ring-R, Mediso, Hungary). Matlab code was developed 
to edit the image header so that the essential attributes could be added to the gamma 
image (See Appendix A.1.).  The edited DICOM image could then be loaded into and 
viewed by the clinical nuclear medicine workstation (Hermes Medical Solutions, 
London UK). This provided an interim solution to enable further analysis on the 
standard nuclear medicine workstation prior to any further revision of the IDL software 
as mentioned in Section 2.5.3.       
 
2.5.5 Hybrid image 
For this version of HGC, the 2-D optical images were captured directly from the optical 
camera electronics with the aid of bespoke interface software. The gamma camera 
produced a planar image. As the position of both the optical camera and gamma detector 
(distance between the CCD and the pinhole collimator was 10 mm) were calibrated, 
this resulted in a constant scale factor for all distances. However, differences in the 
alignment of each image required minor spatial corrections. The camera system allowed 
either single- or dual-modality mode acquisition during operation.   
 
The magnification of the systems depends on the distance between the object being 
imaged and the collimator. This required the gamma image to be modified to match 
with the optical image by applying an appropriate scale factor and adjusting the 
orientation. The gamma image was superimposed on the optical image using the pixel 
addition method, with co-registration of both the gamma image pixel and optical image 
pixel. Figure 2.18 shows an example of the optical, gamma and hybrid images. The 
fused images were saved and displayed in any type of the image formats, which 
included Tagged Image File Format (TIFF) or Joint Photographic Experts Group 
(JPEG).  
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Figure 2.18: Example of the fused images (right) - a combination of the optical image (left) and gamma 
image (middle) of a phantom filled with red colour radioactive solution in the wells.  
 
2.6 NebulEYE Mini Gamma Camera 
The Universities of Nottingham and Leicester through their spin-out company Gamma 
Technologies Limited further developed the prototype HGC, in collaboration with 
Xstrahl Limited (Surrey, UK). This was intended to translate the laboratory prototype 
to a standard medical device. The NebulEYE mini Gamma Camera System (Nebuleye) 
was manufactured by the industrial partners. Figure 2.19 shows a photograph of the 
pre-commercial prototype Nebuleye at Queen’s Medical Centre and the essential 
components of the camera head (Figure 2.20). The technology of the camera was 
similar to the HGC with minor modifications and taking ergonomic and manufacturing 
factors into consideration. Table 2.3 shows the technical details of the Nebuleye.  
 
Chapter 2. The SFOV Hybrid Optical Gamma Cameras| 50 
  
 
 
 
Figure 2.19: Photograph of Nebuleye Mini Gamma Camera System v1.0. 
 
 
  
Figure 2.20: (Left) Photograph of the Nebuleye held on an articulated arm. (Right) Cross-sectional 
schematic diagram of the Nebuleye (Image courtesy of GTL).  
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Table 2.3: Technical details of the Nebuleye [100]. 
Gamma camera detector 1.5 mm thick CsI(Tl) coupled to CCD97 
Detector Operating Temperature -10°C to -1°C 
Energy Range 30-200 keV 
Collimator 1.0 mm diameter pinhole 
System Weight 80 kg 
Height 1.978 m  
Width 1.449 m 
 
The intended use of the device was for intraoperative and bedside hybrid optical-
nuclear imaging. It was mounted onto a positioning arm and trolley to assist with 
movement and positioning of the camera at patient’s bedside and in the operating 
theatre.    
  
2.6.1 Nebuleye Gamma Camera integrates with optical imaging 
The Nebuleye gamma camera consisted of 1.5 mm thick CsI(Tl) crystal scintillator 
coupled to CCD, pinhole collimator, optical camera, mirror and cooling system, 
encapsulated in a re-designed plastic enclosure made from Acrylonitrile Butadiene 
Styrene (ABS). It was designed to be compact enough to be handheld by the operator 
and weighed approximately 1 kg. The Nebuleye utilised a single 1.0 mm diameter 
pinhole collimator. It was made from tungsten 6 mm thick in a circular shape around 
the pinhole and 3 mm thick at the sides. The pinhole collimator had a 60 degrees 
acceptance angle. Figure 2.21 shows the fabricated pinhole collimator removed from 
the camera head. 
 
 
Figure 2.21: Pinhole collimator of Nebuleye. 
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2.6.2 PC with Nebuleye software  
The camera system was equipped with an integrated, medically approved PC operating 
in Windows Operating System 7 Professional. A second touch-screen display monitor 
was provided offering multiple in-theatre user configurations. Bespoke Nebuleye 
software was developed using C# 4.0 programming language and was provided to 
control use and calibration of the camera system. Figure 2.22 shows the main page of 
the beta software providing menu options for various functions and applications.   
 
 
Figure 2.22: User interface of the Nebuleye software. 
 
2.6.3 Image acquisition, processing and storage 
As with the HGC, Nebuleye acquired the gamma image frame by frame over a period 
of time and the raw image was stored in .rec file extension. Simultaneously, the optical 
image was captured in either auto focus or fixed focal distance mode and the image 
data was kept in JPEG format. Both images were combined to produce a planar hybrid 
optical-gamma image in the same orientation. The hybrid images were stored and 
displayed in JPEG format. It is worth noting that at the time of writing DICOM 
compliance was never available with the current version of software (beta v1.3.320) 
which was still under development particularly for image post-processing and image 
storage. 
 
2.6.4 Cart  
The Nebuleye was supplied as a fully assembled cart based system (Pro-cart, ITD 
GmbH, Johanniskirchen, Germany) to assist movement in the clinical environment. 
This was an IEC 60601 Approved Cart with integrated mains isolation. The basic frame 
of the cart carried a shelf for holding the electronics box, an articulated arm to hold the 
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camera head, a keyboard holder with mousepad and twin monitor mountings. Brakes 
on the cart wheels and a push handle eased the control of the system during manoeuver, 
positioning and storage.  
     
2.6.5 Sterile sheath 
To maintain the sterility of the camera system during intraoperative procedures, a 
camera sheath specifically designed for the camera head was used. The sterile drape 
was manufactured by P3 Medical Limited (Bristol, UK) with a cap to fit into the camera 
head, and optical window and an adjustable sheath with three acrylic adhesive straps, 
long enough to cover the articulated arm and the cable (Figure 2.23), permitting the 
correct connection and operation of the camera. The transparent cap window with 
removable objective lens cover enabled the incoming light photons to pass through 
while minimising image degradation caused by the photon attenuation processes.  
Table 2.4 provides details of the sterile sheath.   
 
 
Figure 2.23: The sterile drape fitted on the Nebuleye. (Inset) Clear cap window to allow production of 
the optical image. 
 
Table 2.4: Technical details of the sterile sheath. 
Size 150 × 2500 mm 
Method of sterilisation Ethylene Oxide 
Cap material Solid co-polyester sheet 
Sheath material Ethylene Butylene Styrene Block Copolymer 
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2.7 Summary 
This chapter has described the development of the compact SFOV gamma camera 
systems and incorporation of the optical cameras to become the hybrid optical gamma 
camera systems. Detailed descriptions of the HGC and Nebuleye were provided and 
this version of the camera systems, unless otherwise stated, were used in subsequent 
work described in this thesis. Prior to clinical use, characterisation work (as discussed 
in Chapter 3) and evaluation work using clinically mimicking phantom and test objects 
(as discussed in Chapter 5) were required to rigorously assess the performances of the 
camera systems. In addition, ethical and regulatory requirements as well as safety 
assessments needed to be addressed to ensure the device was safe to be used clinically.  
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Characterisation of the SFOV 
Hybrid Optical Gamma Camera 
 
 
3.1 Introduction  
Testing the performance of gamma cameras is essential in order to determine if the 
device meets the manufacturers’ specifications and is operating within the set parameter 
limits throughout its period of clinical use. The testing schemes adopted by the 
manufacturers have been based on the methods developed by international standards 
organisations such as National Electrical Manufacturers Association (NEMA) and the 
International Electrotechnical Commission (IEC). The main internationally harmonised 
standards relevant to medical gamma camera manufacturing are the NEMA NU 1-2012 
Performance Measurements of Gamma Cameras [101] and IEC 61675-2:2015 
Radionuclide imaging devices - Characteristics and test conditions - Part 2: Gamma 
cameras for planar, whole body, and SPECT imaging [102]. 
 
User acceptance tests or validation tests are carried out by the user after the camera has 
been installed in the clinical environment. The user test protocols should be identical, 
or as near as possible, to those used for the factory testing.  This allows the user to 
assess if the camera complies with the specifications set by the manufacturer. These 
tests of the camera also provide baseline performance data for comparison with future 
routine performance tests for quality control purposes. National authorities and 
organisations such as American Association of Physicists in Medicine (AAPM), United 
States of America (USA) and Institute of Physics and Engineering in Medicine (IPEM), 
United Kingdom (UK) have also published detailed test protocols for regular use in the 
clinical setting. Both the acceptance and reference tests are required to be repeated if 
there has been a change in camera components, such as due to equipment breakdown 
or a major service that could affect camera performance.  
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Routine quality control tests are performed at regular intervals as specified in the local 
protocols and operating procedures. Some of these are operational checks which should 
be carried out daily before the camera is used. The results of these tests are then 
compared with the baseline values to determine if the pre-defined performance limits 
are met. Details of the routine quality control tests for the SFOV Hybrid Optical 
Gamma Camera are discussed in Section 6.5. At the time of writing, there was a lack 
of harmonised protocols for the testing of SFOV gamma cameras. Moreover, the SFOV 
Hybrid Optical Gamma Camera involves the combination of gamma and optical 
cameras both of which require individual image quality assessment in addition to 
checking the alignment of fused images. Figure 3.1 summarises the levels of a gamma 
camera performance assessments based on the International Atomic Energy Agency 
(IAEA) publications [103].  
           
 
Figure 3.1: Performance assessments throughout a gamma camera’s life cycle (Based on IAEA Human 
Health Series No. 6 [103])  
• by the manufacturer with harmonised protocols in 
factory settings 
• to determine the required specifications are met and 
compare with other similar device
• NEMA, IEC standards
Factory testing
• by the user and/or technical specialist after 
installation or major change of device component(s) 
with harmonised protocols
• to confirm the manufacturer's specifications are met 
Acceptance 
testing
• by the user before clinically use or major change of 
device component(s) using national, in house or 
manufacturer protocol
• to establish the device baseline performance 
• IPEM, AAPM, IAEA guidelines
Reference testing
• by the user routinely using national, in house or 
manufacturer protocol in clinical settings  
• to confirm the performance limits are met Routine testing
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In this chapter, the tests for characterising the performance of the new prototype 
Nebuleye camera are described. The camera was assessed using a set of modified 
characterisation protocols specifically developed for SFOV cameras. The test results 
were then compared with the prototype HGC.  
 
3.2 Performance characterisation of the cameras 
The Nebuleye mini gamma camera system is a combined optical and gamma camera 
system intended for intraoperative and bedside hybrid imaging.  The system provides 
gamma images to illustrate the physiological information of a living subject 
administered with a radiopharmaceutical, and optical images to show the anatomical 
information of the region of interest. The camera head is mounted onto an ergonomic 
arm and cart to assist the movement and positioning of the device, enabling the camera 
system to be used at patient’s bedside and in the operating theatre.  
 
The performance of the pre-commercial prototype Nebuleye camera was assessed using 
protocols that had been specifically developed for testing SFOV gamma cameras. These 
test protocols were modified procedures developed by the Universities of Leicester and 
Nottingham [104, 105], based on those produced by the Institute of Physics and 
Engineering in Medicine (IPEM) [106] and the International Atomic Energy Agency 
(IAEA) [103]. The testing procedures were adjusted to suit the newly designed camera 
system and were harmonised to make inter-comparison possible between similar 
imaging systems.  Most of the procedures have two test components, namely an 
intrinsic and extrinsic measurement. An extrinsic test, which is also known as a system 
test, includes the effect of the collimator. Bugby et al [105] has reported the 
performance tests of SFOV gamma cameras which includes intrinsic uniformity, 
sensitivity, intrinsic and extrinsic spatial resolution, spatial linearity and count rate 
capability. The system uniformity and sensitivity, detector head shielding leakage, 
optical-gamma alignment, as well as optical image quality test were carried out 
experimentally for the first time.   
 
During the experimental period, the software and hardware were in a period of 
development. The two camera systems used in the characterisation tests were the early 
pre-commercialised prototype of Nebuleye (Nebuleye 2 and Nebuleye 3) which were 
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provided by the manufacturer for testing and research purposes. These cameras were 
almost identical except that the optical rig in Nebuleye 3 was upgraded to provide a 
more accurate alignment for gamma-optical image fusion. This version of software did 
not include ‘blob detection’ feature, hence the software mentioned in Section 2.5.3 was 
used to analyse the gamma images, enabling further quantification work to be carried 
out. All radioactivity used in the experiments was obtained from the radiopharmacy 
unit at Queen’s Medical Centre and assayed using a dose calibrator (CRC®-25R, 
Capintec Inc, NJ, USA).   
 
Image analysis was carried out using IDL software v8.5.1 (Exelis Visual Information 
Solutions, Inc., Boulder, CO, USA),  ImageJ 1.50b (NIH, USA), MATLAB® R2015b 
(The MathWorks, Inc., Natick, Massachusetts, USA) and GraphPad Prism version 6.07 
for Windows (GraphPad Software, La Jolla California, USA). The following 
parameters were assessed: 
a) Intrinsic spatial resolution (Section 3.2.1) 
b) System spatial resolution (Section 3.2.2) 
c) Intrinsic uniformity (Section 3.2.3) 
d) System uniformity (Section 3.2.4) 
e) Intrinsic sensitivity (Section 3.2.5) 
f) System sensitivity (Section 3.2.6) 
g) Spatial linearity (Section 3.2.7) 
h) Count rate capability (Section 3.2.8) 
i) Detector head shielding leakage (Section 3.2.9) 
j) Optical-gamma alignment (Section 3.2.10) 
k) Optical image quality (Section 3.2.11) 
  
3.2.1 Intrinsic spatial resolution 
The intrinsic spatial resolution is a measure of the sharpness and detail of a gamma 
image, without use of the collimator.  It is normally reported either as the full width at 
half maximum (FWHM) of the line spread function (LSF) produced from a thin line 
source, or point spread function (PSF) obtained from a point source, or as the minimum 
separation of two sources that can be discriminated from each other.    
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The testing protocol used for this work was based on the method suggested by Bugby 
et al. [105]. The camera head was turned to face vertically downward. A 10 mm-thick 
lead mask, containing a machined slit of 2 mm width and 20 mm length in dimension 
was placed on the face of the un-collimated gamma camera. The position of the slit was 
carefully aligned with the x and y axes of the camera head. The distance between the 
mask and scintillator detector was 8.5 mm due to camera design. The camera was 
irradiated by gamma fluxes originated from a 3 mm-diameter 99mTc point source 
(15.3 MBq) placed 250 mm away from the mask (Figure 3.2). Images were acquired 
containing 18000 frames (30 minutes). The procedure was repeated with the lead mask 
rotated through an angle of 90°.  
 
 
Figure 3.2: Photograph of experiment set up during intrinsic spatial resolution test. A 99mTc point source 
was positioned at a distance of 250mm from the attached slit mask.  
 
In each case the resulting image was a line corresponding to the spatial distribution of 
detected events resulting from the gamma rays that passed through the slit mask. A line 
profile was drawn on the image display perpendicular to the slit image and presented 
as edge response function (ERF). Then the line spread function (LSF) was derived by 
performing the first differentiation of the ERF. Each peak of the LSF plot was fitted 
with Gaussian distribution model in order to determine the full width at half maximum 
(FWHM) and the full width at tenth maximum (FWTM) values.  
 
Slit mask 
99mTc 
source 
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Figure 3.3 (a) shows an example of the resulting image for the intrinsic resolution test 
with the slit mask positioned horizontally. Due to the lead mask not being perfectly 
aligned with the detector array principal axes, the acquired image was rotated to account 
for the misalignment. Figure 3.3 (b) shows the ERF across the line profile with the 
summed number of counts at y-axis. The low level signal (5 ± 4 counts) at both sides 
of the image indicates the background count level while the high count levels (176 ± 
12 counts) represents the counts within the slit.  Where the number of counts within the 
slit remains level the graph shows a plateau situated between steeply ascending and 
descending edges. The derivative of the ERF generates the LSF as shown in Figure 3.3 
(c).  The two peaks indicate the edges of the slit profile. The results were then presented 
in absolute values (modulus of negative values) with Gaussian model fitted as shown 
in Figure 3.3 (d).   
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Figure 3.3: (a) Example image of the slit mask (rectangle shaped) taken by the camera with 30 minutes 
acquisition time was plotted as (b) ERF. (c) LSF was calculated as the first derivative of the ERF and (d) 
the absolute value of the results were Gaussian fitted. 
 
a 
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Table 3.1 tabulates the mean resolution measurements of the camera using both edges 
of the slit images where the slit was orientated parallel and perpendicular to the detector 
array’s principal axes in respective acquisition. The measured resolution of the camera 
was approximately 4 to 5 pixels (pixel size 64 µm × 64 µm).   
 
Table 3.1 Intrinsic resolution measurement of Nebuleye. 
Parameter Measurement 
FWHM (mm) 0.28 ± 0.02 
FWTM (mm) 0.52 ± 0.03 
  
3.2.2 System spatial resolution 
System spatial resolution (Rs) is the measure of the sharpness of the image recorded 
with a gamma camera, which includes the effect of collimator and can be estimated by:  
 
 R𝑠 = √R𝑖
2 + R𝑐
2 3.1 
 
where Ri is the intrinsic resolution and Rc is the collimator resolution. For pinhole 
collimators, several parameters determine the collimator resolution, these include 
pinhole diameter, source-to-collimator distance (SCD), the angle between the source 
and the central axis, the length of the collimator hole, the pinhole acceptance angle and 
the collimator material (which affects the linear attenuation coefficient) and energy of 
the radionuclide imaged. This measurement is more clinically relevant in comparison 
to the intrinsic spatial resolution. As a rule of thumb, the system spatial resolution 
degrades as the SCD increases. For SFOV gamma cameras mounted with a pinhole 
collimator, the system spatial resolution is normally reported as the FWHM and FWTM 
of a LSF or PSF at the non-magnifying point with scattering medium.   
 
The measurement was carried out with the 1 mm diameter pinhole collimator in place 
and the camera head was turned to face vertically downward. A 1 mm diameter 
capillary tube (source width identical to the geometric resolution of the pinhole at the 
non-magnifying point) filled with 39.3 MBq of 99mTc (at a concentration of 
78.6 MBq ml-1) was used as line source. The capillary tube was positioned as a straight 
line in between two PMMA plate of 5 mm in thickness which placed adjacent to each 
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other as shown in Figure 3.4. Image acquisition was carried out for 300 s with a PMMA 
block 10 mm in thickness placed in between the camera head and the line source. Then 
the procedures were repeated with various PMMA blocks thickness range between 
20 mm and 70 mm at 10 mm interval. 
 
  
Figure 3.4: (Left) Photograph of equipment set up during system spatial resolution test. A PMMA plate 
10 mm in thickness was positioned between a 99mTc line source (arrow) and the camera head. (Right) 
Example image of the line source with 10 mm PMMA as the scattering medium, taken by the camera 
with 5 minutes acquisition time. Image was post-processed with the multiplication of 100 and smoothing 
filter of 1 pixel was applied. Magnification factor was incorporated on the image scale bar.  
 
Figure 3.4 (right) shows the resulting image of the test with a line corresponding to the 
shape of a line source. A line profile was drawn perpendicular to the line source and 
the data was Gaussian fitted. The FWHM and FWTM values were calculated. The 
magnification factor was taken into consideration during the calculation of the values 
based on the SCD. These values were then plotted against the thickness of PMMA and 
the graph was fitted by linear regression. From the linear equations, the FWHM and 
FWTM at the non-magnifying position (SCD at 10 mm) were extrapolated since the 
experimental measurement was not possible at this position due to the occupancy of the 
optical rig in front of the collimator.   
 
Figure 3.5 shows a graph of the computed resolutions against the PMMA thickness. 
Resolution degrades with the increase in the PMMA thickness. The linear relationship 
between distance, d (scattering material) and resolution for the camera are tabulated in 
Table 3.2. The FWTM values increase more rapidly than the FWHM values due to the 
decrease in signal-to-noise ratio (as a result of reducing sensitivity) with increasing 
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thickness of the PMMA as discussed in 3.2.5. The FWHM resolution at the non-
magnifying distance (10 mm) and at the camera head window surface (28 mm) were 
found to be 1.84 ± 0.69 mm and 3.08 ± 0.71 mm respectively.  
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Figure 3.5: System spatial resolution measurements for Nebuleye using 1.0 mm diameter pinhole 
collimators. FWHM (red circles) and FWTM (blue squares) values with the best fitted lines for a range 
of PMMA thickness are plotted (n=3). 
 
Table 3.2: Linear relationship between depth of scattering material and resolution of the camera with 
gradient m and y-intercept c calculated using GraphPad Prism software.  
Resolution Fitted parameters R2 
m c 
FWHM 0.069 ± 0.009 3.081 ± 0.387 0.927 
FWTM 0.126 ± 0.016 5.624 ± 0.706 0.927 
 
3.2.3 Intrinsic uniformity  
The intrinsic uniformity is a measure of the degree of uniformity of count density across 
the detector. It is measured by irradiating the camera detector with a uniform flux of 
incident photons, without a collimator in place. The variations of the count density 
within the image indicate changes of camera performance caused by spatial non-
linearity and inaccuracy of energy response. Intrinsic uniformity may be quantified 
either by the changes in uniformity over an entire image or variation in count density 
over a specified distance. In general, a lower value indicates a higher uniformity. 
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A 3 mm diameter point source containing 26.4 MBq of 99mTc was placed 350 mm away 
from the detector face to provide a uniform gamma irradition across the detector (Figure 
3.6). At least two flood images were acquired with 30 minutes acquisition time. Dark 
image, or known as background image were taken with 600 s acquisition time, without 
the presence of radioactive source. Matlab code was developed to analyse the image 
(See Appendix A.3.).   
 
 
Figure 3.6: Experimental set up for the intrinsic uniformity test. A 99mTc point source (arrow) was placed 
underneath of the Nebuleye with the collimator removed. 
 
Figure 3.7 (a) shows an example of the resulting flood field image. Higher count 
densities were found in the middle of the image (count densities gradient gradually 
decreased from bottom to top of image). This could be due to the dark signal gradient 
of the CCD with the increase of detector temperature over image acquisition. Several 
pixels of outliers were noticeable particularly a cold spot indicating lower detection 
efficiency regions. For the flat field correction, a flood mask image was created by 
subtracting the dark image from flood field image followed by normalising the resulting 
image to its maximum pixel value, to create a correction map with consistent dynamic 
range. For uniformity quantification, a flood field image was subtracted with dark 
image and divided by the flood mask image to correct the non-uniformity of the image. 
A median filter was applied to the resulting image and it was subsequently quantified 
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by obtaining the maximum, minimum, mean and standard deviation of counts per pixel 
of the image (Figure 3.7(b)). In this test, the overall and regional changes in the image 
uniformity is reported as integral uniformity, coefficient of variation (CoV) and 
differential uniformity (DU) respectively [106]. Integral uniformity (IU) is a measure 
of the overall uniformity of the whole field of view. It is defined as:  
 
 
IU=
Cmax-Cmin
Cmax+Cmin
×100% 3.2 
    
where Cmax and Cmin are the maximum and minimum counts per pixel of the image. 
CoV is a measure of the overall variation of count density in the image and is defined 
as a percentage (%):  
 CoV=
σ
M
×100 3.3 
 
where σ is the standard deviation of counts per pixel and M is the mean counts per 
pixel. DU can be calculated by Equation 3.4. The mean differential uniformity was then 
computed with 10 times of repeated DU quantification. 
 
 
DU=
C𝑚𝑎𝑥 − C𝑚𝑖𝑛
C𝑚𝑎𝑥 + C𝑚𝑖𝑛
× 100 3.4 
   
where Cmax and Cmin are the maximum and minimum counts per pixel of the image.  
    
  
Figure 3.7: (a) Example of a raw flood field image obtained by Nebuleye 2 and (b) the resulting image 
after flat field corrections were applied. A cold spot (red circle) was observed in the raw flood field image 
indicating lower detection efficiency regions.  
 
a b 
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Table 3.3 tabulates the calculated uniformity measurements of the camera. Integral 
uniformity was more than 50 % indicating poor intrinsic uniformity across the entire 
FOV. Similarly, CoV was higher than DU indicating big difference in count densities 
with pixels of very high or low counts within the FOV. This is further confirmed by 
examining the pixel intensity profile (variation of count densities) across representative 
row of the uniformity-corrected image (Figure 3.8). These values were normalised to 
the mean intensity of the pixels within the selected row. The number of counts were 
range from 49 to 89 counts per pixel (67 ± 9 mean counts per pixel).  
 
Table 3.3: Intrinsic uniformity measurements of Nebuleye. 
Uniformity Measurement Measurement (%) 
Integral uniformity 51.72 
Coefficient of variation 13.54 
Differential uniformity 8.34 
 
 
Figure 3.8: Normalised pixel intensity of the flood image without correction (top) and with correction 
(below) for intrinsic uniformity test. 
 
3.2.4 System uniformity 
Similar to the intrinsic uniformity test, system uniformity is a measure of deviation of 
count densities in an image, which includes the effect of any irregularities in the 
collimator. In this test, the overall and regional changes of an image uniformity are 
reported as the integral uniformity, coefficient of variation (CoV) and differential 
uniformity (DU) respectively. This test was newly introduced to examine the 
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performance of the SFOV gamma camera, as it is a more realistic and clinically relevant 
way of assessing the camera’s performance. It may serve as a daily quality control 
check because it can be performed without removing the collimator. The system 
uniformity test is a measurement recommended by IPEM [106]. For LFOV gamma 
cameras, the test is carried out using a thin flood source of 99mTc (approximately 64 × 
45.5 cm in dimension) placed against the collimator to irradiate the entire FOV with 
uniform flux of photons. 
 
For this measurement, a 40 ml Greiner standard cell culture flask (nominal size (mm): 
70 (L) × 35 (W) × 24 (H)) was filled with 15 ml of mixed coloured water and 99mTc 
pertechnetate solution (TcO4
-) in a concentration of 2.2 MBq/ml. The cell culture flask 
is made of high-grade polystyrene with standard screw cap to avoid the radioactive 
source causing contamination. The camera, fitted with 1 mm diameter pinhole 
collimator, was turned to face vertically downward. The flood source was positioned 
with a source to camera surface distance of approximately 13 mm to provide a uniform 
gamma illumination across the detector. Figure 3.9 shows the experiment set up for the 
system uniformity test. At least two flood images were acquired with acquisition time 
of 30 minutes respectively. A dark image, also known as a background image, was 
taken without the presence of radioactive source with a 200 s acquisition time.    
 
 
Figure 3.9: The flood source placed within field of view of the camera. 
 
Figure 3.10 (a) illustrates an example of the resulting flood field image. Higher count 
densities were found in the middle of the image (count densities gradient gradually 
decreased from bottom to top of image). As discussed earlier, this might due to the dark 
signal gradient of the CCD with the increase of detector temperature over image 
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acquisition. Flat field correction method was identical in Section 3.2.3 where a flood 
mask image was created by subtracting the dark image from flood field image followed 
by normalising the resulting image to its maximum pixel value. Subsequently, a flood 
field image was subtracted with dark image and divided by the flood mask image to 
correct the non-uniformity of the image. Then a median filter was applied to the 
resulting image prior further quantification (Figure 3.10 (b)).  
 
 
Figure 3.10: (a) Example of flood field image and (b) corrected flood image obtained by Nebuleye 3. 
 
Table 3.4 tabulates the calculated uniformity measurements of the camera. The CoV 
value for original image and uniformity corrected image was 35% and 20% 
respectively, where it shows a significant improvement after the correction applied. The 
IU was higher than DU indicating big difference in count densities with pixels of very 
high or low counts within the field of view. It was also higher than the IU quantified in 
intrinsic uniformity test. One of the reasons was due to the spatial non-uniformity 
caused by the pinhole collimator [16]. Figure 3.11 illustrates the pixel intensity profile 
(variation of count densities) across representative row of the uniformity-corrected 
image. These values were normalised to the mean intensity of the pixels within the 
selected row. The number of counts were across a range from 21 to 48 counts (32 ± 5 
mean counts per pixel).  
 
Table 3.4: NebulEYE mini gamma camera system uniformity measurements with uniformity correction 
applied. 
Uniformity Measurement Measurement (%) 
Integral uniformity 70.73 
Coefficient of variation 19.58 
Differential uniformity 16.55 
a b 
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Figure 3.11: Normalised pixel intensity of the flood image without correction (top) and with correction 
(below) for the system uniformity test. 
 
3.2.5 Intrinsic sensitivity 
The intrinsic sensitivity is a measure of the proportion of the detected gamma rays 
emitted from a known activity of radionuclide by a gamma camera without collimator 
in place. It is usually reported as the ratio of the count rate per unit activity measured 
in units of cps MBq-1 at a defined distance from the source to the detector surface. 
Several factors influence the sensitivity of the camera, such as type of radionuclide and 
thickness of scintillation crystal. The sensitivity of the camera is proportional to the 
thickness of the crystal and inversely proportion to the radionuclide energy and the 
thickness of the scattering medium.   
 
A 3 mm-diameter hole was filled with 16 MBq 99mTc to act as point source and was 
placed 250 mm away from the detector surface. The strength of the radioactivity was 
assayed and the exact time of the measurement was also recorded. A flood image was 
acquired with acquisition time of 500 s. The image acquisition was repeated with the 
addition of scattering medium (PMMA range from 10 mm to 70 mm at 10 mm interval) 
in between the source and the camera. The time for each acquisition was recorded. Raw 
images were post-processed (without applying a correction map) and the number of 
counts were quantified. The counts in the region of interest (ROI) of the image was 
used to determine the count rate and the activity was corrected based on the time of the 
measurement and standard decay calculations.  
 
Figure 3.12 shows the relationship between the intrinsic sensitivity of the camera and 
the thickness of the scattering medium. At these experimental settings, the thickness of 
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PMMA required to reduce the sensitivity to half was 67 mm (r2=0.99). The intrinsic 
sensitivity was 12.4 cps MBq-1 with the source positioned at 250 mm away from the 
detector surface, which is approximately 15% of the estimated incident photons 
calculated from the solid angle formulae (Equation 3.5). 
 
 
Ω=4tan-1
αβ
2h√4h2+α2+β2
 
3.5 
where h is the distance of a source placed at the centre of a rectangular detector of 
dimensions α × β. The incident photons on the detector from an isotropic point source 
is the proportion of photons 
Ω
4𝜋
 . In contrast, the theoretical sensitivity of the camera 
with a thickness of 1.5 mm CsI(Tl) crystal is 43.6% at 141 keV [107]. In general, the 
decrease of SFOV gamma camera sensitivity might due to the following reasons:  
a) inefficiency in the detector coupling between the crystal and the EMCCD 
b) losses of count due to the smaller size of detector and the position of the source 
c) attenuation within the source holder 
d) attenuation by the aluminium lid (as the vacuum lid positioned in front of the 
detector) (HVL for aluminium at 140 keV ~18 mm) 
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Figure 3.12: Relationship between intrinsic sensitivity and the depth of scattering medium (n=3). 
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3.2.6 System sensitivity 
The system sensitivity is a test of the count rate response of a collimated scintillation 
camera to a radionuclide source of known radioactivity. It is reported as the ratio of the 
count rate per unit activity measured in units of cps MBq-1 at a defined distance from 
the source to the detector surface (usually at the non-magnifying point). This parameter 
is mainly influenced by the intrinsic sensitivity of the detector and the collimator 
efficiency, g. Therefore, it needs to be measured individually for each collimator. For a 
pinhole collimator, collimator efficiency [14] is given by  
 
 
𝑔 ≈
deffcos
3θ
16b
2
 3.6 
     
where 𝑑𝑒𝑓𝑓 = √𝑑 [𝑑 + 2𝜇−1𝑡𝑎𝑛
𝛼
2
]. Based on Equation 3.6, the collimator efficiency 
is directly related to the effective pinhole diameter and decreases with increasing SCD.   
 
In the experiment, approximately 20 MBq of 99mTc-pertechnetate solution was held in 
a 3-mm diameter well. Then the activity of the source was assayed in the radionuclide 
dose calibrator and the time was recorded. Figure 3.13 shows the experimental setup 
during the test. A 1.0 mm diameter pinhole collimator was fitted in this version of 
camera. A 200 s planar image was acquired, with and without the presence of scattering 
medium. The acquisition was repeated at the source to camera surface distance between 
10 and 70 mm (PMMA range from 10 mm to 70 mm at 10 mm interval). The time for 
each acquisition was recorded. Raw images were post-processed (without applying a 
correction map) and the number of counts were quantified in order to compute the decay 
corrected count rate in the ROI selected in the image.  
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Figure 3.13: Experimental set up for system sensitivity test. 
 
In this test, a series of measurements using the same point source (with or without 
scatter in between source and the camera) at different SCD were taken to measure the 
system sensitivity. Figure 3.14 shows the relationship between the system sensitivity 
and the SCD in comparison with the calculated collimator efficiency. The measured 
system sensitivity and the calculated collimator efficiency decreased with the increase 
of the SCD. By extrapolating the measurements, the system sensitivity was 8.86 cps 
MBq-1 at the non-magnifying distance and 3.82 cps MBq-1 at 50 mm away from the 
collimator without the presence of the scatter. With the presence of the scattering 
medium, the system sensitivity was lower in comparison with the data acquired without 
the scattering medium. 
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Figure 3.14: Relationship of the collimator efficiency and system sensitivity (blue line-without scatter; 
red line-with scatter) of the camera with the depth of scattering medium (n=3).  
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3.2.7 Spatial linearity 
Spatial linearity is a measure of the spatial distortion calculated by assessing an image 
of a line produced by a slit mask. It is carried out intrinsically therefore excludes the 
effects of collimator. It is reported as the absolute linearity (maximum deviation from 
best-fit line) and the differential linearity (standard deviation of the best-fit line) in the 
unit of mm. As this is an SFOV gamma camera, a slit mask was used to create a line in 
gamma image. The experimental set up was identical to the intrinsic spatial resolution 
test, enabling the images generated from the test were used for this purpose. The same 
experimental procedures were repeated with the lead mask rotated through 90°. This is 
to examine the non-linearity of the line image in both x and y direction.  
 
Figure 3.15 shows the resulting image of the slit mask irradiated by the uniform gamma 
flux in both the horizontal and the vertical orientation. Ideally the line in the image 
should appear straight. Due to the lead mask not being perfectly aligned to the x and y 
axes of the detector arrays, the acquired image was rotated to account for the 
misalignment. For both images, pixel intensity profiles of the ROI within the slit image 
were obtained and the profiles were fitted with Gaussian function. The peak value of 
the Gaussian distribution was determined and considered as the estimated center point 
of the slit profile. Then the difference between each center point and its mean value was 
calculated in term of mean, maximum and standard deviations. Then all measurements 
were converted to the unit of µm. During the analysis, 120 of 132 rows across the slit 
were included in the calculations. Those excluded rows were out of the ROI or due to 
low signal-to-noise ratios.  
Table 3.5 tabulates the results of the linearity measurements for the camera.  
 
  
Figure 3.15: Horizontal and vertical slit images with the regions of interest (red rectangle). 
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Table 3.5: Linearity measurements of Nebuleye. 
Linearity Measurement Measurement (µm) 
Vertical Horizontal Average 
Mean deviation 50.3 108.0 79.2 
Absolute linearity 198.0 288.0 243.0 
Differential linearity 38.0 66.0 52.0 
 
3.2.8 Count rate capability 
The count rate capability of a scintillation camera is a measure of the relationship 
between the recorded count rate and the intensity of incident gamma photons. Ideally 
the recorded count rate is directly proportional to the incident count rate, however the 
performance does deteriorate at high count rates. As the count rate increases, there is a 
chance of recording two events at the same time, resulting in counting losses. This 
causes the recorded count rate to deviate from the incident count rate especially when 
high count rates can result in signal losses where the camera detection process may be 
paralysed or part-paralysed. IPEM [106] and Bugby et al. [105] suggested that this 
parameter should be reported in term of the input count rate, in cps units at which there 
is a 20% difference between the recorded and input count rate. In contrast, NEMA [101] 
and Cherry et al. [14] have recommended that the observed count rate at 20% loss 
should be reported. The maximum recorded count rate is also typically stated [101, 103, 
106]. 
 
This test was carried out intrinsically without the presence of scattering medium. The 
decaying source method was used to determine the recorded count rate at each specific 
time interval, until the activity of the source was negligible. In this experiment, a series 
of nine point sources containing 99mTc pertechnetate solution with known activities 
range from 2 to 550 MBq was filled in a vial. The activity of the source was measured 
in the radionuclide dose calibrator and the time of day was recorded. Figure 3.16 shows 
a vial filled with radioactive source placed at 350 mm away from the detector surface 
during the test. Each source was imaged with 10 s acquisition. The acquisition was 
repeated at 1 hour intervals over 6 hours to ensure that a range of input count rates were 
included.  
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The exact time of each acquisition was recorded. Raw images were post-processed 
(without applying a correction map) and the number of counts were quantified in order 
to compute the background and decay corrected count rate. The incident counts were 
calculated based on the activity of the source at the time the image was taken using the 
solid angle formulae (Equation 3.5). Recorded count rate versus incident count rate was 
plotted and a line of best fit calculated for the linear region was generated in order to 
calculate the relationship between the measured count rate and the incident count rate. 
 
 
Figure 3.16: The radioactive source was placed 350 mm away from the uncollimated Nebuleye. 
 
Figure 3.17 shows the count rate response curve obtained for the Nebuleye. It illustrates 
that the camera was paralysable. The linear region of the curve occurred at low count 
rates (r2=0.993) suggesting that the detection efficiency of the camera was almost linear 
for incident count rate up to 11 kcps. The input count rate and recorded count rate at 
which there is a 20% loss was 15.71 kcps and 2537 cps respectively. The maximum 
recorded count rate was 2845 cps. As described in Section 3.2.5, the detection 
efficiency of the camera without the collimator was approximately 15% of the incident 
photons. This has resulted in the measured count rate being lower in comparison with 
a typical LFOV gamma camera. The maximum recorded count rate for a clinically used 
LFOV gamma camera [13, 108] is 350 kcps. To standardise the comparison between 
the SFOV and LFOV gamma camera, the recorded count rate at 20% loss and maximum 
recorded count rate was reported in our study. One of the limitations was that the test 
source 
camera 
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was performed without the presence of scattering material, consequentially irrelevant 
to real clinical scenario where scattered radiation arising from the patient. This may 
underestimate the count rate capability of the camera and the recorded count rate may 
significantly decrease in clinical situation.     
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Figure 3.17: Recorded count rate versus incident count rate curve of Nebuleye.  
 
3.2.9 Detector head shielding leakage 
The sides and back of a gamma camera’s detector head are surrounded by shielding 
material to eliminate any unwanted radiation from being detected by the camera. These 
radiation sources might originate from within the patient, or from cosmic rays and 
background radiation. Detector head shielding leakage is a measure of the sufficiency 
of the shielding material within the camera head. The test is usually carried out using a 
99mTc source, and along with another radionuclide which produces gamma energy at 
the highest end of the range of those used clinically.  
 
IAEA [103] has also recommended a measurement of the count rate of a 4 MBq 99mTc 
source positioned at twelve sites around the detector head as well as other potential 
leaking points such as any cable outlets. Each acquisition takes about 100 s. Then all 
measurements are divided by the reference count rate acquired using the same source 
positioned 10 cm in front of the collimated camera head to calculate the percentage of 
leakage at each point. All readings should be background corrected. Additional tests 
should be carried out using a radionuclide corresponds to the maximum design energy 
of the camera. The maximum percentage of shielding leakage is reported. If the 
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shielding is insufficient, the percentage value obtained could therefore exceed a value 
of 100%. 
  
For a typical LFOV gamma camera, NEMA [101] has suggested that two types of 
measurement should be carried out. Firstly, the count rate of a test source placed at 
different distances on top of the patient couch but outside the FOV is obtained. Each 
measurement is then compared with the reference count rate measured using the same 
source positioned 20 cm away from and directly in front of the camera collimator. 
Secondly, two sets of count rate measurements are required with a source placed at 2 m 
away from the detector, at the side and in front of the system.  
 
The shielding leakage test for the SFOV gamma camera was modified from the IAEA 
protocol [103] to accommodate the specific requirements of the SFOV gamma camera 
design. As the camera head was a compact shielded enclosure accommodating all 
components it was necessary to check if there were any weak points that potentially 
lead to the unwanted radiation to reach the detector. Twelve check points were 
determined with particular consideration of the exit point of the cable and the joints in 
the shielding. A 4 MBq 99mTc solution in a volume of 0.1 ml was filled in a syringe to 
act as point source. 
 
The collimated camera head was positioned with the detector window facing 
downward. The measurements were carried out with the source placed next to the 
camera head at respective designated positions (Figure 3.18). Then the source was 
located on the central axis of the collimator at SCD of 10 cm (position 12) to obtain the 
reference count rate. Each data was performed with 100 s acquisition. The radioactive 
source was subsequently removed and the background count rate was measured. The 
procedures were repeated using a 4 MBq 111In source in 0.1 ml of the same type of 
syringe. The shielding leakage at each position measured was expressed as a percentage 
of the reference count rate according to IAEA recommendations [103].  
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Figure 3.18: (Left) Schematic diagram of the camera head showing the position of the source during the 
shielding leakage test. Position number 12 is the reference point where the source was placed 10 cm in 
front of the collimator. (Right) Photograph of the experiment set up illustrating the camera head mounted 
on an articulated arm and the source held by a clamp on a retort stand placed adjacent to the camera head.  
 
Figure 3.19 and Table 3.6 shows the shielding leakage at designated positions of the 
camera head as the percentage of the on axis reference value using different 
radionuclides. This ranged from 3.1 % to 135.7 % and 8.1% to 175.1 % for 99mTc and 
111In respectively. The magnitude of the shielding leakage measured using 111In is 
relatively higher than those measurements performed using 99mTc. Both of the polar 
plots are in a butterfly pattern, suggesting that the highest leaking points are at positions 
numbered 2, 3, 9 and 10. With reference to the camera diagram, these might be due to 
the weak joints between the shielding material and the nearest distance from the source 
to the detector. The straight line at the collimator axis was the reference count rate at 
100 %.   
 
 
 
 
 
 
 
 
 
Position 
number 
source 
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Table 3.6: Mean count rate as a percentage of the reference count rate at various positions of the camera 
head.  
Position Percentage of the reference count rate (%) 
99mTc 111In 
1 6.1 ± 2.5 26.6 ± 4.5 
2 135.7 ± 218.8* 155.7 ± 7.8 
3 76.8 ± 12.1 175.1 ± 35.4 
4 17.4 ± 11.8 86.6 ± 3.3 
5 5.3 ± 1.8 20.6 ± 2.7 
6 3.1 ± 0.8 8.1 ± 0.2 
7 6.2 ± 4.2 21.2 ± 1.8 
8 13.5 ± 4.6 69.4 ± 3.4 
9 59.7 ± 39.1 156.8 ± 16.1 
10 30.1 ± 29.4 147.5 ± 3.8 
11 8.4 ± 2.5 20.8 ± 16.2 
*Large standard deviation due to high leakage value in one of the measurement.  
  
 
Figure 3.19: Polar plots of the shielding leakage (%) corresponds to the position around the camera head 
using 99mTc (left) and 111In sources (right).   
 
Detailed investigations were carried out around the region of the highest radiation 
leaking points. Sixteen points were equally distributed over a 360o cross section of the 
camera head (Figure 3.20). From this experiment, the shielding leakage as the 
percentage of the reference count rate at each position was between 11.6 % and 
644.7 %. The polar plot shows the distribution of the radiation leakage pattern where 
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three distinct regions were to be poorly shielded. The unwanted photons that reach the 
detector may cause the deterioration of the image quality and accuracy where more 
noises will present in the image as shown in the Figure 3.20 (inset). The maximum 
percentage of shielding leakage for the camera was 644.7 ± 18.4 %. 
 
 
Figure 3.20: (Left) Photograph of the camera head showing the source position number during the 
shielding leakage test. (Inset) Hybrid image acquired with the source placed at the suspected leaking site 
of the camera head showing insufficient shielding of the camera head. (Right) Polar plot of the percentage 
shielding leakage (%) corresponds to the position around the cross sectional diagram of the camera head.     
 
3.2.10 Optical-gamma image alignment 
The SFOV hybrid optical gamma camera consisted of both a gamma camera and an 
optical camera. The accuracy of alignment of both modalities mainly depends on the 
position of the optical camera, mirror and the pinhole collimator. It is desirable to 
achieve as close alignment of the two cameras as possible but this will depend on the 
design and construction of the system. In practice software corrections are necessary to 
ensure the image of the same structure on the gamma image and on the optical image 
will be accurately superimposed. An optical-gamma alignment test is a measure to 
assess the alignment accuracy of the optical and gamma images. It is expressed as the 
deviation of the centre of mass of a landmark between the gamma image and optical 
image.   
 
Alignment accuracy tests for an inter-modality superimposed images are a unique 
aspect of the performance testing for a hybrid camera, such as SPECT-CT and PET-
CT. In the context of PET-CT scanner, the typical method used to assess the alignment 
accuracy of this modality is to image a test object which has structures that are visible 
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on both PET and CT [109]. Capillary tubes or syringes filled with F-18 solution can be 
used as a source and placed at different locations in the FOV of the scanner. The gamma 
images show the radiation distributions within the test object and the boundaries are 
clearly shown in the CT imaging. The resulting fused image is then used to evaluate the 
alignment accuracy using the software provided by the manufacturer.          
       
The Nebuleye 3 was used in this test as the optical mount had been previously modified 
by the manufacturer. Before performing the alignment accuracy test, the scale factor 
and the x-y axes shift values of each camera system were determined and subsequently 
applied to each image set. The alignment accuracy test was carried out using a hot spot 
phantom with several holes at a separation distance (Figure 3.21). Five holes were filled 
with a solution of approximately 1 MBq of 99mTc in total mixed with red liquid dye. 
Image acquisition was carried out over a 120 s with the phantom positioned at SCD 
between 45 and 150 mm. Resulting images were post-processed and analysed using 
ImageJ 1.47v (National Institute of Health, US). 
 
 
Figure 3.21: (Left) Photograph of the experiment setup during the alignment test using hot spot phantom. 
Circular ROIs were drawn on the spots within the post-processed gamma (middle) and optical (right) 
images. 
 
To determine the scale factor, the ratio between the distance of centre-to-peripheral 
spots of the optical image and gamma image were calculated using images acquired at 
different SCDs. The distances between centre of mass (COM) of the centre spot and 
the peripheral spot in each case were measured. Five circular ROIs were drawn on the 
hot spots within the gamma images, and on the visible well within the optical images 
respectively (Figure 3.21 centre and right images). The average scale factor of the 
camera was 4.55 ± 0.12. This scale factor was then applied to the gamma image and the 
image size was resized to 512 × 512 to match with the optical image size.  
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To calculate the x- and y-axes shift, the difference between the COM of hot spots in the 
scale factor corrected gamma images and the COM of the corresponding ROIs in the 
optical image in x-y directions were quantified. The average shift was 2.3 ± 1.3 pixel 
for the x-axis and 15.5 ± 1.7 pixel for the y-axis. After applying the scale factor and x-
y axes shift correction, the centre and peripheral deviation (in mm with magnification 
factor applied) of the COM between the optical image and the gamma image were 
calculated. For the Nebuleye, the deviation of the COM between gamma and optical 
images was 0.31 ± 0.32 mm at centre and 0.65 ± 0.36 mm at peripheral.  
  
3.2.11 Optical image quality 
The optical camera (uEye XS Industrial Camera, IDS Imaging Development Systems 
GmbH, Obersulm, Germany) of the Nebuleye mini gamma camera system utilised a 
5.04 Megapixels CMOS sensor, an integrated autofocus lens and a digital signal 
processing (DSP). To assess the image quality performance, it involves the 
measurement of the characteristics such as dynamic ranges, speed, resolution and noise 
using objective and reproducible methods [110]. International Organisation for 
Standardisation (ISO) has developed a harmonised framework of standard test charts 
measuring these parameter on digital still optical cameras [111]. These extensive 
performance tests can be performed using a commercially available program such as 
Imatest [112]. However, the software is relatively expensive and complicated.  
 
Bob Atkins [113] has suggested a robust but simpler method to assess the image quality. 
A modified test chart (Figure 3.22) printed on a 4” × 6” glossy paper is used as the lens 
testing target which featured the following test patterns: 
a) Resolution: resolution patterns, Siemens star pattern, sine wave logarithmic 
horizontal resolution target, concentric circle patterns 
b) chromatic aberration: black border 
c) lens focusing: checkerboard pattern 
d) image noise: grey patches 
e) visual assessment of image quality: text blocks  
f) calibration: 100 mm long line, grey scale test strip 
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To assess the lens of a typical digital camera, three or more test charts are attached to a 
sheet of pegboard (top left, centre, bottom right). The centres of the camera and the test 
chart are aligned. The camera is fitted on a tripod while for indoor testing, light 
conditions should be uniform and no reflections from the test targets. The lens testing 
chart image is subsequently being analysed.   
 
 
Figure 3.22: The resolution test chart suggested by Bob Atkins [113]. 
 
Part of methodologies suggested by Bob Atkins was adopted to examine the 
performance of the optical component of the hybrid optical gamma camera due to its 
simplicity and user friendly reason. It was a quick and simple test aimed to understand 
the basic performance of the optical camera particularly the resolution. The test chart 
was printed on a glossy photo paper and attached on the flat table in the clinical 
environment. The alignment between the camera and the test chart was adjusted to the 
right angle in two steps. Firstly, a leveller was used to establish a horizontal plane of 
the camera mounted on the articulated arm. Then a thumbtack or nail with straight and 
thin rod was placed in the centre of the chart at right angle where only the tip of the rod 
was visible.  
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This model of camera enables the end-user to select appropriate fixed focal distance 
(FFD) based on clinical scenario. Multiple optical images of the specified test pattern 
(e.g. resolution patterns and Siemens star pattern) were acquired with different FFD 
and camera-source distance (CSD) settings. The FFD was set within the range from 120 
to 180 (manufacturer arbitrary units) and SSD was between 40 mm and 120 mm. The 
resultant image was showed on the display screen of the camera system. Visual 
assessment was carried out in the same clinical environment by an assessor standing 
approximately 50 cm away with the observer’s eye level parallel to the display screen.            
 
The resolution pattern was observed to determine the minimum line set that could be 
resolved in the image. Table 3.7 tabulates the visual assessment results of the resolution 
test pattern on the selected images. The data can be served as baseline performance for 
the camera. The highest spatial frequency (3.2 lp/mm) was observed with the settings 
of FFD 120 and CSD at 60 mm. The best resolution was achieved at the CSD of 60 
mm, which was approximately 100 mm for the object distance. This was the minimum 
object distance for this model of the optical camera to achieve its optimum 
performance. With the FFD set at 180, no line set was able to be resolved.  
 
Table 3.7: The smallest group of line set (lp/mm) which can be observed in images acquired with 
different FFD and CSD settings. 
CSD (mm) FFD 
120 130 140 150 160 170 
40 2.5 2 1.6 1.25 1.1 1 
60 3.2 2.5 2.2 1.6 1.1 1 
80 2.5 2.2 2.2 1.8 1.1 1 
100 2.2 2 2 1.8 1.25 1.1 
120 1.6 1.6 1.6 1.6 1.25 1 
 
To further understand the resolution on the sensor, the magnification factors at various 
CSD are needed. The magnification factor is the ratio of the height of image and the 
height of the object. The Siemens star pattern was used for the calibration purposes and 
the magnification factor was tabulated in Table 3.8. Then the resolution on sensor 
corresponded to the line set resolved at difference CSD was calculated. The resolutions 
on sensor were range between 71 and 291 lp/mm.    
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Table 3.8: Magnification factor and the calculated resolution on sensor (lp/mm) at different SSD. 
SSD (mm) Magnification FFD 
120 130 140 150 160 170 
40 1/71 178 142 114 89 78 71 
60 1/91 291 228 200 146 100 91 
80 1/112 280 246 246 202 123 112 
100 1/130 286 260 260 234 163 143 
120 1/151 242 242 242 242 189 151 
 
Another test pattern used for the analysis was the Siemens star pattern. The diameter of 
the centre of the star pattern to merge or blur was measured in four different angles. 
The average diameter was subsequently computed in considering the magnification 
factor. Figure 3.23 shows the results the diameter of the centre corresponded to the CSD 
(left) and FFD (right) values. The error bars indicates the standard deviation of the 
repeated measurements. The smaller the diameter of the star pattern starting to merge, 
the higher the resolution of the camera system. The left graph illustrates that the lowest 
resolution of the star pattern occurred with the CSD at 40 mm. This was due to the CSD 
setting below the minimum object distance causing the focus shift.  
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Figure 3.23: Relationship between the diameters of the centre of the star pattern to merge and (left) the 
CSD and (right) FFD (n=4).   
 
Generally, the results were consistent for the CSD settings range from 60 to 120 mm 
and the FFD settings range from 120 to 140. It was increased gradually with the FFD 
setting at 150 onwards. Figure 3.24 demonstrates the examples of the Siemens star 
pattern taken with different CSD and FFD settings. Rings of apparent sharpness in the 
star pattern image (alternate appearance of blurred ring and ring of sharpness) were 
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observed in most of the images acquired at CSD 40 mm. This was due to the CSD 
setting below the minimum object distance causing the focus shift.  
 
  
Figure 3.24: Siemens star pattern acquired using uEye XS optical camera at CSD 40mm and FFD 120 
(left) or 160 (right). The diameter of the centre of the star pattern to merge or blur for image acquired 
using FFD 120 was bigger than image with FFD 160.   
 
3.3 Comparison of the performance characteristic between HGC and 
Nebuleye  
As described in Chapter 2, the technology used in manufacturing the camera head of 
HGC and Nebuleye were identical. Theoretically the performance of these two cameras 
were comparable and correlated well with each other. However, due to different 
manufacturer, software, electronics and design features of the camera heads, certain 
performance characteristics may differ between the two cameras. Newly developed 
testing protocol and analysis method had incorporated these differences to make the 
characterisation works feasible to the Nebuleye and HGC. Performance of a standard 
LFOV gamma camera (Brightview X, Philips Healthcare, Milpitas, CA, USA) [108] 
was also compared with the SFOV gamma cameras. Table 3.9 summarises the 
performance of the HGC, Nebuleye and LFOV camera system.  
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Table 3.9: Comparison of the technical performances of the HGC, Nebuleye and standard LFOV clinical 
camera system.  
Parameter HGC  Nebuleye BrightViewXa 
Intrinsic spatial resolution 
FWHM (mm) 
FWTM (mm) 
 
0.32 ± 0.05 
0.58 ± 0.05 
 
0.28 ± 0.02 
0.52 ± 0.03 
 
3.3 
6.3 
System spatial resolution 
FWHM (mm) 
FWTM (mm) 
 
2.43 ± 0.25 
4.36 ± 0.43 
 
1.84 ± 0.39  
3.37 ± 0.71 
(LEHR) 
7.4 
14.0 
Intrinsic Uniformity  
CoV (%) 
Integral Uniformity (%) 
Differential Uniformity (%) 
 
16.39 
72.30 
11.58 
 
13.54 
51.72 
8.34 
 
NA 
2.5 
2.0 
System uniformity  
CoV (%) 
Integral Uniformity (%) 
Differential Uniformity (%) 
 
24.53 
86.21 
21.86 
 
19.58 
70.73 
16.55 
 
NA 
NA 
NA 
Intrinsic sensitivity (cps/MBq) 17.0 
at 250mm 
12.4 
at 250mm 
NA 
System sensitivity  
(cps/MBq) 
14.68 
at 10mm 
6.60 
at 50mm 
8.86 
at 10mm 
3.82 
at 50mm 
124.78 
(LEGP) 
Spatial linearity  
Absolute (mm) 
Differential (mm) 
 
0.10 
0.02 
 
0.24 
0.05 
 
0.50 
0.10 
Count rate capability  
Input count rate at 20% loss (cps) 
Recorded count rate at 20% loss (cps) 
Maximum recorded count rate (cps) 
 
18620 
2432 
2937 
 
15710 
2537 
2845 
 
NA 
300000 
350000  
Detector head shield leakage  
(max leakage % at 141 keV) 
547.9 644.7 NA 
a Equipped with NaI(Tl) detector in a dimension of 406  × 539 × 9.5 mm;  
NA- Not available 
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Most of the characterisation test results of HGC were based on the experimental data 
provided by the University of Leicester [107]. These raw data were then processed 
using the same data analysis method as the Nebuleye. Another part of the tests were 
newly introduced or modified specifically for SFOV gamma cameras. They were 
carried out in the identical settings for both of the cameras. These included the 
following tests: 
a) Intrinsic uniformity (analysed using Matlab with median filter applied) 
b) System uniformity (new experimental and analysis method)  
c) System sensitivity (quantified using experimental data) 
d) Count rate capability (observation using higher activity)  
e) Detector head shield leakage (new experimental and analysis method) 
 
For comparison purposes, intra-class correlation coefficient (ICC) test was performed 
on suitable testing results to assess the reliability of the measurements. The ICC (single 
measures), 95 % confidence interval (CI) and p-value was reported.      
 
Both the SFOV gamma cameras utilised similar CsI(Tl) having a thickness of 1.5 mm 
and EMCCD as the photon detector. The intrinsic spatial resolution was 0.28 ± 0.02 
mm and 0.32 ± 0.05 mm at FWHM for Nebuleye and HGC respectively. The difference 
of the resolution in term of FWHM between the cameras was less than a pixel’s width, 
i.e. 0.04 ± 0.05 mm. Similarly, the difference of the system spatial resolution between 
the two cameras was 0.59 ± 0.46 mm at FWHM and 0.99 ± 0.83 mm at FWTM where 
the effect of the collimator was took into consideration. The system spatial resolution 
of a standard LFOV gamma camera mounted with low energy high resolution (LEHR) 
collimator was 7.4 mm at FWHM which was about threefold higher than the SFOV 
gamma camera. This indicates that the SFOV gamma camera with a pinhole collimator 
could offer higher resolution images without the involvement of any sophisticated 
image processing.  
 
The intrinsic uniformity of the SFOV gamma cameras was 13.54 % and 16.39 % for 
the CoV of the uniformity image produced by Nebuleye and HGC respectively. With 
the collimator included, the system uniformity increased to 19.58 % and 24.53 %. 
Figure 3.25 shows the corrected uniformity image acquired using Nebuleye (left) and 
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HGC (right). The CoV values for HGC was slightly higher as there were several hot 
pixels appeared on the original flood image possibly due to the manufacturer defect of 
the CCD. In general, the uniformity results are relatively higher than the performance 
of a standard clinical gamma camera. These posed a limitation in the camera 
performance and may need further improvement in future camera development.       
        
  
Figure 3.25: The corrected uniformity image acquired using Nebuleye (left) and HGC (right). 
 
The sensitivity of both the Nebuleye and HGC was studied intrinsically and 
extrinsically. With a point source placed at 250 mm away without the presence of a 
scattering medium, the intrinsic sensitivity was 17.0 cps/MBq for HGC and 12.4 
cps/MBq for Nebuleye. For the system sensitivity, it was 14.68 cps/MBq and 8.86 
cps/MBq for HGC and Nebuleye respectively with the SCD at 10 mm (ICC 0.936, 95% 
CI 0.676 to 0.989, p < 0.001). For the count rate capability test, the recorded count rate 
at 20% loss was 2432 cps and 2537 cps for HGC and Nebuleye respectively (ICC 0.998, 
95% CI 0.996 to 0.999, p < 0.001). Based on the ICC test, both sets of test results were 
in strong agreement (p < 0.001).     
 
For the shielding leakage test, the maximum percentage of leakage at 141 keV was 
547.9 % and 644.7 % for HGC and Nebuleye respectively. These values were above 
the reference value, indicating that the unwanted or background radiation may be 
detected and form as part of the image produced. The position of the maximum 
percentage of leakage was measured at similar height of camera head (position 2-3 or 
9-10) suggested that the current shielding may not be sufficient. For the spatial linearity 
test, the absolute linearity for both HGC and Nebuleye were 0.10 mm and 0.24 mm 
respectively. These were significantly smaller than a standard LFOV gamma camera.  
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3.4 Summary 
This chapter has described the performance testing of the new prototype Nebuleye 
camera. This work has further extended the scope of testing and was successfully 
applied to characterise an SFOV hybrid gamma camera for medical use. The newly 
introduced tests enabled the system uniformity, system sensitivity, detector head 
shielding leakage, optical-gamma image alignment and optical image quality of the 
hybrid camera to be assessed objectively. These tests, combining with the 
characterisation protocol developed by Bhatia et al. [104] and Bugby et al. [105], 
formed a complete and rigorous testing scheme to assess SFOV hybrid optical gamma 
cameras and to compare with other similar SFOV gamma cameras.   
 
Overall the performance of the SFOV gamma cameras was found to be comparable 
when assessed using the same testing protocol. The SFOV gamma cameras have 
superiority in term of resolution and linearity in comparison with the standard LFOV 
gamma camera. With the better understanding of the characteristics of the camera, it 
provides the basis of the experimental work to further evaluate the performances of the 
camera in preclinical and clinical arenas as discussed in Chapter 4, 5 and 8. 
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Preclinical imaging using the SFOV 
Hybrid Optical Gamma Cameras 
 
 
 Introduction  
In vivo small animal imaging is highly valuable for biomedical research as it has the 
capabilities for the non-invasive study of dynamic biological processes in a preclinical 
model of disease at the molecular and cellular level. Over the years, this approach has 
been widely used in evaluating the therapeutic effectiveness of new treatment regimens, 
assisting in the identification of new disease biomarkers, new tracer development and 
drug design [114]. It provides important information in bridging from in vitro studies 
of diseases and explaining the pharmacological mechanisms of pharmaceuticals prior 
to their translation into clinical use.  
 
Dedicated preclinical imaging modalities such as optical, fluorescence, SPECT, PET, 
CT and MRI are commercially available and can produce high quality images. Each 
modality has its own advantages and limitations with regards to resolution, sensitivity, 
signal penetration capability and cost. Immense efforts have been made to complement 
the weaknesses of individual imaging modalities through the innovation of multimodal 
imaging methods, for instance the combined radionuclide and CT imaging.    
 
In nuclear and optical imaging the recent development of multimodal imaging probes 
have propelled non-invasive imaging into a new generation of advanced applications 
[115]. Most of the probes are still in the developmental stage and are yet to be translated 
into clinical use. This advancement is believed to enhance the performance of in vivo 
imaging and may be of benefit to some clinical procedures, in particular in radioguided 
surgery [116]. The combination of two modalities are currently being investigated using 
dual signals emitted from the same probe.           
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Given the current interest in hybrid tracers [117] the development of the HGC to 
become a hybrid gamma-fluorescence camera was considered. Preclinical 
radionuclide-fluorescence imaging may provide added values in this research area. This 
chapter describes the initial assessment of the SFOV hybrid optical gamma cameras for 
use in small animal radionuclide imaging. Part I of the chapter explains the performance 
assessments using bespoke mouse phantoms. Part II describes the use of the SFOV 
gamma cameras in imaging newly developed near infrared fluorescent-radioactive 
hybrid probes.  
 
 Small animal imaging 
The ability to investigate in vivo, anatomical and functional details of experimental 
disease models provides detailed information on pharmaceutical uptake, retention and 
metabolism. The hybrid image, now commonly used fusion of functional and 
anatomical images, can be obtained without having to move the experimental subject 
from one camera to another. Figure 4.1 shows examples of the range of multimodal 
imaging for preclinical animal studies. 
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Figure 4.1: Examples of the commercially available multimodal imaging systems and its applications in animal studies. (a) PET image of 18F-FDG distribution in mice; (b) 
SPECT-CT images of 111In-DTPA-octreotide in mice; (c) Contrast-enhanced whole-body microCT angiogram; (d) Fluorescence-mediated tomography-derived matrix 
metalloproteinase activity in a mouse aorta; (e) Bioluminescence imaging of mouse with orthotopic hypopharynx tumour model; (f) Contrast-enhanced whole-body MR 
angiogram; (g) Fluorescence-mediated tomography-CT image; (h) Multiphoton laser scanning microscope image of a melanoma-bearing mouse expressing vascular green 
fluorescent protein (GFP), using second harmonics generation to detect collagen; (i) Ultrasound image (B-mode) of left ventricle of a mouse. Image taken from [118].
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Amongst these modalities, preclinical SPECT-CT and PET-CT scanners are widely 
used for research purposes in biomedical and life sciences. Figure 4.2 shows example 
of preclinical SPECT-CT and PET-CT imaging systems used in the SPECT PET and 
Optical animal imaging facility (SPOT), at the University of Nottingham. Spatial 
resolution and sensitivity are the main performance parameter in determining good 
quality images in small animals such as mice and rats. For small animal SPECT 
imaging, the imaging systems must have adequately high spatial resolution (≤1 mm 
[114]) and sensitivity to provide a high quality and accurate visualisation of the 
molecular distribution and concentration of the tracer under investigation [119]. Figure 
4.3 shows examples of high quality SPECT-CT (top) and PET-CT (bottom) images of 
mice administered with radiotracers.  
 
  
Figure 4.2: Photograph of (left) nanoScan PET-CT and (right) nanoScan SPECT-CT (Mediso Medical 
Imaging Systems, Budapest, Hungary) in the University of Nottingham preclinical imaging facility 
(SPOT).  
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Figure 4.3: (Top) SPECT-CT images of mouse with kidney excretion of 99mTc-Exendin-4 [120]. 
(Bottom) PET-CT images of nude mouse bearing a tumour on the right leg after administered with 
34 MBq 64Cu-labelled tumour associated antibody [121]. 
 
High spatial resolution SPECT camera design was attained by using a pinhole 
collimator with an aperture diameter in sub-millimetres range and increasing camera 
sensitivity by using multiple pinholes, for example 75 pinholes within U-SPECT II 
Chapter 4. Preclinical imaging using the SFOV Hybrid Optical Gamma Cameras| 96 
 
 
scanner collimator [122]. This camera configuration with the aid of post-processing 
software, enabled the acquisition of high quality small animal SPECT images [114]. 
Table 4.1 summarises performance characteristics of the preclinical SPECT and PET 
scanners at Nottingham for comparison with the HGC.    
 
Table 4.1: Comparison of the SPECT, PET and HGC characteristics.  
 NanoScan PET 
Mediso (122S) [121] 
NanoScan SPECT 
Mediso [120, 123] 
HGC [107] 
Detector material LYSO NaI(Tl) CsI(Tl) 
Crystal dimension 
(mm) 
1.12 × 1.12 × 13 280 × 280 × 9.5 8.19 × 8.19 × 
1.50 
Collimator NA M3 pinhole 1 mm pinhole 
FOV (mm) 100 (axial) 270 × 270  40 × 40** 
Energy window 
(keV) 
250 - 750 200 - 600 30 - 265 
Spatial resolution 
(FWHM, mm) 
0.7* 0.3 1.8 
Sensitivity  8 % 13000 cps/MBq 6.6 
cps/MBq**  
*With 3D OSEM image reconstruction 
** Based on SCD at 50 mm 
NA-not available  
M3-multifocus, multisize, multi-pinhole (16, 25, 36 pinhole per aperture) 
 
At the time of investigation SFOV gamma cameras were not widely used for imaging 
preclinical animal models. Celentano et al. [124] and Autiero et al. [125] have reported 
the use of a prototype fluorescence and radionuclide planar imaging system in mice 
studies. Scintigraphic images were acquired using a semiconductor pixelated detector 
(Silicon or CdTe detector) with a 1 mm diameter pinhole collimator. Other reports have 
described the preliminary assessment of a portable gamma camera in sentinel node 
localisation in pigs and mice [126, 127].  
   
 Phantom imaging  
The performance of the SFOV gamma camera systems used in this work has been fully 
characterised as discussed in Chapter 3. With the introduction of these camera systems 
into preclinical imaging it is crucial that there are systematic methods to evaluate the 
Chapter 4. Preclinical imaging using the SFOV Hybrid Optical Gamma Cameras| 97 
 
 
performance and limitations of SFOV gamma cameras used in animal studies. A 
number of phantoms have been designed and fabricated to assess the performance of 
SFOV gamma camera systems such as the sentinel node phantom (Section 5.3.1) and 
head and neck phantom [128], however the design of these anthropomorphic phantoms 
was not relevant to animal studies.  
 
With this in view, there was a need for the systematic assessment of the SFOV gamma 
cameras using phantoms specifically designed to simulate preclinical imaging, such as 
in mice imaging. The commercially available phantoms such as NEMA NU4 Micro-
PET Image Quality Mouse Phantom (QRM Quality Assurance in Radiology and 
Medicine GmbH, Moehrendorf, Germany) [129] and Micro Hollow Sphere Phantom™ 
(Data Spectrum Corporation, Durham, NC, USA) [130] have mainly been used for the 
quality control testing of preclinical PET or SPECT scanners. However, there is still a 
challenge in the complete filling of small cavities with radioactive solutions without 
bubbles. In addition these commercial phantom can be relatively expensive.    
 
It was envisaged that low cost, simple and versatile phantoms simulating the preclinical 
situation was needed. It is important to examine the performance of the SFOV gamma 
cameras prior to use in animal imaging. The aim of these studies was to assess the 
imaging performance of the SFOV gamma cameras using bespoke mouse phantoms. 
 
 Phantom descriptions 
Phantoms simulating the anatomy of a mouse were designed and developed at the 
University of Leicester. They were used to assess the imaging performance of SFOV 
gamma cameras in the research laboratory of the nuclear medicine clinic at Queen’s 
Medical Centre, Nottingham University Hospitals NHS Trust and the SPOT preclinical 
imaging facility at the University of Nottingham. 
 
 Mouse skeletal phantom 
The mouse skeletal phantom (Figure 4.4) was designed to simulate the skeleton of a 
typical mouse for use in bone scintigraphy. The phantom was fabricated using a PMMA 
plate of dimensions 130 mm (L) × 70 mm (W) × 5 (H) mm. Shallow pits or holes 
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simulating the mouse skeletal anatomy were created on the PMMA plate allowing 
radioactive solution to be filled within the predefined holes. 
 
  
Figure 4.4: (Left) Photograph of mouse skeletal phantom filled with red-colour liquid within the skeletal 
cavities. (Right) Example x-ray Micro-CT Scans of a mouse. (Image taken from Micro CT Laboratory, 
University of Calgary) [131]. 
  
 3-D printed mouse phantoms 
3-D printed mouse phantoms were designed from high resolution 3-D magnetic 
resonance microscopy animal data, as described in [132]. Two mouse phantoms with 
different organ cavities and sizes were fabricated at the Space Research Centre 3-D 
printing centre, University of Leicester. Table 4.2 summarises the technical details of 
the phantoms. The organ cavities were anatomically correct fillable volumes with two 
outlet holes to ease the filling and draining process. These provided a realistic and 
flexible method to test any reporter (radionuclide or contrast agent) for use in small 
animal SPECT-CT, PET-CT or fluorescence cameras, and were considered useful for 
imaging with the SFOV gamma cameras.  
 
5 mm 
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Figure 4.5: Photograph of 3-D printed mouse phantoms, (left) Phantom A and (right) Phantom B. 
 
Table 4.2: Technical specifications of the 3-D printed mouse phantoms.  
 Phantom A  Phantom B  
Descriptions Adult mouse with 
lung cavity 
Baby mouse with lung and 
liver cavities, transparent 
surface 
Organ volume (mm3) 0.6 0.25 (lung) / 0.45 (liver) 
Length (nose to tail) (mm)* 105.57 ± 0.12 79.33 ± 0.12 
Width (mm)* 26.52 ± 0.72 20.27 ± 0.12 
CT number (body)* 150.99 ± 51.52 -57.31 ± 37.54 
*Measurements were performed on CT images using VivoQuantTM 2.50 software (Invicro, Boston, MA, USA). 
 
 Mouse skeletal phantom imaging assessment 
The phantom was used to assess the imaging capabilities of the HGC and Nebuleye 
SFOV hybrid gamma cameras in the research laboratory. Initial imaging was focussed 
on regional scintigraphy where 10.7 MBq of 99mTc solution (activity concentration of 
107 MBq/ml) was filled in the pelvis and hind limb regions of the phantom as shown 
in Figure 4.6 (within the yellow dashed line). Images were taken with acquisition time 
of 60 s and the cameras were positioned at SSD of between 0 and 40 mm. Figure 4.7 
shows the resulting scintigraphic images acquired using Nebuleye positioned at 
different SSDs. With these acquisition settings, the fine details within the pelvic region 
were not resolved, however the radionuclide source pattern within the limb regions 
could be clearly seen.       
Lung Liver 
Lung 
Filling hole 
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Figure 4.6: (Left) Mouse skeletal phantom filled with red-coloured 99mTc solution. Only pelvis and hind 
limbs regions were filled up with the radioactive source during initial regional scan (region marked with 
yellow dashed line). (Right) Photograph of the experiment set up using HGC.  
 
   
   
Figure 4.7: Regional scintigraphy of the phantom filled with 99mTc solution at pelvis and hind limbs 
regions. The images were acquired using Nebuleye positioned at different SSDs (as indicated in the 
images) with imaging time of 60 s. 
 
Further imaging assessment was undertaken of whole body imaging where the 
simulated skeletal system (excluding the tail) was filled with the 99mTc solution at an 
activity concentration of 48 MBq/ml. A series of images was undertaken with the 
camera placed at SSD of 50 mm and 100 mm, and imaging time varied between 1 and 
5 minutes. Figure 4.8 shows example planar images of the phantom acquired using 
Nebuleye positioned at SSD of 50 and 100 mm with imaging time of 1, 3 and 5 minutes. 
0 mm 10 mm 
20 mm 
5 mm 
15 mm 40 mm 
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The hind limbs region were not within the FOV of the camera positioned at SSD of 50 
mm. With the increase of imaging time, the visibility of the pattern of the skeletal 
system was increased, however not at the high resolution expected.       
 
60 s 180s 300 s 
   
   
Figure 4.8: Whole body skeletal phantom imaging acquired using Nebuleye positioned at SSD of 50 mm 
(top row) and 100 mm (bottom row) with the different acquisition times as indicated.  
 
 3-D printed mouse phantom imaging  
Two 3-D printed mouse phantoms described in 4.3.1.2 were used to assess the imaging 
performance of the SFOV hybrid optical gamma cameras using 0.5 mm and 1 mm 
pinhole collimators. The lung and liver cavities of Phantom A and Phantom B were 
filled with 38 MBq and 43 MBq of 99mTc solution respectively. Special care were taken 
to prevent any air bubbles trapped within the cavities. After filling the hole outlets were 
sealed using self-adhesive tape to prevent any surface radioactive contamination.  
 
Imaging was undertaken with the Nebuleye fitted with 1 mm diameter pinhole 
collimator, positioned above and posterior to Phantom A at SSD of 10 mm and Phantom 
B at SSD of 100 mm respectively. The imaging duration time for both image 
acquisitions was 30 minutes. Figure 4.9 illustrated the optical and hybrid images 
obtained from both image acquisitions. The hybrid images provide the location of the 
lung and liver cavities within the mouse phantom. However, it was disappointing that 
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the gamma images failed to show the discrete separation between the right and left lobes 
of lung or the lung and liver cavities for these camera configurations.     
 
Optical Hybrid 
  
  
Figure 4.9: (Top row) Resulted images of the Phantom A filled with red-colour 99mTc solution in the lung 
cavities. (Bottom row) Images of the Phantom B filled with the same radioactive source in the lung and 
liver cavities. Both images were acquired using Nebuleye fitted with 1 mm pinhole diameter positioned 
at 10 and 100 mm away from the camera.    
 
Further imaging were performed using HGC fitted with 0.5 mm pinhole collimator and 
imaging time of 30 minutes. Oblique views were acquired with the HGC positioned 15° 
tilted from the central axis. The view from this angle was selected due to the apparent 
separation between lungs and liver cavities as shown in Figure 4.10 (red arrow). Figure 
4.11 shows the optical and hybrid oblique views obtained. With this camera 
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configuration, the images obtained partially show the separation of the lung and liver 
cavities.      
 
 
Figure 4.10: Photograph of the 3-D mouse phantom experiment set up. The HGC was positioned above 
Phantom B (oblique ~15° from central axis). The green line indicates the border of the lung cavities while 
blue line indicates the liver cavities.   
 
  
Figure 4.11: Optical and hybrid images of Phantom B acquired using HGC fitted with 0.5 mm pinhole 
collimator.  
 
For comparison purposes, imaging of Phantom B with a standard preclinical SPECT-
CT scanner (NanoSPECT/CT®PLUS, Mediso Medical Imaging Systems, Budapest, 
Hungary) in the SPOT preclinical imaging facility was performed. The images were 
viewed using VivoQuantTM 2.50 multi-modal image processing software (inviCRO, 
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Boston, USA). Figure 4.12 shows the SPECT-CT images of different plane of views in 
which there was a distinct demarcation between the lung and liver cavities.  
 
 
Figure 4.12: Sagittal (left), coronal (middle) and transverse (right) view of SPECT-CT image of Phantom 
B (CT acquisition: 45 kVp, 500 ms; SPECT acquisition: 240 projections)  
 
 Discussion 
Imaging with the mouse phantoms using the SFOV gamma cameras has demonstrated 
the challenges in imaging the relatively small sizes of tissues or organs in these models. 
The mouse skeletal phantom provided a simple method to assess SFOV gamma 
cameras in bone scintigraphy. It was however found that the planar images obtained 
from the camera could not resolved the fine details of the small bone structure where 
the separation of the active regions was of the order of 1 mm, however the overall 
pattern of the radioactive source within the phantom could be clearly visualised. One 
disadvantage is that filling of the radioactive solution was time consuming due to the 
fine structure of the phantom. Since it was not possible to seal the activity in the 
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phantom there was a risk of contamination during use. In addition, the radioactive 
solution was found to evaporate over a period of time resulting in non-uniform 
distribution of the radionuclide during the experiments. 
 
The 3-D printed phantom offered a novel method for assessing imaging capabilities. 
Over the range of SCD used, the separation between the organs (lung and liver) was 
not resolved. The 3-D printed mouse phantom featured selected organs to provide a 
robust and realistic test object not only for assessing the SFOV gamma cameras, but 
also for SPECT and PET imaging. These phantoms can be filled with radioactive 
sources of different activity concentrations, and could possibly to be used for routine 
testing of dual-modality radio and near-infrared fluorescent (NIRF) probes in future.  
 
 Evaluation of a hybrid near infrared fluorescent-radioactive 
probe for tumour necrosis imaging 
 Introduction 
Tissue necrosis is a form of cell death caused by external factors or disease, such as 
radiation, and loss of blood supply and is an important factor in tumour growth and 
cancer progression. It is characterised by cell swelling, irreversible plasma membrane 
damage, and organelle breakdown. The detailed processes are discussed elsewhere 
[133]. Since each necrotic dying cell releases pro-inflammatory signals, the amount of 
tissue necrosis can be used as a prognostic factor or predictor of various cancer diseases 
[134]. As a rule of thumb, a higher amount of necrosis represents more aggressive 
tumour cell growth and is usually associated with poor patient prognosis.  
 
Xie et al. [115] have reported the use of near infrared fluorescent (NIRF) carboxylated 
cyanines, namely HQ5 and IRDye 800CW (800CW), which shows significant necrotic 
avidity to quantify tumour necrosis, through optical imaging. This NIRF imaging 
technique provides promise for whole body imaging of small animals as well as 
imaging superficial tissues in human subjects. However, the penetration depth of the 
emitted lights from NIRF agents coupled to biomolecules in living subjects is limited 
to 1-2 cm [135], resulting in the  insufficient detection of light signal from deep seated 
tissues when viewed externally.  
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Nuclear medicine imaging has been used clinically over the decades to image various 
diseases including deep seated tumours due to its high photon penetrative capabilities. 
At the time of this study the Leiden University Medical Center (Leiden, the 
Netherlands) had newly developed cyanine-based radioactive probes for multimodal 
tumour necrosis imaging. NIRF and SPECT imaging were being carried out to evaluate 
the efficacy of the probe in animal tumour models. The aim of this study was to explore 
the feasibility of the SFOV hybrid optical gamma cameras for preclinical imaging, 
particularly to evaluate the in vivo imaging performance of an 111In-labelled probe. 
  
 Method  
 Animal and probe 
The Leiden University Medical Center (Leiden, the Netherlands) prepared the animal 
models and probes for this study. Two female athymic nude mice (BALB/c nu/nu, 6 
weeks old) (Charles River Laboratories, L'Arbresle Cedex, France) were implanted 
with bilateral and subcutaneous 4T1-luc2 tumour cells (PerkinElmer, Waltham, MA, 
USA) onto the lower back region. The mice were identified as M1 and M2 in this 
experiment. Tumours were allowed to grow for approximately 1.5 - 2 weeks after 
tumour implantation until they reached a size of 6 - 7 mm in diameter. Figure 4.13 
shows a photograph of the tumour bearing mouse with two lumps in the lower back.  
 
 
Figure 4.13: Photograph of the 4T1-luc2 tumour bearing mouse. Two bilateral and subcutaneous tumours 
(red circles) can be clearly seen in the lower back of the nude mouse.  
 
The newly developed dual-modality probe (111In-DTPA-RGD-800CW) was prepared 
in-house and administered intravenously into the tumour bearing mice (32 MBq each). 
All experimental surgical and analytical procedures were performed under isoflurane 
gas anesthesia (3% induction, 1.5-2% maintenance) in 70% pressurised air and 30% 
oxygen gas. Animals were sacrificed by cervical dislocation at the end of the 
experimental period. All animal experiments were carried out according to local animal 
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health, ethical requirements and the research was approved by the Animal Welfare 
Committee of Leiden University Medical Center, the Netherlands.  
 
 Imaging 
All imaging was carried out using the Nebuleye and HGC SFOV gamma cameras fitted 
with a 1 mm diameter pinhole collimator. Prior to administration a sample of the tracer 
containing approximately 13.8 MBq was placed in an Eppendorf tube and images 
recorded to test the correct operation of the camera. Following the administration of the 
radiolabelled probe to the mice, the Nebuleye was used to acquire in vivo images of the 
mice at different time points up to 31 hours 41 minutes after administration. The camera 
was either held by the operator or placed on top of a foam or plastic stand during image 
acquisition. Figure 4.14 shows a photograph of the Nebuleye in use during animal 
imaging. After the final imaging the M2 mouse was sacrificed and several tissues were 
excised. Further ex vivo imaging was then carried out. The hybrid planar images of the 
mice were presented in a fused optical-gamma display. A standard SPECT image 
produced by a 3-headed U-SPECT-II gamma camera (MILabs, Utrecht, the 
Netherlands) was available for comparison. 
   
 
Figure 4.14: Photograph of the animal imaging setup at Leiden University Medical Centre using 
Nebuleye. The camera was positioned on an ad-hoc foam stand to minimise motion effect during image 
acquisition.   
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 Results 
Figure 4.15 shows an example of the optical, gamma and fused image of an 111In-
labelled probe in the Eppendorf tube, acquired by Nebuleye during the control testing 
of the camera system. This was the first use of the camera for in vivo radionuclide 
imaging studies in experimental animals in this case nude mice bearing 4T1-luc2 
tumour cells. Figure 4.16 shows the optical, gamma and the fused images of the mouse, 
105 minutes following the administration of 111In-labelled probe. Based on the gamma 
image, these radiotracers could be clearly seen to be accumulated within the central part 
of the body (possibly liver, kidney) and the bladder (excretion).    
 
   
Figure 4.15: (Left) Optical, (middle) gamma and (hybrid) images of Eppendorf tube filled with 111In-
labelled probe (arrow), acquired using Nebuleye positioned on a plastic stand 7 cm away from the source 
and with a 500 s of imaging time. The gamma image also indicated that there was a small amount of 111In 
source contaminated on top part of the tube.       
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Figure 4.16: Example image of mouse in supine position, acquired by HGC at 105 minutes post-
administration of 32 MBq 111In-labelled probe, placed at SCD of 12 cm for a 30 s acquisition time: (a) 
optical (b) gamma (c) hybrid images. Images were cropped and post-processed.  
 
Further imaging was performed using the Nebuleye at different distances and imaging 
times, with the mice in a prone position. Figure 4.17 (top) shows the images of mouse 
M1 26 hours 42 minutes following administration of radiolabelled probe (SSD 12.5 cm; 
10 minutes acquisition) while Figure 4.17 (bottom) shows the image of mouse M2 at 
30 hours 52 minutes post-administration of the probe (SSD 7 cm; 20 minutes 
acquisition). Even though the acquisitions were carried out at nearer imaging distance 
and with longer imaging times, both sets of data only showed a single bright blob within 
a b 
c 
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the central part of the body and did not identify activity within the tumour masses 
implanted on the back of the mice.       
 
Gamma Optical Hybrid 
   
   
Figure 4.17: Gamma, optical and hybrid images of the (top) mouse M1 acquired using Nebuleye 
positioned at SSD of 12.5 cm (on top of a plastic stand) with 10 minutes acquisition time and (bottom) 
mouse M2 acquired at SSD of 7 cm and 20 minutes imaging time.    
 
At this time point, mouse M2 was sacrificed as planned in the study protocol and 
additional images were taken using Nebuleye at a closer distance, focusing on the 
central region of the body. Figure 4.18 shows the images acquired by Nebuleye with 
mouse M2 placed directly on top of the imaging window (~SCD 30 mm). Two bright 
blobs shown in gamma image (Figure 4.18 (a)) were detected with this camera settings, 
representing the radiotracer distribution within the kidneys. As the camera distance 
setting was too close to the mouse, the optical image produced did not show any specific 
anatomical landmarks that could be identified. Figure 4.19 shows series of gamma 
image from the same study acquired using different lengths of acquisition time. 
Subjective visual assessment found that the shape of the kidneys could be clearly 
defined within a minute acquisition time and that there was no advantage by imaging 
over times greater than 100 s.     
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Figure 4.18: The (a) gamma (b) optical (c) hybrid images showing activity distribution in the right and 
left kidneys, acquired 31 hours 41 minutes following administration of 32 MBq 111In to the mouse M2. 
The gamma image was acquired by Nebuleye facing upward and the mouse M2 was placed supinely on 
the top of the camera imaging window, with 200 s acquisition time. 
  
   
   
   
Figure 4.19: Gamma images of the same mouse imaging setup displayed in cumulative time series (from 
10 s to 200 s as indicated in the images). Gaussian blur filter (4 pixel) was applied.  
 
Ex vivo imaging were performed with the excised kidney, tumour and muscle tissues 
(control) from mouse M2 using the HGC. Figure 4.20 shows the image of radiotracer 
distribution in the excised tissues. The hybrid image confirmed accumulation of the 
a b c 
10 s 20 s 30 s 
40 s 50 s 60 s 
100 s 150 s 200 s 
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radiotracer in the kidneys whereas there was no uptake seen in the tumour and muscle 
tissues. For comparison the coronal SPECT image of the same mouse acquired using 
the preclinical SPECT camera system (shown in Figure 4.21), show that the distribution 
of the radiotracer was similar and radiotracer uptake within the kidneys can be clearly 
seen. 
       
   
Figure 4.20: (Left) Optical, (middle) gamma and (right) hybrid images of the excised tissues (kidney (red 
arrow), tumour and muscle), acquired using HGC handheld by operator with camera at 3 cm away from 
the tissues and with a 300 s of imaging time.  
  
 
Figure 4.21: 2-D coronal plane gamma image generated from SPECT of mouse M2, taken approximately 
36 hours after administration of 32 MBq 111In probe. The image was acquired using a 0.6 mm mouse 
pinhole collimated, 3-headed U-SPECT-II gamma camera (MILabs, Utrecht, the Netherlands) with 
energy settings at 171 and 245 keV and a window of 20%. Subsequently, the image was reconstructed 
using 20 Pixel-based subsets for rapid multi-pinhole (POSEM) iterations with 4 subsets, 3-D gauss 0 mm 
(FWHM) filtering and a 0.2-mm voxel size, and with decay and scatter corrections integrated into the 
reconstruction (image provided by LUMC). 
 
 Discussion 
This was an exploratory experiment carried out at Leiden University Medical Centre to 
assess the imaging performance of the SFOV gamma cameras (Nebuleye and HGC) in 
experimental animal tumour models. During this work, additional modifications were 
made to the HGC to explore the proof of concept of NIRF imaging. A bandpass filter 
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with nominal center wavelength of 850 nm (FWHM 100 nm) was fitted to the existing 
optical camera. Even though exploratory NIRF imaging was carried out concurrently 
in this study, using the modified HGC, the pilot results were not discussed in this thesis 
until more promising results have been obtained. An example image (Figure 9.2) is 
shown in the general discussion in Chapter 9. There was limited access to the mice for 
radionuclide and fluorescence imaging since the imaging was performed sequentially 
on an individual mouse, and it was necessary to minimise unnecessarily prolonged 
periods of anaesthesia to reduce any adverse effects on respiration, cardiovascular 
disruption or thermoregulation caused by prolonged anaesthesia [136].  
 
The probe developed in this study was intended for HT29 tumour cell necrosis imaging, 
however following dissection it was shown that the cells did not grow as expected. 
Alternatively, 4T1-luc2 tumour cells were introduced to the nude mice to complement 
the study. No specific uptake of the probe was expected in the 4T1-luc2 tumour cells, 
and this was confirmed from the gamma imaging results. The images show that the 
sensitivity and spatial resolution of the SFOV gamma cameras require further 
improvements for the animal studies especially when imaging a mouse in which the 
sizes of the organ are relatively small.  
 
 Summary 
Preliminary phantom assessments were undertaken using bespoke phantoms to 
examine the performance of the SFOV gamma cameras for use in preclinical imaging. 
The results of the animal study obtained for the first time have demonstrated the 
feasibility of using SFOV hybrid optical gamma cameras for imaging mice injected 
with newly developed 111In labelled tracers. As expected the hybrid cameras do not 
have the superior imaging capability equivalent to SPECT imaging due to the relative 
lower sensitivity and resolution of planar imaging, however they may have a role in 
planar imaging of experimental animal models in a similar way to bioluminescence 
imaging where the fluorescent image is fused with a standard optical image. The 
relatively low cost in manufacturing the SFOV gamma cameras could offer a quick 
look solution for screening large numbers preclinical imaging studies. Further 
investigation is needed to improve the system sensitivity and resolution and to develop 
camera systems for combined gamma-NIRF imaging in future.   
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Assessment of the potential use of the 
SFOV Hybrid Optical Gamma 
Cameras for Breast Cancer Surgery  
 
 
 Introduction  
Breast cancer is the most common cancer diagnosed in women worldwide. In 2014, 
Cancer Research UK estimated that there were 55,222 new cases of breast cancer and 
11,433 deaths in the UK [137]. The disease is mainly divided into two categories, 
namely invasive and non-invasive breast cancer (carcinoma in-situ). Invasive breast 
cancer has the potential to spread from the primary tumour site to other parts of the 
body, through the bloodstream or the axillary lymphatic system, resulting in secondary 
or metastatic breast cancer. The findings using diagnostic imaging modalities provide 
important information for the staging of the disease.  
 
The treatment of the breast cancer may vary depending on the stage of the disease. In 
general it involves surgery or radiotherapy to treat local disease in combination with 
chemotherapy, endocrine therapy or biological therapy to treat systemic disease. The 
axillary node status is a major prognostic factor and is used for tailoring patient-specific 
treatment [138]. The conventional approach to determine the node status was axillary 
lymph node dissection. However this approach carries risks of both acute and late 
morbidities for the patient, with complications such as lymphedema [139].  
 
Sentinel lymph node biopsy (SLNB) is a less invasive method to assess nodal 
involvement in breast carcinoma [140].  This is currently performed with the aid of 
radioguided gamma probe detection. With the current development of high resolution 
SFOV gamma cameras and the increasing interest in the intraoperative applications 
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[54], it was considered that the hybrid gamma cameras may offer potential in the 
localisation of the sentinel node as well as the primary tumour in the breast conserving 
surgery (BCS). This chapter describes the pre-surgical assessment of the SFOV hybrid 
optical gamma cameras for use in intraoperative imaging of patient with breast cancer. 
The cameras were assessed objectively and subjectively using phantom simulations and 
test objects. The test results were then compared with images produced by a clinical 
LFOV gamma camera and a commercially available SFOV gamma camera system.  
 
 Intraoperative imaging in Breast Cancer Surgery 
Povoski et al. [141] has summarised the use of a gamma probe for the intraoperative 
detection of radionuclides. In radioguided breast cancer surgery, the applications 
include sentinel lymph node biopsy (SLNB), radioguided occult lesion localisation 
(ROLL), sentinel node and occult lesion localisation (SNOLL) and radioactive seed 
localisation (RSL) procedures. Gamma probes provide an audible signal that indicates 
the level of radiotracer uptake in breast tissues allowing the surgeon to harvest the 
suspicious nodes or tissues in the same way as surveying an area of ground with a metal 
detector. 
    
With the current technological developments it is apparent that SFOV handheld gamma 
cameras may offer potential clinical utility in any of the aforementioned areas of 
investigation currently carried out using gamma probes. In addition, high resolution 
portable gamma cameras may provide added values in SLNB procedure when no 
standard LFOV gamma camera is available, in cases of difficult drainage or extra-
axillary drainage, where there is low radiopharmaceutical uptake within the target 
tissues, when sentinel lymph nodes (SLNs) are located close to the injection site or 
where there is radiation scatter caused by high activity at the injection site [142].  
 
 Sentinel lymph node biopsy (SLNB) 
Sentinel Lymph Node Biopsy (SLNB) is regarded as the standard method to determine 
the likelihood of cancer spreading from a primary breast tumour and becoming 
metastatic throughout the lymphatic system in cases of early-stage breast cancer with 
clinically negative nodes [140]. It is based on the assumption that invasion of malignant 
cells at the sentinel node triggers potential metastatic growth. Figure 5.1 illustrates the 
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human lymphatic networks and shows an example of cancerous cells migration from 
the primary site to the SLNs.  
 
 
Figure 5.1: Schematic drawing of the lymphatic network (left) and the migration of cancerous cells from 
primary tumour to SLNs through lymphatic vessel. Images taken from [143]. 
 
The standard protocol for the SLNB procedure involves the administration of a 99mTc-
labelled radiotracer (Table 5.1) such as 99mTc-nanocolloid albumin and a blue dye 
(Patent Blue V, Laboratoire Guerbet, Aulnay-sous-Bois, France) to identify the location 
of the sentinel node. A handheld gamma probe is used during surgery to identify the 
uptake of the radiotracer in the node [141]. This gives an audible signal or a visible 
display shown as a count rate. In some centres, lymphoscintigraphy is performed using 
a standard gamma camera or SPECT-CT scanner to image the distribution of the tracer 
prior to surgery (Figure 5.2), however this is not usually carried out in UK departments, 
because most surgeons are now proficient in using the gamma probe alone.  
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Table 5.1: 99mTc-based radiopharmaceutical used in SLNB procedures taken from [143]. 
Colloid composition  Size range (nm) Notes 
Human serum albumin 3–600 
 
Registered in different countries 
in Europe; not approved in USA 
Stannous/stannic hydroxide 30–200 Approved in some European 
countries 
Rhenium sulphide 8–68 Registered in different countries 
in Europe 
Sulphur colloid 
0.1 µm filtered sulphur colloid 
50–1000 
30–50 
Registered in USA 
Antimony trisulphide 2–16 
17–23 
Registered in Australia 
Calcium phytate 150–200 
150–1500 
Mainly used in Japan; size 
depends on Ca2+ concentration 
 
  
Figure 5.2: Example of lymphoscintigraphy (left) and axial plane of SPECT-CT imaging (right) 
performed using clinical camera systems prior SLNB procedure, taken from [143]. Red arrow indicates 
the injection site and the green arrows show the sentinel nodes. 
  
The amount of administered radioactivity typically varies between 3.7 MBq and 370 
MBq depending on the study protocol and patient morphology [144-146]. Only a small 
fraction of the injected radiopharmaceutical clears from the injection site to accumulate 
in the SLN (typically ranging between 0.1 % [147] and 1.0 % [148] of the injected dose 
per lymph node). One of the major factors to determine the efficiency of the nodal 
uptake is the size of the particulate with smaller nanoparticles (<10 nm) generally being 
more suitable for lymphoscintigraphy or rapid SLNB and larger particles (>100 nm) 
being retained longer in the first encountered lymph node [143].  
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Recent developments in SFOV gamma camera technologies offer real time 
intraoperative imaging in SLNB procedures [46, 47, 58, 64, 81, 88, 149-152]. This can 
provide additional information to surgeons in localising the sentinel node, in guiding 
the direction and margin of the dissection and in reducing the potential to miss the 
involved nodes. It is thought that these gamma cameras may also allow monitoring of 
the clearance of the radioactive sentinel node within the lymph basin and localisation 
of deeply seated nodes or nodes adjacent to another source of radioactive uptake which 
cannot be detected by the non-imaging probe.  
 
 Radioguided occult lesion localisation (ROLL) / Sentinel node and occult 
lesion localisation (SNOLL) 
Due to the advances in mammographic imaging and the widespread use of breast 
screening programmes, about 25-35 % of breast cancer detected are non-palpable at 
diagnosis [153, 154]. The accurate identification of the non-palpable lesions pre- and 
intraoperatively as well as the precise localisation of the tumour with its adequate 
resection margin are crucial in the quality of surgical care as these factors affect the 
oncological and cosmetic outcomes [155]. Previously wire guided localisation (WGL) 
has been the standard technique used in guiding the surgical resection of non-palpable 
breast tumours where a guide wire is placed in situ under ultrasonographic or 
radiographic control.            
 
Radioguided occult lesion localisation (ROLL) is an increasingly popular technique, 
which was first reported by Luini et al. in 1998 [156]. The ROLL technique involves 
the injection of 99mTc-labelled macro-aggregates of human serum albumin to the breast 
tumour under the guidance of ultrasonography or mammography. The amount of 
injected activity typically ranges from 3.7 MBq [156] to 90 MBq [157]. A gamma probe 
is used intraoperatively to identify the site of the tumour and to determine the resection 
margins.  
 
This procedure can be combined with the SLNB procedure to harvest SLN, which is 
also known as the combined sentinel node and occult lesion localisation (SNOLL). It 
may involve the additional injection of radioactive source 99mTc-nanocolloid using 
subdermal technique. Several research groups have reported the first use of the SFOV 
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gamma cameras in ROLL and SNOLL procedures [48, 158, 159]. These studies showed 
that the cameras provided intraoperative imaging to guide the localisation of tumour 
and may predict tumour dissection margins. It was also stated that the use of the camera 
may shorten the surgical time in comparison with use of the gamma probe [158].          
 
 Radioactive seed localisation (RSL) 
In 2001, Gray et al. reported a seed localisation technique in the biopsy or lumpectomy 
of non-palpable breast lesions [160].  Radioactive seed localisation (RSL) is another 
radioguided surgical technique to identify occult breast tumours by using the insertion 
of a sealed radioactive 125I seed in the breast tissue to be excised, under ultrasonographic 
or mammographic guidance (Figure 5.3). The gamma probe is then used to locate the 
radioactive seed in order to guide the surgeon to the suspicious opacity or lesion during 
the surgical procedure. Other research groups also proposed the use of a dual-head 
gamma camera system equipped with a parallel-hole low energy collimator to localise 
the radioactive seed [161]. The RSL procedure was found to be simpler than the ROLL 
technique and due to the longer physical half-life of the 125I seed, it could be inserted 
prior to surgery without causing discomfort to the patient [162].  
 
 
Figure 5.3: Example showing the use of mammographic X-ray imaging to reconfirm that the seed has 
been accurately inserted within an invasive ductal carcinoma of the left breast. Taken from [163].  
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Similar to ROLL procedure, the use of SFOV gamma cameras in RSL could be 
beneficial. The camera used should be sensitive enough to detect lower energy gamma 
rays (~35 keV) emitted from 125I and should have the spatial resolution to resolve a 
radioactive seed of small physical size (~1 mm in diameter). Pouw et al. [164, 165] 
reported the feasibility of the application of a freehand SPECT, a unique combination 
of conventional gamma probe with an optical tracking system in RSL. The imaging 
system provided continuous real time 3-D gamma images with information about depth 
and location of the radioactive seeds, thus enabling accurate and adequate excision of 
the tumour. In addition, it was suggested that the RSL technique may improve daily 
clinical logistics and reduce the workload of the radiology department. 
 
 Assessment of the performances of SFOV gamma cameras in 
SLNB 
With the introduction of SFOV gamma camera systems into surgical practice it is 
essential that there are rigorous methods for testing, evaluation and quality control as 
discussed in Chapter 3. Further understanding of the performance and limitations of 
SFOV gamma cameras in SLNB procedure is important to ensure a high quality 
surgical care.  There has to date been limited systematic assessment of SFOV gamma 
cameras, particularly with phantoms designed to simulate the specific intended area of 
use, such as SLNB in breast cancer. The commercially available phantoms have mainly 
been used as training devices for simulation of the sentinel node detection process [166-
168].  In addition, special features of the phantom such as the presence of high activity 
at the injection site, the different node depths (ND), the node-to-injection site separation 
(NS) and the node-to-injection site activity ratio (NIR) which mimic clinical scenario 
are necessary.  
 
Some investigators have reported the use of simple bespoke phantoms in evaluating the 
performance of SFOV gamma cameras. Krohn et al. [169] performed a thorough 
assessment of mobile intraoperative imaging systems using a modified Jaszczak 
phantom. This phantom was commercially available and relatively expensive.  Lees et 
al. reported the fabrication of a mini Williams Phantom with four wells in different 
diameters adjacent to each other specifically to assess the spatial resolution of SFOV 
gamma cameras [170]. Ferretti et al. has also described the use of four small spheres 
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for image quality testing [59]. These phantoms offer an inexpensive and simple method 
for the performance testing, however both phantoms must be filled with radioactive 
solution before use and the difficulty in doing this can be a major limitation due to the 
small cavities to be filled. 
 
For any given SLN procedure differences in patient morphology may result in the 
accumulation of high activity at the injection site or low radioactivity uptakes of the 
node. These may cause radiation scatter effects if there are nodes located adjacent to 
each other, subsequently reducing the chances in detecting the true sentinel node [54]. 
There remains a need for a low cost, simple, versatile and reproducible phantom that 
simulates the clinical situation to investigate these issues and to assess and compare the 
new generation of camera systems entering surgical use. The aims of the study were to 
design a phantom and methods for assessing the specific imaging performance of SFOV 
gamma cameras for sentinel node imaging and to the compare performance with a 
standard LFOV gamma camera. 
 
 Design and construction of the sentinel node phantom 
The phantom was designed to simulate the presence of a SLN and the injection site (IS) 
in a volume similar to that of the human breast, using movable radionuclide sources 
contained in syringes of different sizes. This allowed for the use of liquid sources with 
minimal risk of contamination (as used in a previous design of Perkins et al. [171]) and  
allowed the phantom to be safely and easily reconfigured during use. This modular 
concept phantom consisted of a series of PMMA plates with a layer of bars to provide 
flexibility in positioning the sources accurately within the phantom, allowing node 
depth and node-to-injection site separation to be varied. The use of syringes provided a 
convenient way to load the designated activity concentration of radionuclide.  
 
The phantom was fabricated in the Department of Medical Physics and Clinical 
Engineering, Queen’s Medical Centre, Nottingham University Hospitals NHS Trust 
from Polymethyl-Methacrylate (PMMA), commonly known as acrylic glass. The base 
structure of the phantom was a cube-shaped PMMA support frame, in a dimension of 
120 mm (W) × 130 mm (D) × 110 (H) mm. It was assembled with four 10 mm thick 
plates. This offered pre-determined spaces to accommodate other components of the 
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phantom with variable configurations. Figure 5.4 illustrates the photograph of the 
sentinel node phantom assembly.  
 
 
 
Figure 5.4: (Top) Photograph of the sentinel node phantom assembled with PMMA plates and bars within 
the cube-shaped support frame. Bigger syringe on the top left of phantom represented the injection site 
and the smaller syringe simulated the node. (Bottom) 3-D representation of the sentinel node phantom 
assembly.  
 
Sixteen independent plates and nine bars were stacked within the PMMA support 
frame. A plastic screw was fastened at the end of each PMMA bar to aid insertion or 
removal of the bar during use. The upper surface of the phantom was covered with a 
PMMA plates 
PMMA bars 
Syringe (node) 
Syringe (IS) 
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5 mm thick PMMA plate mimicking the skin surface. BD Plastipak® syringes (Becton, 
Dickinson and Company, Ireland) with maximum volumes of 20 ml and 1 ml were used 
as cavities representing the injection site and node respectively. The syringes were 
partly filled with radioactive solution and sealed with a blind hub to create discrete 
regions of radioactivity at the node-to-injection site activity ratio required.  
 
This phantom design allowed for node depths of between 15 mm and 95 mm and node-
to-injection site separations ranging between 25 mm and 95 mm (centre-to-centre 
distances). This dimensional configuration was based on previously published data 
where the size and depth of breast tumour and node were reported as having a mean 
node depth of 35 mm [172], tumour size of 17 ± 9.4 mm [173] and node size of 7 mm 
[174], with the mean distances from primary tumour to nodes varying between 65 and 
125 mm [175]. Additional syringes could be added to simulate the presence of multiple 
node uptakes should that be required. Table 5.2 summarises the technical specifications 
of the phantom. 
 
Table 5.2: Technical specifications of the sentinel node phantom. 
Features Dimensions (mm) Quantity 
PMMA bars with plastic screw  10 × 120 × 10  9 
PMMA plates 100 × 120 × 5 13 
75 × 120 × 5  1 
75 × 120 × 10  2 
PMMA syringe stopper 10 × 20 × 10  1 
 
Construction of the phantom was straight forward and could be easily undertaken by 
most clinical engineering workshops. The prototype was constructed at a cost of £360 
including materials and labour. Syringes are readily available in all Nuclear Medicine 
Departments and this allows the flexibility for calibration in a standard radionuclide 
activity calibrator and filling with any radioactive liquid at various activity 
concentrations or volumes.  
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 Phantom assessment methods  
 Performance of SFOV gamma cameras 
The sentinel node phantom was used to assess the HGC in the research laboratory of 
the nuclear medicine clinic at Queen’s Medical Centre, Nottingham University 
Hospitals NHS Trust and the Bioimaging laboratory at the Space Research Centre, 
University of Leicester. The performance tests involved the investigation of the 
detectability of a hot spot (node) in the acquired gamma images. During the tests, the 
phantom was used with two syringes filled with radioactive solution. Syringe 1 
(injection site) and Syringe 2 (sentinel node) were filled with 3.0 ml and 0.1 ml of 
99mTc-pertechnetate solution respectively, with node-to-injection site activity ratios 
between 1:100 and 10:100. Figure 5.5 illustrates the experimental set up of the phantom 
imaging tests.  
 
 
 
 
Figure 5.5: (Left) Photograph and (right) schematic diagram of the phantom imaging tests set up. 
 
Syringe 1 was placed at the top left of the phantom, underneath the 5 mm thick square 
PMMA plate to simulate the injection site. Syringe 2 was positioned at different ND 
(between 15 and 95 mm from surface) and NS (between 25 and 95 mm) to simulate the 
node. Series of planar image were acquired with 60 seconds acquisition time. The 
optical camera was used to verify the position of the phantom during the experiments. 
 
Cooling system 
CCD 
Scintillator 
Pinhole collimator 
Optical camera 
Mirror 
Syringes 
Phantom 
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Resultant images were post-processed and analysed by using ImageJ 1.47v (National 
Institute of Health, US). Any outlier pixel(s) (bright spots) were removed and the image 
was filtered and enhanced by improving image contrast. Cumulative detection mode 
was chosen to present all images in this study while centre-point detection mode images 
were used for quantification purposes.  
 
Figure 5.6 gives an example scintigraphic image of the phantom for a NIR 10:100, 
positioned at SCD of 180 mm. The node was positioned at 35 mm beneath the phantom 
surface and 65 mm (centre-to-centre) away from the injection site, which reflected the 
average position as mentioned in Section 5.3.1. Multiple images were acquired with 
different ND, NIR, SCD, NS settings, with the presence of high activity from the 
injection site. Figure 5.7 shows the example of the gamma images acquired at different 
NS and ND. The detectability of the sentinel node was assessed by quantifying the 
contrast-to-noise ratio (CNR) of the node (Section 5.3.2.3) and by the visual 
examination of images (Section 5.3.2.4).  
    
 
Figure 5.6: Gamma image of the simulated IS and node (arrow) (ND:35mm; NS: 65mm) filled with 20.2 
MBq and 2.27 MBq 99mTc-pertechnetate respectively placed at SCD 180 mm. Image was taken using 0.5 
mm diameter pinhole collimator HGC with acquisition time of 60 seconds, subsequently applied with a 
6.0 pixel Gaussian smoothing filter and cropped.  
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Figure 5.7: Image of the phantom with the presence of high activity at injection site acquired using HGC. 
The node containing 0.2 MBq 99mTc (NIR 1:100), at the depth of 15 mm (row a), 45 mm (row b), 55 mm 
(row c) and NS of 25 mm (left column), 35 mm (middle column) and 45 mm (right column). Acquisition 
time for each image was 60 s. Images on row c do not show the node, the apparent features in both these 
images are due to scattered events from the injection site. 
 
The phantom imaging acquired by the HGC gave a good indication of the potential of 
the sentinel node phantom in assessing different types of gamma camera. In light of 
this, the phantom was used with a second SFOV gamma camera - CrystalCam CXC-
CT40A Gamma Camera (Crystal Photonics GmbH, Germany). Figure 5.8 shows the 
experimental set up during the imaging test with the camera system. This camera is 
equipped with changeable parallel-hole collimators (either low energy high sensitivity 
(LEHS) or low energy high resolution (LEHR)), having limited FOV but higher 
sensitivity compared to HGC, resulted shorter image acquisition time.    
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Figure 5.8: (Left) Photograph of the experimental set up during the detectability test. (Right) Gamma 
image of the simulated IS and node (arrow) (ND:15mm; NS: 35mm) filled with 20 MBq and 0.2 MBq 
99mTc-pertechnetate respectively placed at SCD 20 mm. Image were taken using CrystalCam gamma 
camera mounted with LEHS collimator with acquisition time of 5 seconds. The displayed image was 
post-processed with the change of pixel size from 2.5 mm/pixel to 0.625 mm/pixel to smooth the image.  
 
 Performance comparison with standard LFOV gamma camera  
For comparison purposes, imaging with a conventional LFOV gamma camera 
(Nucline™ X-Ring-R, Mediso, Hungary) was performed at nuclear medicine clinic, 
Queen’s Medical Centre, Nottingham University Hospitals NHS Trust. Scintigraphic 
images were acquired using the LFOV gamma camera fitted with a LEHR parallel-hole 
collimator for 60 s in a 128 × 128 matrix. The SCD was set similarly to the performance 
test carried out with the HGC. Images were viewed using a dedicated nuclear medicine 
workstation (Hermes Medical Solutions, London UK). Figure 5.9 shows the 
comparison of the images acquired using LFOV and SFOV gamma cameras in which 
the node at NS 25 mm could not be resolved by the LFOV gamma camera.   
 
 
 
5mm 
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Figure 5.9: Comparison of images acquired using the (row a) LFOV and (row b) SFOV gamma cameras 
with NS of 25 mm (left) and 35 mm (right) at ND of 15 mm. The image acquisition was performed with 
60 s acquisition time at SCD of 50 mm. The arrow indicates the simulated node.  
 
Initial use of the sentinel node phantom for the assessment of Brightview XCT SPECT-
CT camera systems (Philips Healthcare, Milpitas, CA, USA) was also explored. 
SPECT-CT system is one of the standard imaging modality used in pre-operative 
lymphoscintigram. The SPECT-CT images shows both anatomical and nuclear 
information which may guide the surgeon during SLN localisation procedure. Figure 
5.10 illustrate the experiment setup and an image acquired by this camera system. With 
the aid of the CT image, the coronal view of the phantom image shows excellent 
demarcation between the simulated IS and node.    
 
a 
b 
 
15 mm 15 mm 
Chapter 5. Assessment of the potential use of the camera for Breast Cancer Surgery| 129 
 
 
 
 
 
Figure 5.10: (Top) Photograph of the phantom imaging set up in the SPECT-CT camera. (Bottom) 
Example of hybrid SPECT-CT image at ND of 35 mm, NS of 25 mm centre-to-centre and acquired using 
the camera (LEHR collimator) with 1800 s acquisition time. The arrow indicates the simulated node.   
 
 Quantitative assessment (CNR) 
Quantitative assessment was carried out by measuring the contrast-to-noise ratio of the 
node (CNRn) using the equation 5.1. 
 
 CNRn=
Nn-N0
σ0
 5.1 
 
a 
b 
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where Nn is the value of pixels in a node area, N0 is the value of pixels in the background 
area and σ0 is the standard deviation of pixel values in background areas. The 
detectability of a node was correlated with the threshold CNR of the hot spot in the 
image. It was evaluated following Rose criterion [14, 176] where any hot spot with 
CNR value exceeding 3-5, considered to be detectable. The quantification was carried 
out using ImageJ 1.47v (National Institute of Health, US) and the measurements were 
performed three times in order to calculate the standard deviation. 
 
CNR measurements were carried out with the phantom images of nodes located at 
depths between 15 mm and 55 mm with NS of 25 mm and different NIR (1:100 and 
10:100), acquired by the HGC. The CNRn values were ranged between 3 and 62 as 
shown in Figure 5.11. The graph shows that higher radioactivity uptake by the node 
(higher NIR) increases the CNR values. However, the relationship between CNR and 
ND are inversely proportional. In particular, the phantom image assessment showed the 
detectability limits of node seated at depths below 45 mm with NS of 25 mm and NIR 
of 1:100. This indicates that the HGC will be capable to detect sentinel node which 
normally situated at mean depth of 35 mm.    
 
 
Figure 5.11: CNRn values (NS of 25 mm) as a function of ND and NIR (1:100 and 10:100). The images 
were acquired with 1 minute acquisition time using HGC mounted with 1 mm diameter pinhole 
collimator placed at SCD of 50 mm (n=3).  
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 Qualitative assessment  
Two subjective types of visual assessment were performed to determine whether a node 
was detectable in an image acquired by either SFOV or LFOV gamma camera. The first 
assessment was carried out by a medical physics postgraduate researcher to visually 
assess the images followed by categorising them as visible (V), partially visible (P) and 
not visible (N). The second examination was performed by three independent assessors, 
two nuclear medicine professionals and a medical physics postgraduate researcher. 
After randomisation, anonymised gamma images were reviewed on a 24'' flat-screen 
LCD nuclear medicine workstation. Each image was assessed and graded according to 
a standard grading scale in Table 5.3.  
 
 
Table 5.3: Grading scores for detectability assessment of gamma image 
Grade Descriptions Examples 
1 Node not detected.  
 
2 Node partially detected (very faint or partially hidden by 
injection site). 
 
3 Overall node detected without discrete border between node and 
injection site/background (node not clear).  
 
4 Overall node detected with discrete border between node and 
injection site/background, but not excellent image quality.   
 
5 Excellent node detectability with good image quality.  
 
Note: Example gamma images obtained using HGC from the phantom studies. 
 
Table 5.4 summarised the results of the visual assessment of the node detectability. It 
was noticeable that the detectability of radioactivity distributions in the node degraded 
with the increasing depth of the node position. The phantom simulation tests revealed 
that, by visual examination of the images, the LFOV gamma camera could not detect 
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low-activity (0.2 MBq) in nodes with a NS of 25 mm at any depth whereas the HGC 
could detect the node up to the depth of 45 mm, i.e. images are impaired beyond that 
depth. Results from the independent visual assessment scores also suggested that the 
SFOV gamma camera had superior detectability for nodes at NS of 25 mm in 
comparison to the LFOV gamma camera for the same conditions (Table 5.5).  
 
Table 5.4: Node detectability of the phantom images acquired with NIR 1:100, different ND and NS. 
Images were acquired in 60 s using conventional LFOV gamma camera mounted with LEHR parallel-
hole collimator and HGC fitted with 1 mm diameter pinhole collimator.     
Node depth (mm) 
SFOV LFOV 
Node-to-injection site separation (mm) 
25 35 25 35 
15 V V N V 
25 V V N V 
35 P V N V 
45 P V N V 
55 N P N V 
65 N P N P 
75 N P N P 
85 N P N P 
95 N P N P 
V, visible; P, partially visible; N, not visible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5. Assessment of the potential use of the camera for Breast Cancer Surgery| 133 
 
 
Table 5.5: Average scores of detectability of node by three evaluators.  
Node 
depth 
SFOV LFOV 
NS (mm) 
25 35 25 35 
15 4.67 4.67 1.00 4.33 
25 3.67 2.33 1.67 5.00 
35 2.33 3.00 1.33 5.00 
45 2.67 2.33 1.67 4.33 
55 2.00 2.00 2.33 3.33 
65 1.67 2.00 1.33 2.67 
75 4.00 3.00 1.00 2.33 
85 2.67 3.67 1.00 2.67 
95 4.33 3.00 2.00 2.67 
Average 3.11±1.02 2.89±0.82 1.48±0.45 3.59±1.02 
 
 Discussion 
The sentinel node phantom was found to be robust and straight forward to construct 
and simple to use. It was used with syringes that are readily available in any hospital 
setting and would be a useful device for any nuclear medicine department or surgical 
unit with appropriate technical or physics support. Preparation of the syringes with the 
radioactive solution was relatively simple and could easily be performed by nuclear 
medicine or physics staff familiar with drawing up radioactivity in syringes. The 
phantom could also be used in quantifying the performances of various camera and 
detector systems, including LFOV planar and SPECT camera systems as well as non-
imaging gamma probes.  
 
With the modular phantom design, the performances and limitations of a camera system 
may be tested with different configurations (varying ND, NS, NIR and activity). The 
simulations in this study did not include any active background activity given that the 
transportation of radionuclide to the sentinel node is within the lymphatic channels and 
does not contribute significantly to systematic background activity. In future use the 
amounts of radioactivity and experimental methods used may be varied depending on 
the individual practices of different centres (such as one or two-day protocols).    
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One of the challenges in the SLNB procedure was the radiation cross talk at the node 
due to the presence of the high activity at the injection site. Visual assessment in the 
phantom studies have shown that the high resolution HGC could resolve the 
radioactivity uptake in the node even though the simulated NS was 25 mm centre-to-
centre from the injection site. Some nodes were not detected during visual assessment, 
for example the node at a depth beyond 45 mm, even though the tabulated CNRn values 
were above the threshold CNR value. To improve the visibility of the node in display, 
image thresholding, masking the high activity injection site and applying appropriate 
filters during post-processing may be used.  
 
The impairment of node detection with the increasing depth is believed to be due to the 
photon scattering and attenuation. Based on the known mass attenuation coefficient of 
PMMA (0.1497 cm2/g at 140 keV), only 50% of the gamma photons will be transmitted 
through 40 mm depth of material. Furthermore, the sensitivity of the HGC is also 
strongly dependent on SCD as previously assessed by Bugby et al. [105]. Here the 
camera performance testing showed that the SFOV gamma cameras can be a useful tool 
for SLNB procedure in BCS. It is also suggested that the camera system may be used 
in other radioguided SLNB procedures such as in melanoma, head and neck, 
gastrointestinal, penile and vulvar cancer surgeries.  
 
 In vitro assessment of the use in radioactive seed localisation  
Iodine-125 labelled titanium seeds are internal markers which are now becoming 
standard clinical practice to mark the location of the breast tumours in a number of 
hospitals worldwide [177]. In the UK, this surgical technique was first introduced in 
September 2014 to replace the wire guided localisation (WGL) technique [178]. This 
technique involves the implantation of the 125I seed with a nominal activity of between 
3 and 10.7 MBq at the centre of the tumour under the mammographic or 
ultrasonographic guidance [165, 177]. A gamma probe is used to transdermally localise 
the seed prior to incision and subsequently to guide the resection of the tumour and 
verify the clearance of the radioactive source from the breast tissues. The probe is also 
utilised to localise the 125I seed in the excised specimen.     
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The application of gamma probes in localising the seed intraoperatively was further 
improved by the use of freehand-SPECT system [165] and dual-head gamma camera 
systems fitted with parallel hole collimators [161]. This localisation techniques were 
able to provide accurate information about depth and location of the seed. In particular, 
the 3-D navigation system of the freehand-SPECT was able to intraoperatively provide 
images in the operating theatre. However, this system still required further optimisation 
in term of spatial resolution (5 mm) and accuracy in localisation especially with the 
deep seated small lesions and lower activity 125I seeds [164]. When undertaking this 
work it was considered that the hybrid optical gamma cameras could potentially offer 
added values to the RSL technique due to its high spatial resolution and ability to 
provide hybrid optical-gamma images. The aim of the study was to examine the 
imaging performances of the SFOV gamma cameras with 125I seed.  
 
 Performance assessments 
Two 125I-seeds (OncoSeed™ model 6711C, Oncura, GE Healthcare, Arlington Heights, 
IL, USA) was used in this work. The initial activity of the seeds was 8.36 MBq (Seed 
A) and 8.33 MBq (Seed B) respectively which decayed over time during the 
experimental work took place between December 2016 and May 2017. The activity of 
the seeds was calculated and summarised in Table 5.6.   
 
Table 5.6: Calculated activity of the 125I seed over the period of the experimental work. 
Days 
Decayed activity (MBq) 
Seed A Seed B 
0 8.36 8.33 
30 5.89 5.87 
60 4.15 4.13 
90 2.93 2.91 
120 2.06 2.05 
150 1.45 1.45 
 
Figure 5.12 shows the photograph and the schematic diagram of the OncoSeed™. It 
consists of a 0.05 mm-thick welded titanium capsule with the ends sealed by arc 
welding. The 125I is adsorbed into a silver rod with dimension 0.5 mm in diameter and 
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3 mm long, which acts as x-ray marker. The seeds were considered as sealed radioactive 
sources and handled according to the national regulatory requirements. Imaging 
assessments were undertaken with HGC and Nebuleye in the research gamma camera 
facility in Medical Physics, Queen’s Medical Centre, Nottingham University Hospitals 
NHS Trust.  
      
 
 
Figure 5.12: Photograph showing scale in mm (left) and a schematic representation (right) of an 125I-
seed. 
 
Feasibility of the source detection using the SFOV gamma camera was described in 
Section 7.4.4. Sensitivity and spatial resolution of the SFOV gamma cameras using the 
125I seeds were assessed, based on the performance test protocol as detailed in 
Chapter 3. The system spatial resolution test was carried out by the imaging the 125I 
seed in place of a line source due to the diameter of the seed being small enough for the 
purpose of quantification. Table 5.7 tabulates the characteristics of the SFOV gamma 
cameras for both HGC and Nebuleye. Further performance assessments were carried 
out mimicking the clinical scenario, which taking into considerations of different source 
depths, source to surface distances (SSD), activity levels and source separations, 
utilising bespoke phantoms to simulate patient anatomy and position. The hybrid 
optical-gamma images were obtained and assessed. Comparisons were made with a 
standard gamma probe and LFOV gamma camera.    
 
 
 
 
 
 
 
Chapter 5. Assessment of the potential use of the camera for Breast Cancer Surgery| 137 
 
 
Table 5.7: Sensitivity and spatial resolution of the SFOV and LFOV gamma cameras using 125I source.  
Parameter HGC Nebuleye Nucline™ X-
Ring-R 
Gamma 
probe** 
0.5 mm 
pinhole 
1 mm 
pinhole 
1 mm 
pinhole 
 
System spatial 
resolution 
FWHM (mm) 
at 10 mm 
0.75 ± 
0.07 
1.99 ± 
0.23 
1.53 ± 
0.23 
7.3 (LEHR) * 14.47 ± 
0.08 
Intrinsic 
Sensitivity 
(cps/MBq) 
0.25 at 250 mm 
 
0.22 at 
250 mm 
45438 at 25 mm 68.38 at 
250 mm 
System 
sensitivity 
(cps/MBq) 
0.02 at 
48 mm 
1.69 at 
48 mm 
0.41 at 
48 mm 
14.14 at 20 mm 
(LEGP) 
Not 
applicable 
*Data taken from [13] using 99mTc source. 
** Navigator GPSTM with 12 mm angled probe (RMD Instruments Corp., Watertown, MA, USA) 
 
 Seed Depth  
The bespoke phantom described in Section 5.3.1 was used to simulate the breast with 
the seed placed at different depths. Imaging assessments were undertaken with 
Nebuleye and 2.43 MBq of 125I seed placed underneath the PMMA of different 
thicknesses within the phantom (Figure 5.13). The camera was position at SCD of 
63 mm using an image acquisition time of 5 minutes. This camera positioning gave a 
nominal FOV of 52 × 52 mm. These experiments were carried out to measure the CNR 
of the acquired gamma images with seed at depths between 0 mm and 25 mm. CNR 
was quantified using the method as described in Section 5.3.2.3.   
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Figure 5.13: (Left) Photograph of the Nebuleye camera positioned above the 125I seed (arrow) placed on 
top of a PMMA plate to simulate the seed on the skin surface. (Right) Images of the seed acquired at a 
depth of 0, 10 and 20 mm PMMA (top to bottom).     
 
Figure 5.14 illustrates the CNR values ranged from 1 to 22, quantified using the 
acquired images. As expected the graph shows that the relationship between CNR and 
ND are inversely proportional, with the deeper seed depths producing lower CNR 
values. The results illustrate that the seed detectability limits of above 20 mm using an 
amount of activity (2.43 MBq) which was typically lower than that used clinically (3-
10 MBq).  
 
 
Figure 5.14: Relationship of CNR values and depths for the 125I seed images acquired using Nebuleye 
mounted with 1 mm diameter pinhole collimator placed at SCD of 63 mm (n=3).  
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125I decays with the emission of the characteristic X-ray of energies 27.4 keV and 
31.4 keV and a 35.5 keV gamma photon. When the low energy photons interact with 
the scattering medium such as PMMA or water attenuation occurs reducing the number 
of photons which could penetrate through the medium to reach the detector. Figure 5.15 
illustrated the percentages of the photon attenuation when interacting with PMMA and 
water, which was calculated based on the National Institute of Standards and 
Technology (Maryland, USA) data for X-ray interaction cross sections and material 
densities [179]. The half value layer (HVL) of PMMA and water for the 125I was derived 
from the attenuation graph by interpolation, these being 15 mm and 19 mm 
respectively. This gives an indication of the depth of the 50 % loss in tissues. 
 
Figure 5.15: Calculated percentage of the photons attenuation when passing through different thicknesses 
of PMMA and water.  
 
 Source to collimator distance 
Similar imaging assessments were also undertaken with Nebuleye and the 2.4 MBq 125I 
seed, without the presence of scattering medium. CNR measurements were made with 
the gamma images of seed placed at SCD between 20 mm and 100 mm. The CNR 
values were ranged between 6 and 224 as shown in Figure 5.16. The detectability of 
the seed is decreased with the increase of the SCD. The 125I seed positioned at these 
settings can be visible, however with the presence of scattering medium, the 
detectability degraded with the increase of the thickness of the scatter as discussed in 
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Section 5.4.1.1. Figure 5.16 (right) illustrates the gamma images acquired at SCD of 
100 mm, with and without the presence of the PMMA. 
 
 
Figure 5.16: (Left) Relationship of CNR values and SCDs for the 125I seed (2.4 MBq) images acquired 
using Nebuleye mounted with 1 mm diameter pinhole collimator. Image acquisition time was 5 minutes 
respectively (n=3). (Right) Gamma images acquired at SCD of 100 mm without scatter (top) and with 
the presence of 60 mm of PMMA (bottom).  
 
 Acquisition time 
Images acquired with different length of acquisition time were also evaluated. The 
Nebuleye was positioned at SCD of 63 mm to take gamma images of 125I seed with low 
(2.9 MBq) and high (6.4 MBq) amounts of activity. CNR measurements were 
performed with the gamma images of the seed taken with acquisition times between 1 
and 30 minutes. The CNR values were ranged between 4 and 40 for seed at lower 
activity level; between 5 and 127 at higher activity level as shown in Figure 5.17. The 
camera was able to detect the seed in all images acquired with this experiment set up. 
The seed was visually identified in all resulted gamma images. Both CNR values 
increased with the increase of acquisition time. However, the graph shows that the 
increase of the CNR values for the images of seed with higher activity level is steeper 
than those with lower activity level. 
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Figure 5.17: Relationship of CNR values and acquisition time for the 125I seed at low (2.9 MBq) and high 
(6.4 MBq) activity levels. Images were acquired using Nebuleye mounted with 1 mm diameter pinhole 
collimator at SCD of 63 mm (n=3). 
 
 Pinhole diameter  
It was considered of interest to assess the effect of the diameter of pinhole collimator 
used in the SFOV gamma camera. Since the pinhole collimator could not be changed 
in the Nebuleye camera this work was carried out using the HGC.  Images were taken 
using HGC mounted with either 0.5 mm diameter pinhole collimator or 1 mm diameter 
pinhole collimator. The seed (2.9 MBq) was position at SCD between 20 mm and 
100 mm and the imaging time was 5 minutes. The CNR values of each of the images 
were quantified. They were ranged between 1 and 67 for images of the seed placed at 
the SCDs from 20 mm to 100 mm as shown in Figure 5.18. In general, the CNR values 
decreased with the increase of SCDs. Higher CNR values were obtained for images 
acquired using the HGC with 1 mm pinhole collimator, due to higher sensitivity. Most 
of the images were above the CNR threshold, however the imaging assessing showed 
the detectability limit for seed placed at SCD beyond 60 mm, acquired using HGC fitted 
with 0.5 mm pinhole collimator.    
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Figure 5.18: Relationship between CNR and SCDs for images acquired using 1 mm (top row) and 0.5 mm 
(bottom row) pinhole collimators. The number of counts within the ROI of the seed were indicated 
underneath of each images (n=3).   
 
Further imaging assessment were carried out to examine the visualisation of two 125I 
seeds (~1 MBq each) positioned in parallel to each other separated at a distance between 
1, 2 and 3 mm at SCD of 30 mm. Images were acquired with 600 s using hybrid optical 
gamma cameras fitted with either 0.5 mm or 1 mm diameter pinhole collimator. Figure 
5.19 shows the gamma, optical and fused images of the two 125I seeds with a separation 
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of 3 mm (edge-to-edge), taken using Nebuleye fitted with 1 mm diameter pinhole 
collimator. This is the minimum separation of two seeds which could be resolved by 
this camera configuration. The quantified system spatial resolution (FWHM) at SCD of 
30 mm was 3.54 ± 0.23 mm.  
 
   
Figure 5.19: Gamma (left), optical (middle) and hybrid (right) images of the 125I seeds placed with a 
separation distance of 3 mm, taken by Nebuleye mounted with 1 mm diameter pinhole collimator with 
SCD of 30 mm and 10 minutes acquisition time.   
 
With the smaller diameter pinhole collimator (0.5 mm) fitted in the HGC, the system 
spatial resolution (FWHM) at SCD of 30 mm was improved to 2.08 ± 0.07 mm. This 
camera configurations enabled us to resolve the two 125I seeds with a separation of 
2 mm. Figure 5.20 illustrates the line profiles of the gamma images. Two peaks can be 
clearly identified in the Gaussian fitted profile generated from gamma image acquired 
with the seeds placed at 2 mm apart, however a single peak was shown with the seeds 
placed closer (1 mm apart).             
 
 
 
 
 
 
 
Chapter 5. Assessment of the potential use of the camera for Breast Cancer Surgery| 144 
 
 
 
 
 
Figure 5.20: (Left) Line profiles (5 pixel width) drawn across the centre of the hot spot(s) in the gamma 
images (right) with seeds placed 1 mm (top) and 2 mm (bottom) apart. The connecting lines were the 
profiles fitted with Gaussian function. 
 
 Clinical simulation  
Pilot subjective assessment were performed to determine the ability of the SFOV 
gamma cameras in localising the seed in clinical simulation. 125I seed (~6 MBq) was 
placed beneath the skin of breast region of an adult cardiopulmonary resuscitation 
(CPR) training manikin. Four designated positions were marked with letters on the skin 
surface (A to D) as shown in Figure 5.21. The number and position of the located seed 
was blinded to the assessors. Six independent participants (nuclear medicine staff) were 
informed of the study objectives and procedure. Imaging was undertaken using 
Nebuleye positioned at SSD of 100 mm using a 2 minute acquisition time. Images were 
processed and displayed on the beta version of Nebuleye software. The participants 
were asked to visually assess the resulted image subsequently determine the position 
and number of seed involved. If the first image was not satisfactory, a second image 
acquisition was taken with a shorter SSD focusing on the ‘suspected area’ as determined 
by the assessor.     
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Figure 5.21: (Left) Photograph of the clinical simulation. (Right) Post-processed hybrid image illustrated 
a bright blob at the position of “C” surrounded with background radiations.    
 
Table 5.8 summarised the details of the clinical simulation assessment undertaken using 
Nebuleye. All assessors were able to determine the correct number of seeds located at 
the designated sites by visual assessment of the resulted hybrid image. Four of the 6 
assessors required second imaging at a nearer SSD in order to confirm the number and 
location of the seeds.  
 
Table 5.8: List of assessments undertaken using the Nebuleye. 
Assessor Number of 
seeds  
Number of seeds determined (at 
correct position) 
Number of 
images taken 
1 2 2 2 
2 1 1 1 
3 0 0 2 
4 1 1 1 
5 1 1 2 
6 1 1 2 
 
 Simultaneous detection of dual radionuclides 
Pouw et al. [180] have reported the use of standard gamma probes for the simultaneous 
detection of dual radionuclides in a combined RSL and SLNB procedures for non-
palpable BCS. These involved the implantation of 125I seeds to guide the excision of 
primary tumours and the administration of 99mTc-nanocolloid for SLNB. To assess the 
potential of the HGC for the combined procedures of RSL and SLNB a pilot laboratory 
study was carried out in an anthropomorphic breast phantom.  
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An 125I seed (6.25 MBq) and 99mTc solution (0.16 MBq) contained in an eppendorf tube 
were inserted into a bespoke anthropomorphic breast phantom developed at the 
University of Leicester [37]. These were placed 2 cm apart (centre-to-centre), 5.5 cm 
away from the dome apex and 2 cm underneath of simulated skin surface of the 
phantom. Imaging was undertaken using the HGC fitted with a 1 mm pinhole collimator 
positioned 5 cm away from the phantom to record an oblique view as shown in Figure 
5.22. Image acquisition time varied between 30 s and 600 s.  
 
 
Figure 5.22: Schematic diagram of the experimental set up and (inset) breast phantom. Image courtesy 
of University of Leicester. 
 
For comparison purposes, imaging with a conventional LFOV gamma camera 
(Nucline™ X-Ring-R, Mediso, Hungary) and an SPECT-CT camera system 
(Brightview XCT, Philips Healthcare, Milpitas, CA, USA) was performed at nuclear 
medicine clinic, Queen’s Medical Centre, Nottingham University Hospitals NHS Trust. 
The energy window width of 20% centered on the photopeaks of the respective 
radionuclides (30 and 140 keV) were set at both camera systems for simultaneous 
acquisition. Images were viewed using a dedicated nuclear medicine workstation 
(Hermes Medical Solutions, London UK). For SPECT-CT image registration, it was 
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performed using ImageJ 1.47v (National Institute of Health, US) due to the local 
Hermes workstation was limited to fuse two sets of image data.  
 
Figure 5.23 shows the gamma images of 125I seed taken with HGC for various 
acquisition times between 30 and 600 s. In this experiment, both radionuclide sources 
could be detected within a 30 s of acquisition time. Although both sources could be 
seen it was not possible to discriminate between the different gamma emission energies. 
With the increase of acquisition time, the demarcation of the individual source was 
found to be more distinct by subjective visual assessment. 
 
Figure 5.24 shows the phantom images acquired using LFOV gamma camera and 
SPECT-CT camera system with the conditions and sources in place as described above. 
Two hot spots can be clearly seen in both images. With the aid of the CT image, the 
SPECT images were fused and displayed in different colour scales (green: 125I; hot 
metal: 99mTc) to ease identification two different radionuclides accumulate within the 
target tissues (simulating activity in the sentinel node and the seed in primary tumour).    
 
   
30 s 60 s 90 s 
   
120 s 300 s 600 s 
Figure 5.23: Gamma images (oblique view) of the dual isotopes acquired using HGC with different 
acquisition times.  
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Figure 5.24: (Left) Scintigraphic image acquired using LFOVgamma camera with 20 minutes acquisition 
time, phantom placed at SCD of 2 cm and matrix size of 128 × 128. (Right) Fused SPECT and CT images 
obtained using SPECT-CT with matrix size of 128 × 128, 120 projections over a 180° rotation in which 
20 s per projection for each detector. Two separate SPECT images of 125I and 99mTc were generated 
simultaneously in addition to the CT image (3 sets of image data) during the imaging session.     
 
 Discussion 
This chapter describes the first results of the use of the SFOV gamma cameras (HGC 
and Nebuleye) in the detection and imaging of 125I seed sources. The camera systems 
have presented the ability for detecting the lower energy (35.5 keV) of gamma photons 
emitted by the 125I as well as simultaneous detection of 99mTc. This would be 
particularly useful in RSL for non-palpable breast tumours and other soft tissue masses 
[181], as a compliment to the current standard procedure using gamma probe. The 
hybrid images could aid the surgeon in localising the seed thereafter confirming the 
position without additional mammography intraoperatively. This may also be a useful 
tool in assessing clearance of radioactivity around the breast tissues and lymphatic basin 
following surgery and localising the seed ex vivo during removal from the excised 
specimen.  
 
A limitation at the time of the investigation was that the energy window setting was not 
possible in current version of hybrid optical gamma cameras, resulting the same colour 
scale image display of photons detected. This limits the potential of the camera to 
segregate tissue masses when dual radionuclides are used simultaneously for example 
during the combined RSL and SLNB procedures. In addition, the 2-D images do not 
provide any estimation of depth of the radionuclide uptake, which would be crucial 
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information for the more accurate excision and harvesting of the sentinel node and 
tumour masses.  
 
Preliminary camera testing have revealed that SFOV gamma cameras were able to 
detect 125I with activity levels typically used in surgery within an acceptable acquisition 
time. In particular the camera was able to detect the 125I seed at SCD of 63 mm (with 
no scattering material in place) within a one-minute acquisition time. In contrast, the 
camera has a detection limit for deep seated tumours to depths less than 20 mm beneath 
the skin surface with the SCD of 63 mm and 5 minutes imaging time. These limitations 
can be improved by prolonging the image acquisition time and shortening SCD to 
increase system sensitivity and spatial resolution, but the decrease in the FOV and 
longer surgery times may be a problem.    
 
The detectability of 125I seeds can also be enhanced by using larger pinhole collimator 
(i.e. 1 mm in diameter). The camera fitted with 0.5 mm pinhole collimator exhibits 
lower sensitivity but higher spatial resolution. It could resolve two seeds placed at a 
distance of 2 mm with the SCD of 30 mm and 10 minutes acquisition time. With the 
increase of the pinhole diameter (1 mm), the camera was able to resolve seeds at a 
separation distance of 3 mm. These images could be useful for localising multiple seeds 
in the same breast which are embedded under mammographic guidance in the case of 
larger lesions (tumour bracketing) or multiple lesions, in order to aid determination of 
surgical dissection margins.  
 
 Summary 
This chapter describes systematic methods for the assessment of hybrid SFOV gamma 
cameras intended for use in breast cancer surgery. A phantom assessment method has 
been established to examine the performance of SFOV gamma cameras in imaging 
sentinel nodes. The qualitative and quantitative assessments performed in these studies 
could be considered as part of the systematic performance tests of SFOV gamma 
cameras carried out prior to clinical use and the results could serve as baseline data for 
future references. This assessment method examines the detection performance of the 
SFOV gamma camera in detecting SLNs at various ND, NS, NIR and activity, exhibits 
the feasibility of its imaging capability in radioguided surgery or other clinical 
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applications. The methods described may also be used for the further objective 
comparison of the detectability of SFOV gamma cameras, LFOV gamma camera and 
SPECT camera systems as well as intraoperative gamma probes. 
 
In addition, this study also demonstrates the feasibility and capabilities of SFOV 
gamma cameras in the detection of 125I seeds and could be a useful tool in RSL with 
the added benefit of providing hybrid optical gamma images for guiding the surgical 
procedure intraoperatively. The tests show the detectability of the 125I seed at different 
depth, SCDs, acquisition time and diameter of pinhole collimator as well as the 
simultaneous detection of multiple radionuclides. This work adds technical information 
to support the future applications of the SFOV gamma cameras for clinical 
investigations as described in Chapter 8.      
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Preparatory studies of the pre-
production prototype SFOV Hybrid 
Optical Gamma Camera prior to 
surgical use 
 
 
 
 Introduction  
Since initial conception, the HGC technology had been developed to enhance the 
operation, stability and performance for hybrid gamma-optical imaging. The potential 
clinical applications were considered to examine new areas such as sentinel lymph node 
biopsy, radioactive seed localisation and theragnostic procedures. As a result of the 
novel design of the camera and the intellectual property (IP) held by the Universities of 
Nottingham and Leicester, a spin out company called Gamma Technologies Limited 
(GTL) was formed in 2013. A Biomedical Catalyst Fund from the UK Technology 
Strategy Board (Innovate UK) was awarded in 2014 to support preclinical prototyping 
of the device for use in clinical and surgical settings. GTL further developed the 
prototype design together with the industrial partner, Xstrahl Limited (Surrey, UK) to 
transform the HGC into a new medical device, known as Nebuleye. The pre-
commercial prototype, Nebuleye was fabricated and sent to Queen’s Medical Centre, 
Nottingham for initial physical evaluation.  
 
In vitro imaging assessment as described in Chapter 5 evaluated the performance of the 
camera in a clinical environment by using bespoke phantoms and test objects. Further 
preparatory work was undertaken to take the Nebuleye to the stage where it was 
acceptable for use in the operating theatre. For use as a medical device in the clinical 
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setting, the camera design and construction was required to meet the UK regulatory and 
ethnical requirements as required by The Medicines and Healthcare products 
Regulatory Agency (MHRA). This chapter describes the preparatory work undertaken 
in order to meet all requirements for a clinical trial of the Nebuleye in the surgical 
department. It outlines the clinical trial study design for use in SLNB in patients with 
breast cancer, the regulatory requirements and the routine quality control scheme for 
calibration prior to surgical use. Ultimately the clinical trial did not go ahead due to the 
commercial partner not obtaining CE marking of the Nebuleye device, however the trial 
protocol has been developed for future use along with the routine quality control testing 
procedures.  
 
 Regulatory requirements 
 CE marking 
All medical devices must be complied with regulatory requirements as stipulated by 
relevant authorities, for example, CE marking in the European Union Directive 
(Council Directive 93/42/EEC on Medical Devices) [182] and the Premarket 
Notification 510(k) under the Subpart E 21CFR807.92 Federal Food Drug & Cosmetic 
Act [183] before commercialisation. The regulatory processes cover thorough 
assessments which include electrical safety and electromagnetic compatibility, quality 
system management and risk management. In the United Kingdom, all medical devices 
must meet the requirements as specified in the Medical Devices Regulations 2002 [184] 
by carrying out a conformity assessment. Part of the assessments are described in the 
harmonised international standards such as family standards of EN 60601 Medical 
Electrical Equipment and Systems [185], BS EN ISO 14971:2012 Medical devices-
Application of risk management to medical devices [186] and BS EN ISO 13485:2016 
Medical devices-Quality management systems (QMS)-Requirements for regulatory 
purposes [187].  
 
At time of the assessments carried out in this thesis, the Nebuleye camera was 
undergoing the process of documentary filing for CE marking in order to be certified 
as a medical device. Based on the Annex IX of the Council Directive 93/42/EEC on 
Medical Devices, the Nebuleye was classified as Class IIa medical device. Figure 6.1 
illustrates the potential pathways to obtain the CE mark for the camera, under the 
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auspices of the Medicines and Healthcare products Regulatory Agency (MHRA), UK. 
The CE mark application filing was carried out by the manufacturer as part of the device 
development, while the contributions of the work undertaken in this study at the 
University of Nottingham were to carry out device characterisation, preliminary human 
factor analysis, in vitro testing and ultimately a clinical study. This provided 
opportunities to identify any major use issues, so that they could be addressed before 
submitting for final regulatory approval.          
 
 
Figure 6.1: Flowchart of the Class IIa medical devices routes to CE marking taken from [188]. 
Device 
Annex VII: Prepare technical 
documentation to support 
declaration of conformity 
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Production 
quality assurance 
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body including 
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sterile products only) 
Audit by notified body 
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 Clinical trial 
The first use of the SFOV Hybrid Optical Gamma Camera for SLN localisation in 
patients undergoing surgery for primary breast cancer was planned as part of this work. 
It was classified as an investigational medical device study and relevant regulatory 
compliance applications were made through the University of Nottingham as the study 
sponsor. The study was granted with a favourable ethic opinion by the UK National 
Research Ethics Committee (Reference Number: 16/YH/0008) and registered in the 
Clinicaltrials.gov database (NCT02621099).  
 
 Study design 
This was a pilot trial of the use of the pre-production Nebuleye in the operating theatre. 
The primary objective of the study was to assess the validity and agreement between 
the camera and standard gamma probe in sentinel lymph node detection during surgery 
by comparing the performance of the camera with the gamma probe, blue dye and with 
the dual techniques (combined gamma probe and blue dye-guided techniques), in terms 
of overall sentinel node detection rate. In addition, the secondary objectives of the study 
were:  
a) subjective assessment of the intraoperative incremental value of the camera 
compared to the conventional gamma probe; 
b) to assess if the additional information obtained by optical imaging aids sentinel 
lymph node localisation and obtain surgeon feedback on use of the camera; and 
c) to determine if the camera could offer additional information on the detection 
of sentinel lymph nodes in the internal mammary chain. 
 
This non-randomised, non-blinded sequential single centre feasibility study was to be 
carried out at the Breast Surgery Clinic, Royal Derby Hospital Centre, Derby. The 
following text describes the study protocol. Figure 6.2 summarises the sequences for 
this study.   
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Legends:  Standard SLNB   Research procedure 
 
Figure 6.2: Study flow-chart. 
PIS and consent form to be given to the potential participant and signed consent obtained
Radiopharmaceutical administration at the Nuclear Medicine Clinic
Record patient information in CRF
Blue dye administration
Draw external skin mark at sternal notch 
Parasternal image acquisition to localise any uptake in internal mammary node(1st image) using 
the camera
Baseline image (axilla) acquisition prior to surgery (2nd image) using the camera
Assessment of baseline image and record number of node(s) in CRF 
Apply sterile sheath to detector head and arm of the camera
Drape the patient
Incision at the site of suspicous node 
Sentinel lymph node localisation using gamma probe
Sentinel lymph node localisation using the camera (3rd image)
Removal and confirmation of sentinel lymph node activity using gamma probe with 10s count 
and visually inspection of blue dye. Record number of counts at node and background
Residual survey using gamma probe, back to previous step (3rd image with camera) if 
additional node is found
Image acquisition of axillary region for residual check (4th image) using the camera
Record number of node detected by gamma probe, blue dye and dual techniques in the CRF
Specimen image acquisition (5th image) using the camera
Specimen delivered to histopathology lab
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 Patient recruitment 
 Patient selection 
The initial approach will be from a member of the patient’s usual care team or the senior 
research nurse who has permission to access patient data.  They will screen the patient 
details for their eligibility according to the criteria as tabulated in Table 6.1. Once 
patients express interest they will be given the patient information sheets (PIS) and 
consent documents before the study takes place.     
 
Table 6.1: Patient selection criteria for this study.  
Inclusion criteria 
1. Female 
2. Age > 18 years  
3. Scheduled for a Sentinel Lymph Node Biopsy procedure for breast cancer 
4. Has capacity to provide written ‘informed consent’ 
Exclusion criteria 
1. Patients who have had a nuclear medicine procedure with administration of a 
radiopharmaceutical within 72 hours prior to the procedure 
2. Patients who have had prior systemic therapy for the breast cancer being 
scheduled for sentinel node biopsy (e.g. neoadjuvant chemotherapy and 
primary endocrine therapy) 
3. Non-English speaking patient  
  
 Informed consent 
Arrangement will be made for the potential participants to meet with the senior research 
nurse (or the breast surgeons who are the chief or co-investigators) who will obtain 
written consent as appropriate. The investigator will explain the details of the trial while 
ensuring that the participant has sufficient time to consider participating or not. The 
investigator will answer any questions that the participant has concerning study 
participation. It will be explained to the potential participant that entry into the trial is 
entirely voluntary and that their treatment and care will not be affected by their decision. 
It will also be explained that they can withdraw at any time. Informed consent will be 
signed and dated by the participants before they undergo any interventions (including 
physical examination and history taking) related to the study. One copy of this will be 
Chapter 6. Preparatory studies of the pre-production prototype camera prior to surgical use| 157 
 
 
kept by the participant, one will be kept by the investigator, and a third copy will be 
retained in the patient’s hospital records. 
  
 Surgical and imaging procedures 
This study will not alter the standard SLNB procedures provided by NHS treatment. 
Once the patient has given written consent to take part in this study, a participant trial 
identity code number will be provided. Following administration of the 
radiopharmaceutical, the participants will come to the operating theatre for the 
preparation of the breast surgery. Immediately prior to surgery, the investigator will 
review the participant’s consent before proceeding with the study in the operating 
theatre.  
 
Daily quality control tests will be carried out on the camera prior to use in the operating 
theatre to ensure the device is functioning correctly. Before each SLNB procedure, the 
researcher will record the patient information in the case report form (CRF) that will be 
limited to details of radiopharmaceutical administered (radiopharmaceutical, activity 
administered (MBq), date and time of administration), breast cancer details 
(symptomatic or screening, stage of cancer and type such as ductal carcinoma in situ or 
invasive carcinoma) and type of surgery. Subsequently, the surgical and imaging 
procedures will be carried out according to the procedures as listed below:  
 
a) After injection of blue dye, the surgeon will draw a mark on the skin at the position 
of the sternal notch. The researcher will acquire images using the camera focusing 
on the parasternal region (covering the 2nd – 4th intercostal spaces on the side of the 
primary tumour) aiming to localise any uptake of the radiotracer within the internal 
mammary nodes (1st imaging sequence). 
b) Subsequently, the researcher will use the camera to acquire images covering the 
axillary area as a baseline (2nd imaging sequence). The number of visualised 
sentinel lymph node will be documented in CRF.  
c) The surgical team will apply a sterile sheath to the detector head and arm of the 
camera to maintain its sterility. The operating area of the patient will be prepared 
as for the routine procedure.  
Chapter 6. Preparatory studies of the pre-production prototype camera prior to surgical use| 158 
 
 
d) The incision will then be carried out once the patient has been prepared according 
to standard surgical theatre procedures. Sentinel node detection will be performed 
using the gamma probe.  
e) Following incision a further image using the camera will be acquired after the 
surgeon has each positive node confirmed with the gamma probe (3rd imaging 
sequence).  
f) Removal of the nodes will be carried out by the breast surgeon according to the 
normal procedure. The surgeon will assess the excised node by the gamma probe 
with a 10 s count and visual inspection of blue dye (dual techniques). The number 
of counts from the node and background will be recorded in the CRF.  
g) After the removal of all sentinel nodes, the surgeon will perform a residual check 
using the gamma probe, followed by the camera (4th imaging sequence).  
h) The number of sentinel lymph nodes located with gamma probe, blue dye 
technique and dual techniques will be documented in the CRF.  
i) After the surgical procedures are completed, the researcher will acquire an image 
of each excised node with the camera positioned away from the patient (5th imaging 
sequence).  
 
For the imaging steps, further descriptions are illustrated in Table 6.2. 
 
Table 6.2: Descriptions of the imaging plan in this study. 
Imaging 
sequence 
Imaging 
location (ROI) 
Description Operator 
1 parasternal 
region 
(rectangle) 
Camera positions at distance of 
3 cm from patient  
researcher 
2 axillary region 
(oval)  
Camera positions at distance of 
3 cm from patient  
researcher 
3 individual 
positive node(s) 
detected (oval) 
Image each node being detected. 
Camera positions as near as 
possible to the node by surgeon and 
image taken by research team. 
researcher 
and surgeon 
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Imaging 
sequence 
Imaging 
location (ROI) 
Description Operator 
4 repeat axillary 
region (oval) 
Camera positions at distance of 
3 cm from patient.  
researcher 
and surgeon 
5 excised positive 
node(s) 
Image each node being excised. 
Camera positions at distance of 
2 cm from the specimen. 
researcher 
Region of interests (ROI): 
 
Notes: Approximately an addition of 20 minutes (including 12 minutes of average image acquisition time and 8 
minutes of camera system positioning time) are required for each patient investigation in this study. 
 
Images obtained using the camera in this study will include gamma, optical and fused 
gamma-optical images in each acquisition. Settings and protocols (SCD, acquisition 
time, acquisition starting time and anonymised image file name) used will be recorded 
in the CRF. In additional to the intraoperative imaging study using the camera system, 
a subjective assessment using questionnaire method will be carried out amongst the 
surgeons to obtain their feedback. No patient information or clinical data will be 
required as part of this survey. 
 
 Data analysis and statistical test 
Demographic and other prognostic information of patients will be tabulated and 
summarised as appropriate. The following data will also be captured:  
a) Detection rate (binary) by gamma probe, blue dye technique, dual technique and 
the camera 
b) Number of node(s) detected by gamma probe, blue dye technique, dual technique 
and the camera 
 
For the quantitative analysis, the distribution of continuous variables will be 
summarised using mean and standard deviation (if normally distributed) or median and 
Localised Sentinel Node 
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range (if not normally distributed); distribution of categorical variables will be 
summarised by presenting the number and percentages that falling into each categories. 
 
The primary performance endpoints are the validity and agreement between the camera 
and the standard gamma probe in sentinel lymph node detection. The detection rate of 
both detection methods (camera versus dual techniques) will be tabulated as binary data 
(yes/no). Validity analysis will be computed for sensitivity, specificity, positive 
predictive value and negative predictive value. Also Kappa (categorical data) statistical 
method will be used to examine the agreement between two methods. Good agreement 
will be claimed if the value of kappa between 0.81 and 1.00.  
 
The secondary endpoints will be assessed according to the following methods: 
a) McNemar-Bowker method will be used to test the symmetry of detection rate 
between both methods (camera versus dual techniques).  
b) Kappa statistics will be used to assess the extent of reproducibility of the camera 
between different observers in sentinel lymph node detection. 
 
Statistical significance will be achieved if the computed p-value is equal to or less than 
0.05. The results of the user scores from the questionnaire will be assessed to determine 
the level of confidence and additional value evident when using the camera during the 
sentinel node biopsy procedure. 
 
 Equipment acceptance tests  
User acceptance tests are important to ensure the camera system complies with the 
specifications set by the manufacturer. These tests may be performed by a competent 
medical physicist or senior technologist acting on behalf of the purchaser, in addition 
to the tests undertaken by the installing vendor. As the Nebuleye was a newly developed 
pre-production prototype camera there were no acceptance test protocols in place. 
Therefore a user acceptance testing protocol needed to be developed specifically for 
this purpose.  
 
The characterisation tests described in Chapter 3 were considered suitable for the 
examination of the essential performance. These tests should be carried out on site after 
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assembling the camera. In additional to the essential performance test, additional tests 
are also necessary in order to provide a comprehensive assessment of the individual 
components of an instrument [189]. It was also considered important to assess the 
software component of the system at this stage to ensure correct functionality. The tests 
described in the subsequent sections were the additional tests carried out following the 
assembly of the Nebuleye camera system in the research laboratory, nuclear medicine 
clinic, Queen’s Medical Centre. These included CCD temperature stability, imaging 
functionality and software testing.  
 
 CCD temperature stability 
The EMCCD used in the Nebuleye camera head required a Peltier cooling system to 
enhance the detector performance. The manufacturer recommended that the working 
temperature of the CCD in the clinical environment should be within -10 °C and -3 °C. 
During use the imaging system was operating in a typical clinical area with the ambient 
room temperature of 20.2°C. The aim of the test was to examine the ability of the 
cooling system to regulate the CCD temperature within the target temperature (between 
-10 and -3°C) over typical time of use in the clinical area.  
 
After powered on the system, the camera was used intermediately (50:50 cycle 
imaging:standby time) for 5 hours. The temperature of the CCD was measured by 
thermistor attached to the EMCCD and the readings were recorded at 60 minutes 
interval (n=3). For comparison purposes, the test was repeated after four months of 
usage. Figure 6.3 shows the relationship of CCD temperature and time. The CCD 
temperature during initial use was capable of maintaining the target temperature up to 
4 hours of the testing time. This indicated that this camera would have to be shut down 
for cooling after the CCD temperature exceeded the target temperature. Subsequently 
the CCD temperature increased beyond -3°C after 2 hours use during the test performed 
4 months later, indicating that the efficiency of the cooling system had deteriorated and 
required manufacturer attention. 
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Figure 6.3: CCD temperature over 5 hours of use measured at initial stage (blue dots) and after 4 months 
use (green dots) (n=3). 
 
 Imaging functionality  
Tests were carried out to assess the ability of the imaging system to provide high 
resolution optical and gamma images. A bespoke mini Williams Phantom (Figure 6.4) 
developed by the University of Leicester was used [170]. The phantom was filled with 
37.2 MBq of 99mTc solution (red colour) in all the wells. Image acquisition was 
performed with the Nebuleye camera head positioned 1 cm away from the phantom and 
600 s imaging time using the acquisition protocol tabulated in Table 6.3.  
 
  
Figure 6.4: Schematic drawing and photograph of the mini Williams Phantom. The diameters of the wells 
were 4, 3, 2 and 1 mm.  
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Table 6.3: Image acquisition protocol for imaging functionality test. 
Parameter Settings 
Gamma camera 
Background subtraction 3800 (checked “integrate”) 
Background threshold 290 
Optical camera 
Orientation Rotate 270 FlipX 
Fixed focal distance  150  
 
Figure 6.5 shows the images of the phantom acquired using Nebuleye. No artefact as 
shown in image (c) was observed on the optical image of the phantom (a) however the 
edge of the phantom was slightly blurred at this camera setting. The gamma image (b) 
was a raw image generated from the integration of photon events detected in all frames, 
resulting a big bright blob. For this version of software, blob detection feature was not 
available, where this post-processing algorithm allows Gaussian distribution to be fitted 
to each light ‘splash’ produced in order to enhance the image quality (as shown in 
image d). No saturation or thresholding was applied during the image display.   
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Figure 6.5: (a) Optical and (b) gamma images of the mini Williams Phantom acquired by the Nebuleye 
gamma camera system. (c) Example of optical image with artefact acquired by Nebuleye; (d) Post-
processed gamma image of the mini Williams Phantom from the same test.    
  
 Software Testing 
During the time of testing, the Nebuleye software was still under development. Each 
version of software as tabulated in  
Table 6.4 was installed in the Nebuleye system for user acceptance test. The aim of the 
test was to assess the functionality and accuracy of the software features. The testing 
scope included all the features in the software:        
a) Main menu 
b) Patient Data Management 
c) Image Analysis 
d) Image Capture 
e) User Management 
f) Quality Control/Calibration 
g) Image Review 
a b 
c d 
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h) Service Mode 
i) Log out 
 
The detected software errors/bugs were sent to the software developer via an online 
reporting system (DoneDone, Chicago, IL, USA). Once the errors had been rectified, a 
new version of software was installed in the Nebuleye system for further evaluation. 
During the testing period, essential features which considered to be crucial for surgical 
application were also proposed for future inclusion in the software. These were included 
but not limited to:  
a) routine quality control module 
b) colour scale feature for image display 
c) increase the acquisition time limit from 40 s to longer acquisition time 
d) clinical grade image format 
e) post-processing features including blob detection algorithm 
f) concurrent process of image saving and acquisition  
g) optical-gamma image orientation and scale 
h) CCD temperature warning sign 
 
Table 6.4: List of Nebuleye software released for testing. 
Version Date of released/installed 
1.3.49 3 August 2015 
1.3.122 25 August 2015 
1.3.143 18 September 2015 
1.3.145 23 September 2015 
1.3.138 24 September 2015 
1.3.202 7 October 2015 
1.3.222 14 October 2015 
1.3.253 23 October 2015 
1.3.320 14 December 2015 
1.3.322 10 March 2016 
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 Routine quality control tests 
Following the acceptance and commissioning tests, routine testing on a camera system 
is essential to ensure adequate performance for ongoing clinical use. The limits of 
acceptability for the results and course of action to be taken if these limits are exceeded 
should be specified [103]. The tests should be simple and easy to be performed by any 
trained end user within a reasonably short time. In the UK, The Ionising Radiations 
Regulations 1999 through Regulation 32 requires every employer to ensure appropriate 
quality assurance programmes are in place including adequate testing of the 
performance of the equipment at appropriate intervals and after any major maintenance 
procedure or change to that equipment [190]. These tests should be carried out using 
standard protocols, so that the results will be comparable. 
 
The full testing protocols to characterise SFOV gamma cameras described in Chapter 3 
were comprehensive and time consuming and required specialist expertise and so would 
be difficult to carry out in a busy surgical department. Moreover, some surgical 
departments may not have regular medical physics and clinical engineering service 
support. Therefore it was necessary to develop routine quality control tests that were 
simple and practical for routine use.  
 
The aim of the work was to develop a scheme suitable for evaluating the performance 
of the Nebuleye in routine basis prior to a clinical trial of first use. These included daily 
checks that were to be carried out on the day the camera was used and the additional 
tests that were to be performed at specified intervals. For this instrument the camera 
head casing was fixed and the collimator could not be removed by the user, therefore 
only extrinsic tests were possible. This section will discuss those suggested daily and 
monthly tests which were carried out on Nebuleye in order to form the baseline data.  
 
 Visual inspection 
Visual inspection aims to ensure that the camera head has no sign of physical damage, 
that the articulated arm has the correct range of motion, the trolley system is functioning 
properly and the cables and plugs are properly connected and have not been damaged 
during use or storage. Each component of the imaging system that needed to be visually 
Chapter 6. Preparatory studies of the pre-production prototype camera prior to surgical use| 167 
 
 
checked is detailed in Table 6.5. This inspection was performed prior to switching on 
the system to check that all components were in satisfactory condition.  
 
Table 6.5: Visual inspection checks on the Nebuleye. 
 
Camera head 
a) The plastic casing surrounding the camera head was 
inspected for signs of damage or puncture.   
b) The camera head was moved through all possible 
motions. 
c) The camera head interlocking system was checked. 
 
Cart based system  
a) The articulated arms were moved through all 
possible motions and to the fullest extent of travel. 
b) Wheel locks were applied.  
c) The main cable was checked, noting any insecure or 
lose cable which could create a potential trip hazard.  
d) The cart handle was checked.  
 
 
Display screen(s) and keyboard & mouse 
a) The display screens were inspected for scratches, 
fingerprints, dust or other debris.   
b) The image monitors were inspected for any 
interference patterns, rolling, lines or other signs of 
improper operation or electrical interference. 
c) Computer keyboards and accessories were checked 
for proper operation. 
 
Control box 
a) The cable connection with the control box was 
inspected. 
b) The control box surrounding was inspected for signs 
of indentation or puncture. 
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Sterile sheath 
a) The packaging was checked to ensure it was intact. 
The plastic sheath was inspected for signs of tears or 
dirt.  
 
Main power switch  
a) The main power switch was turned on to check 
correct operation and power input. 
 
 System uniformity 
System uniformity testing aims to test the system flood field response of the scintillation 
camera including the effect of any irregularities in the collimator. If available a uniform 
flood source containing Cobalt-57 can be used. However since this was not available a 
uniformly mixed solution containing 30 MBq of 99mTc in 60 ml of water sealed in a 
200 ml Corning Tissue culture flask was considered suitable. The culture flask provided 
a sealed container of small size suitable for the assessing the camera uniformity. The 
activity and concentration was determined to be sufficient to create a uniformity image 
within a pre-determined acquisition time of 10 minutes.  
 
In this test, the collimated detector was irradiated by a thin flood source placed adjacent 
to the transparent window of the protective casing for 10 minutes. Figure 6.6 shows the 
experimental setup for the test. Gamma images were processed and analysed as 
described in Section 3.2.4. Subjective visual assessment was undertaken to investigate 
any non-uniformity of the image count densities (refer Figure 3.10 (b)). No detectable 
change of uniformity across FOV was observed in the image. The value of CoV was 
calculated by computing the mean and standard deviation of counts per pixel over the 
image recorded to identify any changes or trends of the value.  
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Figure 6.6: Experimental set up of the system uniformity and sensitivity tests. The camera head was 
positioned above the flask containing the flood source (mixture of 99mTc solution and red coloured dye).  
 
 System spatial resolution 
The system spatial resolution test aims to assess the sharpness of the image produced 
by the camera with the collimator in place. For routine test, a qualitative approach was 
used for a quick assessment of resolution. This approach was easier to perform than the 
quantitative method and involved the entire imaging process including the image 
display. It may be carried out using a test patterns, phantoms showing artificial lesions 
in a suitable anatomical structure or a transmission mask with areas transparent to 
gamma rays. Subsequently assessment was made to determine the capability of the 
camera in resolving the test pattern detail [106].  
  
For spatial resolution assessment, IPEM [106] have suggested that the width of a line 
on the acquired image represents the spatial resolution of the camera, on condition that 
the width of the line or point source is much smaller than the camera’s resolution. For 
LFOV gamma cameras resolution measurement are commonly made using a suitable 
line or point source of the order of 0.5 mm in size. For SFOV gamma camera the sizes 
should be of the order of 1 mm (where the system spatial resolution at the camera 
surface is of the order of 3.08 mm). Filling small holes or cavities with radioactive 
solution can be difficult and poses the possibility of contamination. Hence, a 
transmission mask was considered to be a relatively practical solution. 
 
For the Nebuleye, a lead transmission mask having dimensions 90 × 124 mm was 
designed and manufactured in house with 5 holes of diameter 1.0, 1.5, 2.0, 3.0 and 
4.0 mm aligned in a straight line. This was fabricated using 4 mm thick lead plate which 
has a thickness that was sufficient to attenuate 99% of 140 keV gamma photons. All 
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holes were within the FOV of the camera at the SSD of 1 cm. A uniformly mixed 
radioactive solution as mentioned in Section 6.5.2 was used to irradiate the detector for 
10 minutes. The transmission mask was laid on top of the flask containing activity and 
the collimated camera positioned above the mask as shown in Figure 6.7.  
 
   
Figure 6.7: (Left) Schematic diagram and (middle) photograph of lead mask with holes (in the unit of 
mm). (Right) Photograph of the experiment setup during the routine system spatial resolution where the 
lead mask was placed in between the camera head and the flood source.  
 
Figure 6.8 shows the resulting scintigraphic image of the resolution test pattern. The 
hot spots indicated the hole sizes of the transmission mask which were visualised  by 
the camera and provided a quick assessment of  the system spatial resolution [106]. The 
image was used as the baseline image for future image comparison.  
 
  
Figure 6.8: Example images of the system spatial resolution test displays: gamma image (left), hybrid 
image (right). These images show three hot spots, corresponding to the minimum hole size of 2 mm.    
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 System sensitivity 
System sensitivity is a measure of the count rate response of a collimated scintillation 
camera to a radionuclide source of known activity. The experimental setup for 
measuring this was similar to the system uniformity test as discussed in Section 6.5.2. 
System sensitivity depends on the collimator sensitivity. Due to the pinhole collimator 
configuration of the SFOV gamma camera, the collimator sensitivity was inversely 
proportional to the SCD. Therefore, the measurement should be reported in terms of 
cps/MBq at a specified SCD. The physical size of the flood source and the wall 
thickness of the container should be minimal (about 3 mm) to reduce the effects of any 
source self-attenuation [106].   
 
For consistency of the routine testing, radioactive solution contained in the flask as 
described in Section 6.5.2 was used for all procedures. The image acquisition time of 
100 s was required and the activity of the radionuclide and the time of day were 
recorded. The resulting image was post-processed and the number of counts for each 
image was recorded. Subsequently measured count rate (C) was calculated, corrected 
for background count rate. The decayed activity in the source (A) was also calculated. 
The system sensitivity (cps/MBq) was then computed using the Equation 6.1.   
 
 
Sensitivity=
C
A
 6.1 
 
Since the dimension of the flood source was larger than the FOV of the camera, IPEM 
[106] has suggested that the calculation needs to consider the loss of the photons due to 
the inadequacy of the detector area by using Equation 6.2.  
 
 
Sensitivity=
C
A
×
Ds
Dc
 6.2  
 
where Dc is the area of the field of view of camera and Ds was the area of the source 
both at the specified SCD. The system sensitivity for Nebuleye was 
1.34 ± 0.15 cps/MBq at SCD of 10 cm. 
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 Cooling test 
The cooling test aimed to assess the ability of Peltier cooler to cool down the CCD from 
ambient room temperature to the target temperature within a pre-determined cooling 
period. It should be performed daily before the camera is used. Experimental work was 
carried out to examine the time taken for the CCD to reach the target temperature after 
the initiation of the system. The ambient temperature of the room was recorded using a 
therma-hygrometer. After powering up the system, the temperature of the CCD 
measured by the thermistor in the CCD package was recorded at 2 minutes interval over 
a period of 10 minutes.  
 
Figure 6.9 shows an example where the temperature of CCD decreased over time during 
use. It was able to reach the target temperature of -3°C at approximately 3 minutes after 
the software initiation (n=6). The readings of the temperature measurement remained 
stable at the lowest temperature within 5 minutes of powering up. Therefore, the cooling 
duration for the CCD to reach the target temperature was considered to be within 5 
minutes and thereafter this was used as baseline data for future reference.  
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Figure 6.9: CCD temperature after system initiation (n=6).  
 
 Imaging functionality 
The functionality of both the optical and gamma cameras was required to be checked 
prior to daily use. This test examined the ability of the gamma and optical cameras to 
produce fused images as expected. The images should have no artefacts or deviation 
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from expected quality. Any artefact or suspicious noise that appeared in the image, 
required further investigation. For clinical use, since the availability of radioactive 
sources may be limited in some surgical departments, it was suggested that the most 
readily available point source would be a small amount of 99mTc placed in the tip of a 
one ml syringe preferably capped with a blind hub. For this measurement, the tip of the 
syringe was placed 5 cm underneath the camera head. Image acquisition was performed 
using a 100 s imaging time. Examples of the gamma and optical images produced are 
shown in Figure 6.10. Such images could be used as reference images.  
 
  
Figure 6.10: Gamma (left) and optical (right) images acquired by the Nebuleye with 100 s acquisition 
time. There were three hot spots at the peripheral area due to scattered events or background radiation 
and these can be eliminated by adjusting the threshold and saturation level at image display. The gamma 
image was post-processed with 6.0 pixel Gaussian smoothing filter.  
   
 Background radiation level 
This test aims to check the background count rate of a scintillation camera in the clinical 
environment. The background count rate value is recorded over a period of time to 
illustrate any trends of the values. Significant change of background count rate may 
indicate that there is an increase in environmental radiation from local sources (patient 
administrated with radiopharmaceutical), radioactive contamination of the instruments 
or its surroundings or random noise caused by the device itself or that the detector 
sensitivity has been impaired. For this measurement, the camera head was positioned 
with the detector facing downward using an image acquisition time of 100 s. The image 
was post-processed and the number of counts in each image was quantified. The 
background count rate of the Nebuleye in the research laboratory, nuclear medicine 
clinic, QMC was 0.03 ± 0.03 cps (ranged between 0.01 to 0.18 cps).  
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 Proposed routine quality control scheme and calibration jig design 
Based on the initial physical evaluations of Nebuleye, the previously described 
harmonised routine quality control scheme and the limits of acceptability were 
proposed. These tests were considered as a simple and robust scheme to be carried out 
by the end users, which should be possible in department with limited resources. Table 
6.6 summaries the recommended tests and the acceptance limits for the Nebuleye 
camera. 
 
Table 6.6: Reporting parameter and the limit of acceptance for the routine quality control tests. 
Tests Parameter Tolerance 
Physical 
inspection 
Visual inspection No physical damage, all 
parts functioning. 
System spatial 
resolution 
Visual inspection: minimum 
detectable size of hole (actual 
diameter) 
No significant deviation 
with reference image 
System 
uniformity 
Qualitative: Visual inspection 
Quantitative: CoV 
No significant non-
uniformity 
<10% manufacturer 
specification [103] 
System 
sensitivity 
Counts/s/MBq <10% manufacturer 
specification [103] 
Cooling test Cooling time < 5 minutes to reach target 
temperature 
Imaging 
functionality 
Visual inspection No artefact or significant 
deviation with expected 
image 
Background 
count rate 
Counts/s <20% of the reference value 
[103] 
 
The routine quality control tests discussed above required a flood source and 
transmission mask, positioned in a fixed distance away from the detector during the 
image acquisition. The experimental work described in the previous sections has 
demonstrated the feasibility of the proposed methodology. For future use it would be 
necessary to simplify the testing procedure. Therefore a calibration jig suitable for use 
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with the Nebuleye SFOV gamma camera has been proposed. This should be capable of 
accommodating the required tests in a reproducible manner on a routine tests.   
 
A bespoke calibration jig designed for this purposes was proposed. This was a 
cylindrical shape with a small stand designed to fit in the camera head at a fixed 
distance. This included a sealed cylindrical shaped flat tank of height approximately 
5 mm which could be filled with radioactive solution to act as flood source. The side 
wall of the flat tank is intended to be fabricated using PMMA and it should be thin 
enough to reduce the possibility of the gamma ray self-absorption. Sealable ports should 
be included for easy filling and draining of the radioactive solution which can be 
secured using plastic screws. This is to ensure that the flood source may be sealed 
during use and to minimise any bubble trapping during the flood source preparation.  
 
The jig was designed so that the resolution transmission mask could be slotted in 
between the flood source and the camera. The resolution transmission mask was to be 
fabricated using 4 mm thick lead with holes of different diameter (1, 1.5, 2, 3 and 4 
mm) as previously described. This mask should be easy to insert and remove from the 
jig whenever necessary. Figure 6.11 illustrates the design concept of the calibration jig. 
An interlock system was designed to fit the camera head. A flat base would keep the 
camera standing upright with the flood source in a level position during the test.  A 
spirit level could be included in the design to enable the user to check for horizontal 
placement of the liquid source. 
 
 
Figure 6.11: (Left) Design concept and (right) schematic diagram of the calibration jig attached to the 
camera. (Image courtesy of GTL) 
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 Summary 
This chapter has described the documentation and protocol required for a pilot clinical 
trial of a hybrid optical-gamma camera for use in sentinel node localisation procedure 
during breast cancer surgery. 
 
Although the trial was terminated before it began the protocol and quality control 
testing procedures have been established and are suitable for future use once CE 
marking of the system has been achieved. The initial physical evaluation of the camera 
using the proposed quality control scheme has established the baseline data for 
Nebuleye. These data may be valuable in the initial stage of device development in 
order to monitor the performance of the camera over a period of time during initial 
clinical use. 
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Assessing the capabilities of the pre-
production prototype SFOV Hybrid 
Optical Gamma Camera  
 
 
 Introduction  
Although the clinical trial described in Chapter 6 did not go ahead as planned, the 
camera offered potential in other areas of nuclear imaging. Further work was 
undertaken to explore the use of the camera as a handheld device and to assess the 
capabilities of the system for a range of clinical applications. The Nebuleye camera 
utilised similar detection technology to the HGC which had been calibrated with 99mTc 
(140 keV), 109Cd (22.16 keV and 24.94 keV X-ray) and 241Am (59.5 keV) [43]. It had 
not previously been tested with other radionuclides commonly used in nuclear medicine 
such as 123I (159 keV) and 111In (171 and 245 keV).  
 
Due to the compact nature of the SFOV gamma camera, it allows the device to be 
handheld when in use hence increasing access to procedures which are inaccessible 
when using other larger size gamma cameras. However, the voluntary and involuntary 
movement of the operator may cause deterioration of image quality subsequently affect 
diagnosis accuracy. Experimental work was carried out for the first time to examine the 
operator motion effects when imaging with the SFOV gamma camera. In addition, a 
qualitative survey of the end user feedback pertaining to the ergonomics of the 
Nebuleye design was undertaken as part of the device improvement process during the 
pre-production stage. This chapter examines the imaging consequences of operator 
motion effects and provides user feedback on the system ergonomics, as well as the 
first results of imaging a range of radionuclides including 99mTc, 111In, 123I, 125I and 75Se.   
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 Ergonomics  
Ergonomics, also known as human factors, are crucial considerations in the design and 
manufacture of a medical device which is intended to be used by operators in the 
clinical setting. It can be defined as “the application of knowledge about human 
capabilities (physical, sensory, emotional, and intellectual) and limitations to the design 
and development of tools, devices, systems, environments, and organisations” [191]. 
As with any medical device, the incorporation of human factors in the design and 
construction of the SFOV gamma camera are important if these systems are to be used 
routinely in the clinical settings. As described in Chapter 2 the camera began in the 
laboratory with a rectangle shaped casing surrounded by crude lead covering with sharp 
edges, then gradually progressing through different stages of development until it was 
suitable for use in a clinical environment. Figure 7.1 shows the transformation of the 
final experimental prototype HGC to the current design of Nebuleye.      
 
 
Figure 7.1: Translation of prototype HGC (left) to become Nebuleye (right). Image courtesy of GTL. 
 
All medical devices must demonstrate appropriate safety and performance compliances 
prior to clinical use. Even though the Nebuleye camera head is not intended to be used 
in direct contact with patients, it was still required to demonstrate that the camera was 
electrically safe and electromagnetically compatible. The camera design should be 
robust with solid construction and the surfaces should be easy to clean to maintain 
cleanliness and to prevent any cross infection. The camera was designed for use in the 
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clinic, at the patient bedside and also for use in the operating theatre where the camera 
head and the articulated arm would be required to be placed in a sterile sheath or drape 
to ensure sterility. This is an important consideration to enable repeated use with 
consecutive surgical cases.  
  
The design of the camera head should be compact with flexibility of movement so that 
it may be placed firmly in position over the patient. The user interface should also be 
user-friendly and simple to operate for acquiring and recording good quality images 
within a reasonably short acquisition time. Acquiring standard gamma images often 
takes a few minutes, although most surgeons would prefer to see images available 
within seconds rather than minutes to complete surgical procedures in the minimum 
time possible. It has been suggested that a FOV of approximately 50 mm × 50 mm is 
optimal for surgical application [54]. These factors had been carefully considered 
during the early stage of the Nebuleye design. The following sections describe user 
evaluation of the first pre-production prototype Nebuleye, which was sent to Queen’s 
Medical Centre in 2015.  
 
 Qualitative user assessment 
Patient safety and performance of the medical device are the main factors to be 
considered when introducing new equipment into clinical use. The National Patient 
Safety Agency (NPSA) (now part of NHS England) [192] has published a guidance 
document describing methods of user testing in the pathway of medical device 
development. This document suggests various research methods that may be used at 
different stages of device development, for example ethnography, task analysis and 
focus groups, interviews and questionnaires. These methods are complementary to 
those formal approaches such as Failure Modes and Effects Analysis (FMEA) and do 
not replace the regulatory requirements.  
 
Preliminary human factor analysis with the involvement of a small group of healthcare 
professionals was carried out during the early stage of development of the pre-
production prototype Nebuleye. A questionnaire was designed and used as a quick and 
inexpensive way of collecting the opinions of a small group of potential end users. The 
aim of the evaluation was to assess the system functionality in order to optimise its 
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performance and safety in the clinical environment, particularly in the operating theatre 
during surgical procedures. The data from this survey was needed for further device 
development before finalising the system design and configurations.   
 
Healthcare professionals who were potential users of the camera system were included. 
Nine participants (3 surgeons, 4 clinical scientists, 1 nuclear medicine technologist and 
1 clinical engineer) were invited to the nuclear medicine clinic at Queen’s Medical 
Centre to take part in this pilot study. The camera system was set up in a clinical 
research room, using an adult cardiopulmonary resuscitation (CPR) training manikin in 
a supine position on the patient couch, to simulate the situation in the operating theatre. 
A questionnaire (see Appendix B) containing 19 questions (5-point Likert scale, polar, 
multiple choices or open questions) was distributed and brief introduction of the camera 
system was provided to each individual participant in the study. The participants were 
given the opportunity to ask questions and to use the camera (without any radioactive 
sources), before completing the questionnaire. Feedback on some of the expertise-
related questions were not provided by all respondents hence the sum of responses do 
not equal 9 for all questions.     
 
 Results 
Table 7.1 shows the summary of the selected responses regarding the first impression 
and the added value in intraoperative procedures. On first impression all 9 participants 
agreed that this camera system was suitable for use in the operating theatre and visually 
attractive. Eight participants agreed that it had good surface finishing and 7 were agreed 
that it had appropriate functionality for clinical use. One participant disagreed due to 
the stiffness of the articulated arm and camera head holder joint when moving the 
camera into position. With regards to the the hybrid optical-gamma camera providing 
added value in patient management during intraoperative procedures, when compared 
to a gamma probe, most of the participants agreed that it could ease the localisation of 
uptake (7/8), useful in re-examination of any radioactive residue (8/8), provide images 
for medical-legal purposes (6/8) and potentially assist with dissection of tissue margins 
(5/8).  
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Table 7.1: Responses on the first impression and the added value in intraoperative procedures. 
First impression (n=9) Disagree Unsure Agree 
Suitable for use in the operating theatre 0 0 9 
Visually attractive 0 0 9 
Good surface finishing 0 1 8 
Appropriate functionality 1 1 7 
Added value in intraoperative procedures 
Easier for localisation of uptake 1 0 7 
Assists with dissection of tissue margins 0 3 5 
Re-examination of any radioactive residue 0 0 8 
Provide images for medical-legal purposes 0 2 6 
Note: The sum of responses do not all equal 9 depending on the feedback provided. 
 
Most participants (8/9) had no safety concerns regarding use of this device in the 
operating theatre and were satisfied with the size and the weight of the camera head 
(6/9), articulated arm (9/9) and trolley system (9/9). The participants also showed that 
they felt comfortable when holding the camera head (7/9), with the trolley near the 
patient couch (9/9) and moving the articulated arm (7/9). However, four participants 
thought that the camera system may present difficulties for maintaining sterility in the 
operating theatre while all of them considered the use of a sterile cover to maintain its 
sterility would be practical (9/9). 
 
It is worth noting that there were suggestions to reduce the size of camera holder to suit 
the users with smaller hand size. The average female hand size (length) is 172 mm 
[193]. The current camera holder circumference is 240 mm (~76 mm in diameter) so it 
may be possible to reduce this to 160 mm (or 50 mm in diameter [194]) in future 
designs. 
 
During the survey, most of the participants suggested that the best position for the 
system trolley and the image display in the operating theatre was on the opposite side 
of the surgical couch to the surgeon, allowing the surgeon to view and control the 
system without interrupting the procedures. Of the 7 participants (two participants 
chose not to provide feedback), 6 suggested that an acceptable image acquisition time 
for a single image to localise radioactivity uptake should be 60 s or less. An image 
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acquisition duration is important in any surgical procedure and should be as short as 
possible while providing images of diagnostic quality. In addition, feedback was 
collected on the necessary applications that should be available on the user interface 
software (Table 7.2). These provided useful suggestions to the manufacturer for 
designing applications in future software development.        
 
Table 7.2: Applications in the user interface software. 
Applications (n=8) Disagree unsure Agree 
Real-time dynamic gamma imaging 0 1 7 
Real-time optical video 0 0 8 
Static gamma image 0 0 8 
Static optical image 0 0 8 
Static hybrid image (superimposed) 0 0 8 
Dual-images side by side comparison  0 0 8 
Masking of high activities at injection site 0 0 8 
Contrast enhancement 0 1 6 
Variable colour scales 0 1 7 
Measurement tools (distance, line profile) 0 1 7 
Display of counts in hot spot 0 4 4 
Editing tools/Marker 1 2 5 
 
 Operator motion effects 
During the use of a handheld gamma camera it is to be expected that image quality and 
hence the diagnostic accuracy would be affected by user motion over the period of 
image acquisition. Both voluntary and involuntary patient movement may also affect 
the image quality. Such motions will cause blurring of details in the image. These 
effects could be a real problem as typical static planar nuclear medicine imaging 
requires relatively long acquisition times of approximately 1 to 5 minutes. This has 
been recognised in SPECT-CT and PET-CT whole body imaging where the long 
acquisition times of the PET and SPECT images may result in movement artefacts in 
the reconstructed images when viewed together with the CT images [195-197].  
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Image acquisition using an SFOV handheld gamma camera can be performed with the 
camera head either held by the operator or by a camera holder. Due to the small size of 
the camera head, it is sometimes preferable to hold the camera by hand to bring the 
detector as close as possible to the target organ. The severity of motion may potentially 
be affected by the design of the camera head (e.g. weight and size), the duration of 
holding the camera head, tremor amplitude of individual operator, involuntary motion, 
such as sneezing, or due to other external factors.  
 
 Methods 
To our knowledge no data previously existed on the duration that operators could hold 
such a camera without movement. The aim of this study was to assess the magnitude 
of the movement of the camera caused by the operator. Six potential users (3 nuclear 
medicine technologists and 3 medical physicists) were invited to take part in the hand 
movement study. The Nebuleye was set up in the clinical research room at the nuclear 
medicine clinic, Queen’s Medical Centre. A point source containing approximately 
15 MBq 99mTc-pertechnetate placed in a 3 mm diameter hole of the mini Williams 
phantom was positioned at SCD 7 cm in front of the detector. Each operator was 
requested to hold the camera for 3 minutes at their convenience during image 
acquisition (Figure 7.2). Image acquisition was repeated with the camera head mounted 
on the camera holder of the articulated arm and this data was used as a control for 
comparison purposes.   
 
  
Figure 7.2: Operator hand movement study set up. Point source was placed underneath of the camera 
head held by an operator (left) with extended right hand or mounted on an articulated arm (right) at a 
SCD of approximately 7 cm. 
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In addition, qualitative assessments were carried out to examine the image quality of 
the gamma images of mini Williams phantom (as described in Section 6.4.2) filled with 
8 MBq of 99m Tc pertechnetate in 4 wells. The Nebuleye was positioned at SCD 4 cm 
in front of the camera head, either held by operator or mounted on the camera holder. 
Each image acquisition time was 3 minutes. The resulted images was post-processed 
and visually assessed. Line profiles were plotted horizontally across the hot spots.  
 
 Image analysis and software 
Each scintigraphic image produced by the Nebuleye was processed and saved as a 
multi-frames (2 seconds per frame) DICOM image. The image was then assessed using 
an in house software (MOCO) [198, 199] to determine the magnitude of motion by 
tracking the centre of mass (COM) of the hot spot. The MOCO software was originally 
developed to correct organ motion in planar gamma camera acquisitions by tracking 
the COM of detected gamma photons, and as a consequence could be used to produce 
coordinates of the motion of the COM of activity over time. During the data processing, 
the software determined the COM of counts in the first frame of the image and set this 
as the reference COM (x- and y- coordinates). The COM of each subsequent frame was 
then determined (xn- and yn- coordinates) and the magnitude of the displacement 
(distance in respective x- and y-axes) between the COM in each frame and the reference 
COM was calculated. This information was saved in a text file for further analysis. All 
data was transformed into an absolute value for the calculation of the displacement in 
mm.    
 
 Results  
Figure 7.3 shows the gamma images acquired during the study with different ways of 
holding the camera (either handheld with one or both hands or fixed on the camera 
holder) and plots of the COM displacement in x- and y- axes against the acquisition 
time. With the camera mounted on the camera holder a discrete bright spot was seen as 
shown on the control images (Image name: Control 1 and Control 2). In general the 
gamma images acquired with the camera held by an operator showed blurring of details 
when compared to the control image. For the operator motion study, the images from 
five subjects were included in the data analysis while one had to be excluded due to the 
movement of the camera completely out of the FOV during the acquisition. User 2, 4 
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and 6 held the camera with both hands while User 1 and 3 held the camera with either 
right or left hand. The summary results are tabulated in  
Table 7.3. Taking the results together the COM was found to move away from the 
reference COM by 4.34 ± 2.43 mm and 7.18 ± 3.34 mm in x and y directions 
respectively.   
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Figure 7.3: (Top) COM displacement plotting over image acquisition time for all users. Blue and red 
lines show the magnitude of displacement at x- and y-axis respectively and green line shows the average 
displacement for the control image. (Bottom) Gamma images acquired during the study with the 
Nebuleye held by individual operator or mounted on the articulated arm as the control image. 
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Table 7.3: Summary of the COM displacement (mm). 
User 
Displacement (mm) 
Max Min Mean ± SD Distance 
x y x y x y 
1 14.72 23.11 0.01 0.39 4.89 ± 3.66 13.14 ± 6.44 14.02 ± 10.10 
2 7.24 11.53 0.01 0.03 2.99 ± 2.01 7.33 ± 2.98 7.91 ± 4.98 
3 9.03 6.44 0.10 0.22 5.30 ± 2.35 2.97 ± 1.43 6.07 ± 3.78 
4 5.37 12.81 0.15 0.75 1.90 ± 1.31 8.00 ± 3.10 8.22 ± 4.41 
6 13.75 10.62 0.03 0.02 6.63 ± 2.84 4.46 ± 2.75 7.99 ± 5.58 
Average 10.02 12.90 0.06 0.28 4.34 ± 2.43 7.18 ± 3.34 8.84 ± 5.77 
Control 1.89 2.09 0.00 0.03 0.59 ± 0.43 0.74 ± 0.46 - 
 
Figure 7.4 shows the mean COM displacement over the acquisition time. For the first 
30 seconds of the image acquisition the magnitude of displacement was less than 5 mm; 
however it exceeded 5 mm after one minute of acquisition. This suggests that the image 
acquisition time should preferably be within a minute when the camera is handheld 
during use. From the visual assessment of the gamma images of mini Williams Phantom 
filled with 99mTc source, the image acquired with the Nebuleye held by the operator 
showed blurring of detail compared to the image acquired with the camera held by the 
camera holder. The pixel intensity profiles of both images were generated as shown in 
Figure 7.5.  
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Figure 7.4: Magnitude of COM average displacement over acquisition time (n=75). 
 
    
 
 
Figure 7.5: (Left) Line profiles of the gamma images of mini Williams phantom filled with 99mTc source 
in the wells, acquired by Nebuleye held by the camera holder (top right image) or by the operator (bottom 
right image).  
 
 Exploratory imaging with clinically relevant radionuclides 
As mentioned in Chapter 1 a range of radionuclides is used routinely in diagnostic 
nuclear imaging, these mainly being 99mTc, 111In and 123I. These radionuclides emit 
gamma rays of energies ranging between 80 and 400 keV. The detectors of the SFOV 
gamma cameras tested in this work consisted of an EMCCD and thin layer of the crystal 
scintillator. The cameras did not have a pulse height analyser or an energy window 
setting feature which are typically available in most modern gamma cameras, thus 
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making energy discrimination impossible. For the detector used in the SFOV gamma 
camera there was a high possibility that high gamma energy gamma rays could 
penetrate through the thin layer of the detector undetected, resulting in low detection 
efficiency. As the detection technology used in Nebuleye is identical to the HGC, the 
latter camera was used to test the impact of the camera performance with different 
pinhole diameters and crystal thicknesess due to the current version of Nebuleye was 
limited to 1 mm pinhole collimator and 1.5 mm crystal thickness configurations.     
 
Lees et al. had previously reported the performance testing of the CGC using 99mTc, 
241Am and 109Cd [43]. The gamma rays emitted in the range between 22 keV and 
140 keV were successfully detected by the camera. However most previous work had 
been limited to 99mTc. Gamma ray detection using the SFOV gamma camera may be 
affected by several factors, including the energy and abundance of the emitted gamma 
rays and optimum activity of the radiopharmaceutical. In addition the settings of the 
camera including acquisition time, collimator, and SCD play an important role in 
determining the detection and geometry efficiency.   
 
The prescribed radiopharmaceutical and optimum activity may vary depending on type 
of procedures, the patient weight and individual metabolic characteristics. The image 
acquisition settings of the camera may also depend on the clinical use and the standard 
operating procedures. The aim of the subsequent tests were to explore and examine the 
detectability of common clinically used radionuclides using the camera. Clinical 
radiopharmaceuticals readily available in the nuclear medicine clinic, Queen’s Medical 
Centre (Table 7.4) were used in these tests.  
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Table 7.4: Radiopharmaceuticals used for the detectability test. 
Radionuclide Gamma 
Energy (keV) 
Physical 
Half-life 
Yield abundance 
per decay (%) 
Physical form 
125I 35 60 days 7 Solid (seed) 
75Se 136 120.4 days 59 Solid (tablet) 
99mTc 140 6 hours 90 Liquid 
123I 159 13.2 hours 83 Liquid 
111In 171 2.8 days 90 Liquid 
111In 245 2.8 days 94 Liquid 
75Se 265 120.4 days 60 Solid (tablet) 
 
Approximately 4 MBq of the radiopharmaceutical solutions was used to filled the 4 mm 
diameter well of the mini Williams Phantom. The phantom was positioned at SCD 
30 mm and image acquisition was carried out within the restricted FOV for 10 minutes. 
System sensitivity and resolution of the camera to each radionuclide were quantified 
using the methodology modified from Section 3.2.2 and 3.2.6. 
 
Further investigations were performed to assess the spatial resolution of the camera 
using the phantom. The wells (4, 3, 2 and 1 mm diameter) of the mini Williams Phantom 
were filled with the radioactive solution and placed in front of the camera for imaging. 
The resulting images were visually assessed and compared with the images generated 
by a standard LFOV gamma camera (Nucline™ X-Ring-R, Mediso, Hungary).  
 
 Technetium-99m  
Technetium-99m is the most commonly used radionuclide in diagnostic nuclear 
medicine (principal gamma energy: 140 keV). Typical amounts of activity used in 
clinical studies ranges from 4 MBq for lacrimal drainage studies up to 900 MBq for 
parathyroid imaging [200]. Figure 7.6 (left) shows the image formed from a point 
source of 99mTc solution contained in a single well of the phantom. The sensitivity of 
the camera was measured as 3.58 ± 0.07 cps/MBq while the system resolution was 2.82 
± 0.05 mm at SCD 30 mm.        
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Figure 7.6: Detectability test of (left) 99mTc, (middle) 111In and (right) 123I point sources performed using 
the Nebuleye. All images shown using the same image scale.   
 
The geometrical efficiency of the system is proportional to the diameter of the pinhole 
collimator and this is the reason the 1 mm pinhole was selected for the clinical pre-
production prototype camera. For the purpose of comparison further investigation was 
carried out to show the difference in imaging between using pinhole collimators of 
0.5 mm and 1 mm in diameter. As the Nebuleye had only a pinhole collimator with 
aperture of 1 mm in diameter, the HGC fitted with 0.5 mm pinhole collimator was used 
to acquire image for comparison purposes. Figure 7.7 shows the mini Williams 
Phantom images acquired using the SFOV gamma cameras fitted with the different 
diameter of pinhole collimators. The images showed that with the same acquisition 
settings, the system spatial resolution of the camera fitted with pinhole collimator of 
0.5 mm was significantly higher than that with the 1 mm pinhole where four hot spots 
could be resolved as shown by the line profiles.        
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Figure 7.7: (Left) Line profiles generated from the gamma 
images of the mini Williams phantom filled with 5.5 MBq 99mTc 
radioactive solution positioned at SCD 30 mm. Images were 
acquired for approximately 20 minutes using HGC mounted 
with pinhole collimator of 0.5 mm (top right) and Nebuleye 
fitted with 1 mm pinhole collimator (middle right). Similar 
image acquisition setup was performed using the LFOV gamma 
camera mounted with LEHR parallel-hole collimator. The 
resulted image (bottom right) was cropped to image size 
identical to the SFOV gamma image.   
 
 
The phantom images produced by the SFOV gamma cameras and a standard LFOV 
gamma camera were also compared. Figure 7.7 (bottom right) shows the gamma image 
acquired using a standard LFOV gamma camera equipped with LEHR collimator. 
Visually, the spatial resolution of the SFOV gamma camera was superior to the LFOV 
gamma camera where the hot spots within the mini Williams phantom was not resolved 
during the same image studies.  
  
 Indium-111 
Indium-111 emits principal gamma rays of 171 and 245 keV. Clinically it is used in 
radiopharmaceuticals for imaging infection, inflammation and somatostatin receptor 
imaging and for gastric emptying studies [201]. The amount of activity prescribed for 
adult clinical studies ranges between 10 – 200 MBq [200]. Figure 7.6 (middle) shows 
the gamma image formed from a point source of 111In solution filled in the mini 
Williams phantom. A relatively higher noise level was present in the image due to the 
detection of the higher energy (245 keV) gamma rays and subsequent scattered events. 
The sensitivity of the camera to 111In was measured as 5.35 ± 0.04 cps/MBq while the 
resolution was 3.31 ± 0.04 mm at SCD 30 mm.     
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It is widely documented that an increase of SCD results in the degradation of camera 
geometric efficiency and resolution [14]. This was confirmed by the phantom studies 
where the Nebuleye camera was used to image mini Williams Phantom placed at SCD 
of 3, 5 and 8 cm. Figure 7.8 shows the phantom images acquired at different SCDs. 
With the increase of the SCD, the resolution of the camera decreased where the 
individual radioactive sources in the respective holes within the phantom merged to 
become a large bright blob.  
 
   
Figure 7.8: Gamma image of the mini Williams Phantom filled with 14.3 MBq 111In radioactive solution 
placed at SCD of 30 (left), 50 (middle) and 80 mm (right). Images were taken using 1 mm diameter 
pinhole collimator Nebuleye with acquisition time of 20 minutes. Images were smoothed with a 2.0 pixel 
Gaussian filter. 
 
 Iodine-123 
Iodine-123 emits gamma rays (159 keV) with the energy relatively similar to that of 
99mTc. This radionuclide is commonly used for Parkinson’s disease imaging (DaTscan) 
or neuroectodermal tumour imaging (MIBG scintigraphy). Clinical administered 
activities range between 2 and 400 MBq [200]. Figure 7.6 (right) illustrates the gamma 
image acquired by the Nebuleye gamma camera and looks similar to the gamma image 
of 99mTc. The sensitivity of the camera to 123I was measured at 2.95 ± 0.04 cps/MBq 
while the resolution was 2.93 ± 0.05 mm at SCD 30 mm. 
 
Intrinsic resolution and detection efficiency of gamma cameras depend on the 
scintillation detector thickness. Thicker crystals result in wider spreading of 
scintillation light resulting in reduced intrinsic resolution [14]. As the Nebuleye had 
only a 1.5 mm in thickness CsI(Tl) crystal, it was considered valuable to compare this 
with the HGC fitted with 0.6 mm thick crystal detector. Mini Williams phantom images 
captured by the HGC gamma camera revealed that the camera with thinner crystal could 
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resolve the hot spots better when using the same acquisition settings as shown in Figure 
7.9.     
 
  
Figure 7.9: Gamma image of the mini Williams phantom filled with 123I radioactive solution placed at 
SCD 30 mm. Images were taken using HGC equipped with 0.6 mm thick crystal detector (left) and 
Nebuleye  with crystal detector of 1.5 mm in thickness (right). Image acquisition time was approximately 
20 minutes. 
 
 Iodine-125 seeds  
Iodine-125 is used as a sealed source seed for permanent radioactive seed implant 
procedures. It emits relatively low energy gamma rays (35 keV) and for therapy the 
principle therapeutic action is by Auger-electron emission to treat tumours such as 
prostate cancer. A more recent application of this source is the radioactive seed 
localisation technique in breast cancer surgery where an 125I seed with activity ranging 
between 3 and 8 MBq is implanted within the tumour under ultrasound or radiological 
control. Figure 7.10 shows the cumulative time series for the images of a seed acquired 
using the Nebuleye. Visual assessment found that the seed could be detected with an 
acquisition time within a minute and the bright blob appears clearer with the increase 
in acquisition time.      
 
 
 
 
 
Chapter 7. Assessing the capabilities of the pre-production prototype camera| 196 
 
 
   
   
   
   
   
 
Figure 7.10: Gamma images of the 125I seed (2.43 MBq) placed at SCD 63 mm, acquired using Nebuleye 
fitted with 1 mm pinhole collimator. Image acquisition time is indicated on each image. Images were 
smoothed with a 2.0 pixel Gaussian filter.  
 
 Selenium-75  
Selenium-75 is used as an oral capsule formulation containing Tauroselcholic [75Se] 
acid (SeHCAT) (GE Healthcare, Braunschweig, Germany) and has principal gamma 
energies of 136 and 265 keV. It is used for measuring bile acid pool loss and in the 
investigation of bile acid malabsorption [202]. The typical prescribed dose is 0.4 MBq 
per investigation [200] and the activity retained after 7 days is measured using an 
uncollimated LFOV gamma camera. 
 
1 min 2 min 3 min 
4 min 5 min 
10 min 
6 min 
20 min 30 min 
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For this investigation the collimated Nebuleye was used to acquire an image of the 
SeHCAT capsule (~0.35 MBq) placed at SCD 40 mm, using a 38 minute acquisition 
time. The sensitivity of the camera to 75Se was measured at 5.69 ± 0.18 cps/MBq. Figure 
7.11 shows the resulting hybrid image of the SeHCAT capsule. The detected photons 
may also include the scattered or unwanted radiation that leaked through the camera 
head shielding due to the higher energy of the gamma rays.    
 
   
Figure 7.11: (a) Optical, (b) gamma and (c) hybrid images of SeHCAT capsule acquired using Nebuleye 
positioned at SCD 40 mm. 
 
 Summary 
The experimental work described in this chapter has provided new and essential 
information to bridge the gap between laboratory testing and clinical use. It has 
provided baseline data on user feedback and the imaging consequences on operator 
motion effects, as well as examining the detectability of a range of radionuclides. In 
particular the results indicate that users would consider that imaging during surgery 
should be achieved in the order of 1 minute and user motion limits handheld image 
acquisition to within 2 minutes.  
 
This is the first time the new pre-commercial device, the Nebuleye has been tested in a 
clinical environment and provides a better understanding of the camera capabilities for 
the preclinical imaging described in Chapter 4 and the clinical trial described in 
Chapter 8.  
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First Clinical Studies of the SFOV 
Hybrid Optical Gamma Camera  
 
 
 Introduction  
Since the first introduction of the gamma camera in 1958 the basic design and operation 
of gamma cameras has remained the same over the past 50 years. Recent commercial 
developments have been based around dual head hybrid systems with integral scanning 
couches. These systems are bulky and require a dedicated imaging room. The 
availability of smaller mobile gamma cameras in the 1990s have offered scintigraphic 
imaging outside of the nuclear medicine department, however, these cameras were still 
relatively large in size and posed difficulties in close positioning to the organs of 
interest at the patient bedside or during surgical procedures [203].  
 
As described in Chapter 2, recent technological developments have contributed to the 
evolution of handheld SFOV gamma cameras which have increased the portability and 
flexibility of nuclear imaging, creating the possibility of undertaking investigations in 
the operating theatre, intensive care unit, emergency department or hospital ward [54]. 
These SFOV gamma cameras may be of value in providing intraoperative imaging 
where non-imaging gamma probes are currently used [141]. This chapter describes the 
first clinical results of the use of HGC in the nuclear medicine clinic. The aims of this 
study were to adopt and evaluate the performance of the prototype HGC for clinical 
imaging and where possible to undertake the subjective comparison of the images with 
those from a standard clinical gamma camera. The work in this project was funded by 
the Science Technology Facilities Council through a joint CLASP Award to the 
Universities of Nottingham and Leicester. 
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 Methods 
 Hybrid gamma camera  
The HGC as described in Section 2.5 was used in this study. For the clinical study the 
gamma detector was an CsI(Tl) columnar scintillator (either 0.6 mm or 1.5 mm in 
thickness) (Hamamatsu Photonics UK Ltd., Welwyn Garden City, UK) coupled to an 
electron-multiplying charge-coupled device (EMCCD) (CCD97 BI, e2v Technologies 
Ltd., Chelmsford, UK) surrounded by tungsten shielding of 3 mm thickness, to 
minimise image degradation from scattered photons and background radiation. An 
interchangeable 6 mm thick tungsten pinhole collimator with a pinhole aperture of 
either 0.5 mm or 1.0 mm was used for projection of the gamma photons onto the 
scintillation detector. This gave a nominal field of view (FOV) of approximately 60 × 
60 mm at a distance of 50 mm from the camera surface.  
 
A thin optical mirror was mounted across the FOV at an angle of 45o to reflect light 
photons to an optical camera assembly. This provided alignment of the optical images 
with the same FOV as the gamma camera, allowing fusion of functional and anatomical 
detail. The weight of the camera head was 1.2 kg. An HP laptop computer (Hewlett-
Packard Development Company, Palo Alto, California, USA) was connected to the 
electronic control unit via a standard USB 2.0 cable and installed with bespoke software 
(IDL, Exelis Visual Information Solutions, Inc., Boulder, CO, USA) as mentioned in 
Section 2.5.3. Figure 8.1 shows the assembly of the camera system on a cart based 
system (ITD GmbH, Johanniskirchen, Germany). The performance of the HGC had 
been characterised previously as described in Chapter 3 and other publications [105, 
204, 205]. Simple quality control check was carried out during the day of the study.  
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Figure 8.1: A photograph of the HGC mounted on arm and trolley system showing the laptop and 
electronics interface box. 
 
As part of the assessment of the technology, the HGC went through the regulatory 
requirements under the special circumstances for medical devices as outlined by the 
MHRA for clinical research purposes where the device was not intended for subsequent 
commercialisation. The design and construction of the device had been assessed against 
the relevant harmonised standards of the Medical Device Directive with the support of 
the Clinical Engineering Department, NUH NHS Trust. The assessments concluded 
that the device was compliant with the requirements of BS EN 60601-1:2006 
+A12:2014 Medical Electrical Equipment: General requirements for basic safety and 
essential performance. Subsequently, the approval for use of the device in the Trust was 
issued by the Chair of the Medical Devices Management Committee at NUH as 
required by the Trust’s Research & Innovation department. This approval was part of 
the Health Research Authority (HRA) requirements for the clinical trial application.    
 
Camera 
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 Study design and patients recruitment 
This was a non-interventional, non-blinded, single visit study carried out in the nuclear 
medicine clinic at Queen’s Medical Centre, Nottingham University Hospitals NHS 
Trust. Figure 8.2 summarises the study sequences in this trial. The study was approved 
by the UK National Research Ethics Committee (Reference Number: 12/EM/0201) and 
the Research & Innovation Directorate, Nottingham University Hospitals NHS Trust.  
 
 
Legends:  Standard NHS procedure   Research procedure 
 
Figure 8.2: Study flow-chart for the clinical trial.  
 
 Patient selection 
Patients who had been referred to the nuclear medicine clinic as part of a standard 
diagnostic test were invited to take part in this study. An appointment letter was sent 
through a nuclear medicine clinic to book the standard diagnostic test. Once the 
diagnostic test appointment was confirmed, the patients were screened for their 
eligibility by one of the clinical study team. This was done by viewing the clinic on-
line appointment system and the patient record. The selection was according the criteria 
summarised in Table 8.1. Suitable patients were contacted by phone and a brief 
introduction to the study was given. Prospective participants were asked if they were 
Contact eligible participant once diagnostic test appointment was confirmed
Provide the patient information sheet to the participant at least 48 hours prior study
Participant arrives at the nuclear medicine clinic
Radiopharmaceutical administration as part of normal procedure
Participant provides written consent
Image acquisition using the HGC
Standard NHS diagnostic test
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interested in participating in this study. If they expressed an interest to participate a 
copy of the patient information sheet and consent form was sent by mail or e-mail.  
 
Table 8.1: Patient selection criteria for this study.  
Inclusion criteria 
1. Participant must be aged greater than 18 years of age; 
2. Participant must be able to give voluntary informed consent; 
3. Participant must be able to understand the study, willing to co-operate with the 
study procedures and able to attend the study assessment; 
4. Participant had been administered a radiopharmaceutical as part of a diagnostic 
test. 
Exclusion criteria 
1. Female participants who were pregnant, lactating or planning pregnancy during 
the course of the study;  
2. Participants who do not speak or understand English. 
 
 Informed consent 
Patients were given a minimum of 24 hours to carefully consider the participation 
before formally signing consent at the study site. As this was straight-forward study 
only requiring a short attendance for imaging the participants were not requested to 
attend the department to sign consent form before the day of study. On the study day 
one of the clinical study team met the participant and asked if they were still interested 
taking part in the study.  
 
A copy of consent form and patient information sheet was provided to the participants. 
The details of the study were explained by one of the study team. The participants were 
then given opportunity to ask questions, or to share their concerns. Further explanation 
was also provided that their participation was entirely voluntary and that their standard 
treatment would not be influenced by their decision and that they were free to withdraw 
from the study at any time and for any reason.   
 
Once the participant had agreed and signed to take part in the study, a copy of the form 
was given to the participant, while another copy was kept by the investigator in the trial 
master file. A participant study ID number was assigned to maintain participant 
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anonymity during the study. All study documents were stored securely and only 
accessible by trial staff and authorised personnel.  
 
 Imaging 
Following administration of the standard diagnostic radiopharmaceutical, the HGC was 
used to acquire hybrid images of the patient in addition to the routine nuclear medicine 
imaging procedure. These imaging procedures were performed at a time point when it 
was convenient for the patient fitting in with the standard diagnostic test schedule in 
order to minimise unnecessarily interruptions to the normal clinical process.  
 
Each patient participation was approximately 30 minutes and no longer than two hours. 
Prior to the image acquisition, the participant was asked to either sit or lie down, 
depending on the type of the procedure. The HGC was either held by the operator or 
mounted on fixed arm during the imaging. Figure 8.3 shows an example photograph of 
the HGC use during patient imaging. The imaging settings such as SCD, camera 
configuration and time of imaging were recorded in the case report form. Image 
acquisition and processing was undertaken using bespoke software as described in 
Section 2.5.3 and 2.5.4. Image post-processing and display was carried out using 
ImageJ 1.47v (National Institute of Health, US) to remove outlier noise, apply the 
Gaussian smoothing filter and to adjust threshold and saturation levels to improve 
image display. 
 
 
Figure 8.3: Photograph of the head of the HGC which was mounted on an articulated arm during 
imaging of the patient neck area. 
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All acquired gamma and optical images were anonymised and stored in a University 
password protected computer. The hybrid planar images of the patient were presented 
in a fused optical-gamma display. The subjective visual comparison was performed 
where possible by nuclear medicine professionals, who were experienced in observing 
scintigraphic images. Standard images produced by a SPECT-CT either Philips 
Brightview XCT (Philips Healthcare, Milpitas, CA, USA) or General Electric 
Discovery NM/CT 67 (GE Healthcare, Waukesha, VI, USA) were available for 
comparison. As this was a pilot study, therefore no statistical test was performed at this 
stage.  
 
 Results 
Imaging studies were carried out in 24 patients (age range between 30 and 83 years, 
mean: 58.6 years) who underwent routine imaging procedures with 99mTc and 123I. 
These radionuclides were being low energy gamma emitters suitable for use with the 
HGC. Table 8.2 provides a summary of the number of participants, the administered 
radiopharmaceutical and the average acquisition time for each procedure. The 
administration of the radiopharmaceutical was based on the Administration of 
Radioactive Substances Advisory Committee (ARSAC) guidance notes on good 
clinical practice for nuclear medicine in the UK [200].  
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Table 8.2: Summary of the clinical cases, administered radionuclides and activities (MBq) and average 
imaging time, taken from [45]. 
Procedure Radionuclide Administrated 
activity (MBq) 
Mean 
acquisition 
time ±SD (s) 
Number of 
participants 
Lymphatic 
scan 
99mTc 10-20 per 
injection 
349 ± 105 10  
(4 excluded) 
DaTscan 123I 185 893 ± 519 2 
Lacrimal 
drainage scan 
99mTc 1 per eye 263 ± 87 3  
(1 excluded) 
Thyroid 
scintigraphy 
99mTc 
123I 
75-78  
18.5-20  
127 ± 63 
297 ± 98 
2 
2 
Bone scan 99mTc 600-627 266 ± 55 3 
Leucocyte 
study 
99mTc 100-225 345 ± 200 2  
(1 excluded) 
Total    24 
SD-Standard deviation 
 
In this pilot study, the patients were chosen based on the criteria where focal uptake of 
radiotracer within the body may be expected or the SFOV imaging was considered to 
be of interest or have potential clinical value. These included patients undergoing bone, 
thyroid, lacrimal drainage and lymphatic imaging as well as DaTscan studies. The 
resulted images were subjectively assessed. Patient imaging details are given in Table 
8.3. Six patients were not included during the final evaluation due to missing 
information caused by camera malfunction or data errors. There were no safety issues 
reported during the period of the clinical studies. 
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Table 8.3: Details of the clinical studies undertaken using the HGC.  
Subject 
Number 
Procedure Radionuclide Camera configurations Subjective 
assessment of 
image quality 
Pinhole 
diameter 
(mm) 
Crystal 
thickness 
(mm) 
001 LY 99mTc 0.5 0.6 Good  
002 D 123I 0.5 0.6 Poor  
003 LA 99mTc 0.5 0.6 NAa 
004 LY 99mTc 0.5 0.6 Good  
005 LY 99mTc 0.5 0.6 NAa 
006 D 123I 0.5 0.6 Poor  
007 LY 99mTc 0.5 0.6 NAa 
008 T 99mTc 0.5 0.6 Poor  
009 LA 99mTc 0.5 0.6 Good  
010 T 99mTc 0.5 0.6 Poor  
011 LA 99mTc 1.0 0.6 Good  
012 B 99mTc 1.0 0.6 Poor  
013 B 99mTc 1.0 0.6 Poor  
014 T 123I 1.0 0.6 Good  
015 LE 99mTc 1.0 1.5 NAa 
016 LE 99mTc 1.0 1.5 Poor  
017 LY 99mTc 1.0 1.5 Good  
018 LY 99mTc 1.0 1.5 Good 
019 LY 99mTc 1.0 1.5 Good 
020 B 99mTc 1.0 1.5 Poor 
021 LY 99mTc 1.0 1.5 Good 
022 T 123I 1.0 1.5 Good 
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Subject 
Number 
Procedure Radionuclide Camera configurations Subjective 
assessment of 
image quality 
Pinhole 
diameter 
(mm) 
Crystal 
thickness 
(mm) 
023 LY 99mTc 1.0 1.5 NAa  
024 LY 99mTc 1.0 1.5 NAa 
aStudy terminated due to camera error; NA: Not available; LY: Lymphatic scan; D: DaTscan; LA: Lacrimal 
drainage scan; T: Thyroid scintigraphy; B: Bone scan; LE: Leucocyte study.  
 
 DaTscan 
During the early stage of the clinical trial, investigations were aimed at high resolution 
imaging using a 0.6 mm thick crystal and 0.5 mm diameter pinhole collimator. As a 
trade-off, this resulted in reducing the camera sensitivity, therefore prolonging the 
acquisition times to over 5 minutes. Two patients undergoing 123I-ioflupane DaTscan 
investigations were imaged using this camera configuration. An example of gamma 
image acquired using HGC shows scattered bright spots within the FOV with no 
specific photon distributions as compared to a standard DaTscan image (Figure 8.4).  
Localisation of DaTscan uptake in the striatum was not visualised in these exploratory 
investigations, thus there was no further investigation on this group of patients.  
 
  
Figure 8.4: (Left) Example of planar image acquired using the HGC positioned at SCD of 8 cm on top 
of the head (vertex view) of patient 006, 1 hour post-administration of 185 MBq 123I-Ioflupane, with 
100 s acquisition time. (Right) Axial plane (slice 19) of the reconstructed SPECT image of the same 
patient acquired using SPECT-CT camera system 2.5 hours following administration with 1800 s 
acquisition time (30 s per projection).  The image shows high striatal uptake of the dopamine transporter 
agent, 123I-Ioflupane relative to cortex. 
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 Thyroid scintigraphy 
Thyroid scintigraphy was undertaken in four patients, two who had received 99mTc-
pertechnetate and two who had received 123I-sodium iodide (NaI). The initial 
investigations were using a 0.6 mm thick crystal and 0.5 mm diameter pinhole 
collimator camera configuration. Figure 8.5 shows an example of hybrid optical-
gamma image of thyroid scintigraphy acquired using HGC. No focal uptake within the 
neck region was observed due to the sensitivity limitations of the camera. The optical 
images acquired during the start and end of the image acquisition showing significant 
patient movement which deteriorated the quality of the gamma image formed over the 
scanning time.   
 
 
Figure 8.5: Fused optical-gamma image of patient 008 administered with 78 MBq of 99mTc-pertechnetate, 
with an imaging time of 200 s. The number of detected photons was low due to the low sensitivity camera 
configuration and the camera position (~10 cm away from patient’s neck).  
 
Increasing the diameter of the pinhole collimator to 1 mm improved the camera 
sensitivity. Figure 8.6 shows an example of thyroid imaging where radionuclide uptake 
can be seen in the right lobe of the thyroid. This uptake was confirmed from the planar 
gamma image produced by a standard LFOV gamma camera with similar acquisition 
time. Further camera sensitivity improvement were made with the increasing of the 
crystal thickness to 1.5 mm. Gamma images were undertaken with 1.5-mm-thick 
Chapter 8. First Clinical Studies of the SFOV Hybrid Optical Gamma Camera | 209 
 
 
crystal and 1 mm diameter pinhole collimator camera configuration. Figure 8.7 
illustrates an example of thyroid imaging with the presentation of 123I uptake in both 
lobes of the thyroid.  
 
 
Figure 8.6: (a) Hybrid and (b) gamma image of thyroid scan in patient 014 acquired by HGC 110 minutes 
following administration of 20 MBq 123I-NaI, positioned at SCD of 10 cm. (c) LFOV planar gamma 
image of the same patient. Both gamma images were acquired with an acquisition time of 300 s.  
 
The resulting gamma image provides the functional uptake, while the hybrid image 
showing the shape, size and position of the thyroid gland with respect to the skin 
surface. With the increase of nominal FOV (from 112 × 112 to 184 × 184 mm) at further 
SCD setting (23 cm), the thyroid image and other anatomical landmarks (e.g. sternal 
notch) can be clearly seen in the neck region with the aid of the optical image as shown 
in Figure 8.7 (d). In contrast, the increase of SCD from 14 cm to 23 cm resulted in a 
decrease of collimator efficiency by 63 % (calculation based on Equation 3.6). This 
caused a reduction in the photon detection and loss of detail in the gamma image 
displayed in Figure 8.7 (d). When assessing the images the effects of different image 
acquisition parameter (SCD, acquisition time) and level of administered activity should 
be taken into consideration.   
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Figure 8.7: Example thyroid scintigraphy in patient 022, acquired by HGC at 149 minutes post-
administration of 18.5 MBq 123I-NaI, positioned at SCD of 14 cm for a 300 s acquisition time: (a) hybrid 
(b) gamma image (c) LFOV planar gamma image. (d) Hybrid image of the same patient acquired by 
HGC positioned at an SCD of 23 cm, 142 minutes post-administration of the radiotracer.   
 
Thyroid scintigraphy demonstrates the relative functional activity of the thyroid tissues. 
The regional abnormality of the organ can be determined by investigating the variation 
of radiopharmaceutical uptake within the thyroid gland. Clinically further assessments 
are necessary to confirm the involvement of a thyroid nodule by palpation and carrying 
out relevant correlation or with the aid of ultrasonography [206]. Example thyroid 
images taken with the HGC shown in Figure 8.6 (a) and Figure 8.7 (a) illustrate variable 
regional uptake in two of the patients investigated in this study.         
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 Lacrimal drainage scintigraphy 
For lacrimal drainage scan, investigations were undertaken using HGC with 0.6-mm 
thick crystal. Investigation was initiated with the HGC mounted with 0.5 mm pinhole 
collimator. The hybrid images shown in Figure 8.8 provide clear visualisation of the 
radiotracer distribution (99mTc-DTPA) with respect to surface anatomy. These images 
provided good spatial information for identification of regional flow and assisted in the 
identification of clearance via the nasolacrimal duct. In comparison with the 
scintigraphic image of the same patient (Figure 8.8 (d)) acquired using a LFOV gamma 
camera, the distributions of radiopharmaceutical as shown in Figure 8.8(a) are  
different, due to the lacrimal clearance at different time point.  
 
 
Figure 8.8: The (a) gamma (b) optical (c) hybrid images showing activity distribution in the right and 
left eyes and nasolacrimal duct in patient 009, acquired 50 minutes following administration of 1 MBq 
99mTc-DTPA to the surface of each eye. The gamma image was acquired by HGC positioned 10 cm away 
from the source, with 200 s acquisition time. Image (d) is the anterior planar image produced by a 
standard LFOV gamma camera recorded at 25 minutes after administration. 
 
Due to the patient movement during image acquisition, a head support and chin rest 
device was used to minimise the effect while maintaining the SCD constantly 
throughout the procedure. Figure 8.9 shows another example of the lacrimal drainage 
image acquired using HGC mounted with 1 mm pinhole collimator. The source-to-
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camera distance was 7 cm which gave a nominal FOV of 76 × 76 mm, hence the images 
of the right and left eyes were acquired in a separate acquisition.        
 
 
Figure 8.9: The (a) optical (b) gamma (c) hybrid images showing activity distribution in the right and 
left eyes and nasolacrimal duct in patient 011, acquired 90 min following administration of 1 MBq 99mTc-
DTPA to the surface of each eye. The gamma image was acquired by HGC positioned at 7 cm from the 
source, with 300 s acquisition time. Image (d) is the anterior planar image produced by a standard LFOV 
gamma camera recorded at 20 min after administration. 
 
 Lymphatic imaging 
Six lymphoscintigram investigations in patients with oedema were included in this 
study. The HGC was positioned at a suitable distance (SCD ranged between 8 and 25 
cm) in order to acquire image of the designated FOV while maintaining the camera 
sensitivity and resolution. Figure 8.10 illustrates an example of the gamma images 
generated by LFOV gamma camera (a) and HGC at specific regions such as left 
inguinal (b) and injection sites (c). Whilst it was difficult to track the full extent of 
clearance along the lymphatic vessels, the hybrid image (d) of the injection site 
indicated that the camera can be used to show focal uptake in relation to surface 
anatomy.  
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Figure 8.10: Example of the gamma and hybrid images acquired by HGC (1 mm pinhole collimator) in 
patient administered with 12 MBq of 99mTc-nanocolloid at each injection site (two injections on each 
foot) undergoing lymphoscintigraphic imaging. Image (a) is an anterior planar image of lower 
extremities, produced by a standard LFOV gamma camera, 20 minutes following administration with a 
17 minutes acquisition time showing focal uptake at the injection site and the inguinal region bilaterally 
with high activity on the left and right site. Image (b) is the gamma image acquired by HGC on the left 
inguinal region with 5 minutes acquisition time. Gamma image of the feet (c) was acquired by HGC 
positioned at a distance of 21 cm with 5 minutes imaging time, subsequently superimposed with the 
optical image (d).  
 
 Bone and labelled Leucocyte scintigraphy 
For patients undergoing bone and leucocytes investigations, the imaging was focussed 
on regional scan instead of whole body scan. Whilst uptake of the scanning agent was 
visible in those regions of interest, these did not produce any dramatic results due to the 
lack of focal uptake at these sites in the patients studied. Figure 8.11 shows an example 
of bone scintigraphy undertaken with 1.5-mm-thick crystal and 1 mm diameter pinhole 
collimator HGC. Another example of regional bone scan showing radiotracer uptake at 
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patient’s thumb acquired using HGC with 0.6 mm-thick crystal and 1 mm diameter 
pinhole (Figure 8.12).  
 
 
Figure 8.11: (a) Example of a gamma image of the injection site at patient’s right arm acquired by HGC 
(1 mm pinhole collimator, SCD 27.5 cm, 250 s imaging time) of patient 020 undergoing bone scan. (b) 
Planar image of bone within abdominal region of the same patient acquired using the LFOV gamma 
camera. (c) Fused gamma image (a) and the optical image showing the injection site and regional 
radiotracer uptakes within the right elbow and forearm regions of the patient. 
      
   
Figure 8.12: (a) Optical, (b) gamma and (c) hybrid images of right thumb of patient underwent bone 
scintigraphy. Images were undertaken with HGC positioned 45 mm away from the source, 3 hours 
following the administration of 600 MBq 99mTc-hydroxymethylene diphosphate (HDP). (Image provided 
by Alan C. Perkins) 
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 Discussion 
This study has shown novel results of patient imaging using the HGC. It is believed that 
these are the first results of the use of a hybrid optical-gamma camera in a nuclear 
medicine clinic. At the time of writing there were no similar studies being carried out 
by other hybrid SFOV gamma cameras. Based on the literature search, most of the 
clinical applications of SFOV gamma camera have been reported were in radioguided 
surgery such as sentinel node localisation for breast [34, 47, 68, 207-209], melanoma 
[58, 210, 211], penile [63] as well as head and neck tumours [67, 209], radioguided 
occult lesion localisation [158], radioactive seed localisation [165] and primary 
hyperthyroidism [66, 212].     
 
During gamma imaging, for a given SCD, crystal thickness or diameter of pinhole 
collimator, there is also a trade-off between sensitivity and resolution. During the initial 
stage of the camera development, the HGC was designed as a high spatial resolution 
imaging device [43]. This has limited the clinical performance of the camera until 
further improvements have been made to the camera head by increasing the crystal 
thickness and pinhole diameter. Increasing the thickness of the scintillator to 1.5 mm 
and the diameter of the pinhole collimator to 1 mm improved the camera sensitivity. 
This allowed the images to be recorded within 5 minutes. 
 
This study provides the assessment of the imaging performance to determine the most 
appropriate areas for future clinical use. The initial studies showed that the SFOV 
gamma camera system was well suited to small organ imaging including thyroid and 
lacrimal drainage studies, where the radiopharmaceutical uptake could be clearly seen 
corresponding to the patient surface anatomy. The gamma images acquired by the HGC 
in patients undergoing bone and leucocyte scintigraphy were poor in quality caused by 
higher background noise in the acquired images. This may be resulted by insufficient 
detector shielding as discussed in Section 3.2.9 allowing the gamma-rays emitted from 
radiopharmaceutical distribution throughout the patient to be detected. 
 
DaTscan studies were included as the performance of HGC in clinical imaging of 123I 
source was particularly interesting. In previous publications, one study has reported that 
focal uptake might be visualised using planar imaging [213]. However, the results 
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obtained in this study have showed that the vertex planar images were not of diagnostic 
quality, which was due to the low sensitivity of the 0.5 mm pinhole collimator and 0.6 
mm crystal thickness combination. Further investigations may be considered with the 
larger pinhole-crystal combination. 
 
It is worth noting that the distributions of radiopharmaceutical at different time points 
within a patient will vary. As the study design aimed to minimise interruption to the 
routine imaging procedure, image acquisitions undertaken by HGC took place between 
the radiotracer administration and routine imaging times. This has posed a challenge in 
comparing the gamma images produced by the LFOV gamma camera and HGC as these 
images were acquired at different time points following administration of 
radiopharmaceutical. The differences may be minimised by minimising the gap 
between the imaging times for both imaging modalities. Guidance on the optimal 
imaging times was taken from the clinical guidelines published by international 
scientific and professional bodies as tabulated in Table 8.4. For example, the best 
imaging time for a DaTscan is quoted as between 3 and 6 hours following 
administration of the radiotracer [214], during which time the ratio of striatal to 
occipital 123I-ioflupane binding is stable. 
  
Table 8.4: Recommended image acquisition duration and imaging time point.   
Procedure Radionuclide Duration of image 
acquisition (s) 
Recommended post-
injection imaging time  
Lymphatic scan 99mTc 600* Immediately, 45 mins & 3 
hours [215] 
DaTscan 123I 1800 3-6 hours [214] 
Lacrimal 
drainage scan 
99mTc 60 Immediately [216] 
Thyroid 
scintigraphy 
99mTc 
123I 
300 
600 
15-30 mins [206] 
3-24 hours 
Bone scan 99mTc 120-600 1 mins & 2 hours [217] 
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Leucocyte study 99mTc 300-600 30 mins & 4 hours**[218] 
*Based on the scanning time of 10 cm/min and assumption of target length of 100 cm.  
**Referred to diagnosis of abdominal abscess for adult patient. 
 
It is believed that the combination of an optical camera with a gamma camera will have 
a number of benefits for small organ imaging and would be particularly suitable for 
intraoperative and interventional procedures. The optical imaging provides details of 
the patient’s anatomical landmarks, while complement the physiological information 
as provided by the high resolution gamma imaging. This could lead to the use as a 
decisive tool in surgery, apparently for sentinel lymph node localisation and non-
palpable breast tumour localisation using 125I seed and possibly the localisation of 
parathyroid glands and the detection of osteoid osteoma, in particular for cases where 
the injection site is situated adjacent to the radiotracer uptake. In addition, a handheld 
system may be used in surgical procedures in conjunction or as a replacement for a 
gamma probe where images can be obtained for inclusion in case notes, clinical audit 
and for medico-legal purposes. 
 
 Summary  
This clinical study has demonstrated the feasibility and capability of HGC in clinical 
hybrid optical-gamma imaging in patients administered with 99mTc and 123I labelled 
radiopharmaceuticals. The use of the hybrid imaging system has raised new 
possibilities for small organ imaging, where the localisation of radiopharmaceutical 
uptake can be presented in an anatomical context using superimposed optical imaging. 
The compact nature of the hybrid system offers the potential for bedside investigations 
and will be well suited for intraoperative and interventional imaging. This study has 
provided initial information that will be used as part of the process of tailoring this new 
technology for specific clinical applications. 
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Discussion, Future Work and 
Conclusions 
 
 
 General discussions 
The clinical speciality of nuclear medicine has benefitted from the continued 
development of imaging systems and radiopharmaceuticals. This thesis has examined 
the capabilities and the use of a new generation of SFOV gamma cameras, which is 
hoped will continue to extend the role of nuclear techniques for the benefit of patients. 
Specifically, the work has demonstrated the evolution and translation of a novel 
laboratory prototype hybrid optical-gamma camera to a stage where it has become a 
medical device with genuine potential for clinical applications.  
 
The SFOV gamma camera utilised an EMCCD originating from photon detector 
applications in space research, coupled to a columnar-shaped CsI(Tl) crystal and a 
pinhole collimator to form the imaging detector. The gamma camera was co-aligned 
with an optical camera system, offering the ability for high resolution real time hybrid 
optical-gamma imaging. In practice the true ability of such a system can only be 
assessed by simulation and testing with phantoms, preclinical models and by clinical 
use. 
 
The characterisation and image assessment work carried out in this thesis has showed 
the hybrid optical gamma camera was reliable for use in the laboratory and the clinic, 
even after shipping to the Netherlands for preclinical imaging. The work has 
demonstrated its use with a range of imaging radionuclides commonly used in 
diagnostic nuclear medicine procedures such as 99mTc, 123I, 111In and the ability to detect 
125I which has been shown to be of future interest for the localisation of occult breast 
lesions.  
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Part of the camera characterisation work was adapted from the testing scheme 
developed by Bugby et al. [105] and this was implemented on the pre-production 
camera system. Further characterisation work was proposed and successfully tested on 
the camera which included system uniformity, system sensitivity, detector head 
shielding leakage, optical-gamma image alignment and optical image quality. This 
work has been crucial for the objective assessment of the pre-production prototype 
Nebuleye camera and to compare its performance with the HGC and other SFOV 
gamma cameras such as the Crystalcam [71], which have been introduced for medical 
imaging.  
 
In Chapter 4 preclinical work was undertaken using the camera to assess the imaging 
performance in animal studies, in this case to acquire images of mice administered with 
a newly developed dual modality probe. This was part of the camera development in 
order to expand the applications to preclinical imaging and has formed a basis for a 
future development to equip the camera system for near-infrared fluorescence imaging. 
 
The use of SFOV gamma cameras in surgery is expanding rapidly and is taking nuclear 
medicine imaging procedures out of the traditional department setting. Ultimately the 
utility of bedside imaging and radioguided surgery depends upon the specificity of the 
radiopharmaceuticals that are available. Further development of the radiotracers 
coupled with the technological advances in cameras design will expand the range of 
procedures undertaken. The use of hybrid gamma cameras combining optical and 
luminescent/fluorescence imaging with gamma imaging will further expand the range 
of surgical applications undertaken in future. 
 
In light of this, preparatory work was undertaken to bring the camera system into a 
surgical department as described in Chapters 6 and 7. Phantom simulations were 
developed to assess the capabilities of the camera for intraoperative imaging, 
specifically for SLNB in breast cancer surgery. Systematic camera tests were performed 
to examine the source detectability in difficult clinical scenarios such as deep seated 
nodes situated close to high activity at the injection site. This work suggested that the 
use of SFOV gamma cameras may complement the existing sentinel lymph node 
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localisation technique using non-imaging gamma probes. Other potential intraoperative 
imaging applications may include primary hyperparathyroidism, ectopic gland 
localisation and 125I radioactive seed localisation. Furthermore the gamma, optical and 
hybrid images produced may be used for inclusion in patient notes, clinical audit and 
for medico-legal purposes.  
 
With the current camera technology design, there were some limitations that have been 
identified. The system sensitivity of the HGC fitted with a 1 mm diameter pinhole 
collimator (6.6 cps/MBq at SCD 50 mm) was extremely low in comparison with 
standard LFOV clinical gamma camera (125 cps/MBq, BrightviewX, Philips 
Healthcare, Milpitas, CA, USA). The relatively low sensitivity of the SFOV gamma 
camera was due to low detection efficiency and resulted in longer image acquisition 
times to record sufficient photon events to form a diagnostic quality image. If this 
camera is to be used for routine patient imaging, in particular in the operating theatre, 
this may be regarded as unacceptable and have other disadvantages affecting patient 
management [219]. The current weight of the camera head at 1 kg is quite heavy and 
the size of the Nebuleye was still considered relatively large for handheld use. The work 
in Chapter 7 to assess user motion is interesting, since this would suggest the acquisition 
time should not exceed two minutes during handheld use. 
 
It was disappointing that the Nebuleye did not achieve CE marking as a medical device 
and as a consequence the clinical trial of SLNB in breast cancer did not go ahead. 
However, the clinical studies described in Chapter 8 have demonstrated the first results 
of use of the SFOV hybrid optical-gamma camera in medical imaging. This exploratory 
pilot study included patients undergoing bone, thyroid, lacrimal drainage and lymphatic 
imaging as well as DaTscan studies. Due to the compact design of the camera head with 
low profile photon detector, the camera was found to be suitable for small organ 
imaging at patient bedside. The most promising applications were found to be for 
thyroid scintigraphy and lacrimal drainage investigations where the uptake of 
radiotracer could be clearly seen. Further details were shown in the hybrid images for 
instance in the thyroid scintigraphy where the shape, size and position of the thyroid 
gland could be seen corresponding to the skin surface and in lacrimal drainage where 
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drainage of the tracer from the eye through the lacrimal duct could be identified in 
relation to patient surface anatomy.  
 
It is widely acknowledged that there is a trade-off between system sensitivity and 
resolution of gamma cameras. The system spatial resolution of the HGC (2.43 mm at 
FWHM) with 1.5 mm-thick crystal and 1 mm diameter pinhole collimator was 
approximately three-fold better than the standard LFOV clinical gamma camera 
(7.4 mm at FWHM) used in medical research at Nottingham as tabulated in Table 3.9. 
With this high resolution ability, small objects situated adjacent to each other may be 
resolved. However, the system spatial resolution decreased with increase in SCD. This 
deterioration of system spatial resolution was apparent when the SFOV gamma camera 
was moved away from the study subject in order to increase the FOV. With the existing 
small field of view in the systems used this was considered to be a limitation. 
 
Solutions to increase the system sensitivity may be considered by increasing the 
thickness of the CsI(Tl) crystal detector and widening the aperture of the pinhole 
collimator. Improvement of the HGC performance has been achieved by changing the 
crystal thickness from 0.6 mm to 1.5 mm and the pinhole size from 0.5 mm to 1 mm. 
The thicker crystal scintillator will have higher absorption rate for the incoming photons 
which improves the detection efficiency, especially for those photons with energies 
higher than 99mTc, such as 131I (364 keV). However the problem with this approach is 
that this also causes multiple scattering of photons within the detector crystal resulting 
in degrading the spatial resolution of camera [14].  
 
The use of solid-state detectors in SFOV gamma cameras may improve the spatial 
resolution and further reduce the space and weight of the camera head, compared to 
that of the current design of the HGC. The HGC utilises a pinhole collimator which 
also limits the camera sensitivity. However some strategies have to be proposed to 
improve this. Rogulski et al. [220] and Goorden et al. [221] have suggested the use of 
multiple pinhole collimators placed relatively close to the detector. This design has been 
applied in preclinical SPECT system [222] which has shown an improvement in spatial 
resolution while maintaining the system sensitivity. The drawback of the method was 
that it causes minification of the resulting image hence further reducing the FOV.   
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To overcome this limitation, the detector head of the HGC may need to be redesigned 
allowing for a combination of multiple detectors in one camera head. McAreavey et al. 
[77] have reported the design of 2 × 2 configuration of CZT detector module in a 
portable gamma camera. With this camera design and the combination of pinhole 
collimators, the FOV may be improved in comparison with the current version of HGC.  
 
The operating temperature of the EMCCD was regulated by the Peltier cooler, which 
controlled the number of dark noise electrons to be generated within detector. This 
noise is proportional to the operating temperature of the CCD. As shown in the 
temperature stability test of the Nebuleye, the temperature of the CCD exceeded the 
recommended operating temperature limit within two hours after the system was 
powered up for use. At this stage the Nebuleye was not considered suitable for routine 
clinical use. For example such suboptimal performance could interrupt a surgical 
procedure when the camera is needed for a longer operating list. Hence, utilisation of 
an optimum cooling system design is crucial to prolong the duration of CCD 
temperature stability within the target range.   
 
There is still a room to improve the uniformity of the gamma image acquired by the 
SFOV gamma cameras. No other sophisticated algorithms except blob detection 
technique was used in post-processing stage to enhance the image quality. On the other 
hand, camera head shielding design may need careful examination as they were a 
significant number of radiation leakage (details in Chapter 3), suspected through the 
gap between the shielding materials as shown in Figure 2.13. This may degrade the 
gamma image especially when imaging with sources of high activity or where activity 
is distributed throughout the patient.   
 
It is clear that the combination of optical and gamma images provides added value in 
the clinical applications undertaken. High quality optical imaging is important for 
providing anatomical landmarks especially during surgery. In the circumstances when 
the camera is held close to the patient, the blockage of light or shadow on the ROI 
degrades the quality of optical image. Adding an external light source such as LED or 
laser beam at the edge of the camera head may illuminate the ROI while providing real 
time marking on the FOV frame at different SCDs and could be used to add a cross hair 
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mark on the subject surface. This could be beneficial especially in surgical procedures 
where the camera could be used as a guiding tool to localise sentinel nodes or tumours. 
The cross marking using a laser could be used to pinpoint the target and could guide 
the site of incision expose the target tissues.          
 
 Future work 
This work has clearly demonstrated the feasibility and benefits of the SFOV hybrid 
optical gamma cameras in medical and preclinical imaging. Further work in this area 
of research is required to collect more clinical evidence and to assess further 
improvement in the camera performances. At time of writing, a further extended 
clinical trial (HRA reference number: 17/YH/0041) is still on-going to evaluate the 
performance of the HGC in a wider range of clinical investigations. Other clinical 
investigations undertaken so far include renal imaging, imaging of ectopic parathyroid 
adenoma and sentinel node localisation in patients with melanoma (Figure 9.1). Further 
imaging procedures should be carried out in patients administered with different 
radionuclides, such as 111In, 75Se, 131I and 201Tl. Moreover, further efforts to bring the 
camera into the surgical department should be carried out especially to perform the 
SLNB study in breast cancer surgery as specified in the protocol described in Chapter 
6.  
 
 
 
Figure 9.1: First sentinel node localisation study in patient with melanoma performed using the HGC 
with imaging time of 200 s. The hybrid images acquired at the injection site (bottom right, SSD 70 mm) 
and groin region (top right, SSD 40 mm) of patient, 38 minutes following administration of 20 MBq of 
99mTc-nanocolloid. (Left) Planar image of the pelvis region of the same patient, produced by a standard 
LFOV gamma camera, 186 minutes following administration with a 300 minutes acquisition time 
showing focal uptake at the groin region.  
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Further work focusing on the optimisation of the camera design as discussed earlier 
should be undertaken to enhance its performance as a medical device. This should 
include but not be limited to increasing system sensitivity and spatial resolution, 
enlarging the FOV of the camera, improving image post-processing and display, 
optimise the shielding of the camera head, the Peltier cooling system and the optical 
image display. Some work should be considered as part of the on-going clinical trial, 
including the utilisation of larger pinhole apertures, addition of extra features such as 
illumination of the surface being images and a laser marker on the camera surface as 
well as further modification of the software so that the optical and gamma image 
displays are automatically in the same orientation. In the long term, further optimisation 
work should be considered to improve the photon detection technology, camera head 
and collimator design, cooling technique and image post-processing methods.  
 
Another important feature to add is the ability to estimate the depth of the target tissues 
showing radiotracer uptake. Pilot laboratory test results has been reported [37, 85] 
where the depth of the radionuclide source below the anatomical surface can be 
calculated by using the gamma and optical images generated by two well-defined 
geometrically separated hybrid camera systems. To fully implement this concept, the 
suggestion of combining multiple detectors in a compact single camera head may be 
considered, although maintaining the compact size of the camera head may be difficult 
to achieve.  
 
There is an increasing interest in the use of combined gamma and near infrared 
fluorescent probes in preclinical and surgical imaging. Preliminary studies have been 
undertaken [37] using an in-house modified HGC and the addition of bespoke external 
excitation light source attached to the window of the camera head as described in 
Section 4.4.2.2 (Figure 9.2). This modified camera with the aid of an external excitation 
source has already produced the first hybrid gamma-fluorescent image as shown in 
Figure 9.3 however further optimisation will be crucial to improve the performance of 
this camera. With the introduction of hybrid gamma–NIRF probes in the clinic, it is 
envisaged that the ability of acquiring gamma and fluorescent image concurrently using 
the hybrid gamma cameras would be of great benefit for patients undergoing 
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intraoperative procedures such as SLNB and tumour excision. It is hoped that this thesis 
has contributed to the further development of these techniques. 
 
 
Figure 9.2: Laboratory prototype of a co-aligned gamma-NIRF imaging system modified using HGC with an 
addition of a bandpass filter and a LED ring as the excitation light source. Image courtesy of University of 
Leicester.  
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Figure 9.3: Example of (a) fluorescent, (b) hybrid optical-fluorescent, (c) hybrid fluorescent-gamma and 
(d) fused optical-fluorescent-gamma images of the excised tissues (kidney, tumour and muscle) acquired 
using the HGC handheld by operator. The fluorescent image was acquired separately using the modified 
HGC in the same experiment showing high uptake of fluorescence dye within the kidney. For better 
NIRF imaging quality, a commercial fluorescent imaging system (Artemis, Quest Medical Imaging, the 
Netherlands) was used to provide external excitation source.  
  
a b c 
d 
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 Conclusions 
 The work of this thesis has demonstrated the successful translation of a newly 
developed SFOV hybrid gamma camera into clinical use. A full testing scheme to 
characterise the hybrid components of the pre-production prototype camera was 
introduced and implemented, allowing the objective comparison of these cameras 
with other SFOV hybrid gamma cameras. 
 Performance assessments were undertaken in clinical settings using bespoke 
phantoms, in particular for the assessment of the detectability of sentinel nodes in 
SLNB patients undergoing breast cancer surgery.  
 Preparatory work to bring the camera into the surgical department was also 
completed, which included compliance with the regulatory requirements, clinical 
trial study design, the effects of operator motion, ergonomic of camera design and 
a routine quality control testing scheme was proposed.  
 In addition experimental work was performed to explore the feasibility of the 
camera to detect clinically used radionuclides. This has confirmed the ability of the 
camera to detect energies ranging from 125I (35 keV) to 75Se (265 keV).  
 The first clinical results of the use of the HGC for medical imaging was obtained 
in patients undergoing bone, thyroid, lacrimal drainage and lymphatic imaging. 
The camera demonstrated good potential for small organ imaging such as thyroid 
and lacrimal drainage scintigraphy.  
 In addition, the preclinical imaging work has indicated the use of the SFOV hybrid 
optical gamma camera for imaging small animals where hybrid images may be of 
value for screening results in large animal numbers where SPECT imaging may be 
too time consuming.    
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Appendices 
 Matlab scripts  
 
A.1. Modify DICOM header 
x=dicominfo('SFOV.dcm'); 
y=dicominfo('LFOV.0000'); 
z=y; 
xfieldnames=fieldnames(x); 
l=length(xfieldnames); 
  
  
  
for i=1:l 
    % xfieldnames = names of fields in SFOV 
    % x = SFOV 
    % y=LFOV 
    % z=copy of LFOV 
     
    if isfield(z, xfieldnames{i}) == 1 
        z.(xfieldnames{i}) = x.(xfieldnames{i}); 
    end 
    if strcmp(xfieldnames{i}, 'PixelSpacing') == 1 
        z.(xfieldnames{i}) = [x.(xfieldnames{i}); 
x.(xfieldnames{i})]; 
    end 
end   
  
xim=dicomread('SFOV.dcm'); 
dicomwrite(xim, 'SFOV_new.dcm', z, 'CreateMode','Copy'); 
 
 
A.2. Convert images from TIFF to DICOM format 
% to convert tiff images to DICOM images in batch (within same 
folder)  
dirListing = dir('*.tiff'); 
  
counter=0; 
  
for d = 1:length(dirListing) 
    counter=counter+1; 
    a=dirListing.name; 
    b=imread(a); 
        
    [pathstr,name,ext] = fileparts(a); 
    dicomwrite(b, strcat(name,'.dcm')); 
end 
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A.3. Analysis of uniformity test 
%Uniformity correction and quantification for SFOV gamma camera 
%read two flood images and background image 
  
a=dicomread('BCR1.dcm'); 
b=dicomread('image1.dcm'); 
c=dicomread('image2.dcm'); 
  
%convert from uint16 image to double image  
%to change pixel intensity from int to floating number 
a2=double(a); 
b2=double(b); 
c2=double(c); 
%flood1 subtracted with background image and obtained max intensity 
value 
%normalised image with max int value 
d=b2-a2; 
max1=max(d(:)); 
e=d/max1; 
  
%flood2 subtracted with background image and divided with 
normalised image 
f=c2-a2; 
g=f./e; 
  
%select ROI of image for quantification 110x110 
Q=g(12:121,12:121); 
  
%apply median filter (to replace outlier)  
T=medfilt2(Q, [20 20], 'symmetric'); 
  
%quantification  
mean=mean2(T); 
stdev=std2(T); 
max=max(T(:)); 
min=min(T(:)); 
  
%display corrected image in normalised scale 
imshow(T ./ 80); 
  
%obtained pixel profile 
intensity1=T(50,:); 
  
%display ROI of non-corrected image and obtained profile    
I=c2(12:121,12:121); 
imshow(I ./80); 
mean3=mean2(I); 
intensity2=I(50,:); 
xlabel('Pixel'); 
ylabel('Normalised pixel intensity'); 
subplot(2,1,1),plot(intensity2/mean3); 
subplot(2,1,2),plot(intensity1/mean); 
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  Questionnaire 
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